CN115353512A - Heterocyclic urea compound and preparation method and application thereof - Google Patents
Heterocyclic urea compound and preparation method and application thereof Download PDFInfo
- Publication number
- CN115353512A CN115353512A CN202210897430.2A CN202210897430A CN115353512A CN 115353512 A CN115353512 A CN 115353512A CN 202210897430 A CN202210897430 A CN 202210897430A CN 115353512 A CN115353512 A CN 115353512A
- Authority
- CN
- China
- Prior art keywords
- membered
- alkyl
- heteroaryl
- heterocyclyl
- radical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Heterocyclic urea compound Chemical class 0.000 title claims description 511
- 238000002360 preparation method Methods 0.000 title description 12
- 239000004202 carbamide Substances 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 290
- 239000012453 solvate Substances 0.000 claims abstract description 34
- 229940002612 prodrug Drugs 0.000 claims abstract description 31
- 239000000651 prodrug Substances 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 102100029766 DNA polymerase theta Human genes 0.000 claims abstract description 29
- 101001094659 Homo sapiens DNA polymerase kappa Proteins 0.000 claims abstract description 28
- 101000865085 Homo sapiens DNA polymerase theta Proteins 0.000 claims abstract description 28
- 230000000155 isotopic effect Effects 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 239000003112 inhibitor Substances 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 10
- 230000001404 mediated effect Effects 0.000 claims abstract description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 254
- 125000001072 heteroaryl group Chemical group 0.000 claims description 150
- 125000000217 alkyl group Chemical group 0.000 claims description 145
- 125000002619 bicyclic group Chemical group 0.000 claims description 133
- 229910052757 nitrogen Inorganic materials 0.000 claims description 119
- 125000005842 heteroatom Chemical group 0.000 claims description 105
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 99
- 125000003118 aryl group Chemical group 0.000 claims description 96
- 229910052736 halogen Inorganic materials 0.000 claims description 82
- 150000002367 halogens Chemical class 0.000 claims description 82
- 125000001424 substituent group Chemical group 0.000 claims description 57
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 52
- 206010028980 Neoplasm Diseases 0.000 claims description 43
- 229910052760 oxygen Inorganic materials 0.000 claims description 42
- 125000004043 oxo group Chemical group O=* 0.000 claims description 39
- 125000005843 halogen group Chemical group 0.000 claims description 37
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 35
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 32
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 25
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 22
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 22
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 21
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 16
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 16
- 125000004429 atom Chemical group 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 13
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 11
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 150000005840 aryl radicals Chemical class 0.000 claims description 10
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 10
- 125000002950 monocyclic group Chemical group 0.000 claims description 10
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 9
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 8
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 239000012661 PARP inhibitor Substances 0.000 claims description 5
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 229910052720 vanadium Inorganic materials 0.000 claims description 5
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 4
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 125000005561 phenanthryl group Chemical group 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 239000012827 ATM inhibitor Substances 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 102100023037 Wee1-like protein kinase Human genes 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 229910052721 tungsten Inorganic materials 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 229940123309 Immune checkpoint modulator Drugs 0.000 claims 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 9
- 238000011161 development Methods 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 230000003287 optical effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 268
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 231
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 172
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 136
- 238000005481 NMR spectroscopy Methods 0.000 description 108
- 239000000243 solution Substances 0.000 description 108
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 105
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 103
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 84
- 235000019439 ethyl acetate Nutrition 0.000 description 81
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 79
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 74
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 71
- 230000015572 biosynthetic process Effects 0.000 description 66
- 239000000741 silica gel Substances 0.000 description 65
- 229910002027 silica gel Inorganic materials 0.000 description 65
- 238000003786 synthesis reaction Methods 0.000 description 65
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 62
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 59
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 54
- 239000000706 filtrate Substances 0.000 description 54
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 52
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 52
- 239000012074 organic phase Substances 0.000 description 52
- 238000003818 flash chromatography Methods 0.000 description 50
- 125000004432 carbon atom Chemical group C* 0.000 description 49
- 238000003756 stirring Methods 0.000 description 48
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 47
- 239000000203 mixture Substances 0.000 description 43
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- 238000010898 silica gel chromatography Methods 0.000 description 42
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 38
- 235000011056 potassium acetate Nutrition 0.000 description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 239000012043 crude product Substances 0.000 description 30
- 239000012071 phase Substances 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- 239000011541 reaction mixture Substances 0.000 description 29
- 229910000029 sodium carbonate Inorganic materials 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 238000004237 preparative chromatography Methods 0.000 description 27
- 125000006413 ring segment Chemical group 0.000 description 27
- 238000004128 high performance liquid chromatography Methods 0.000 description 25
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 24
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
- 239000002904 solvent Substances 0.000 description 21
- 229910052786 argon Inorganic materials 0.000 description 19
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- UNXISIRQWPTTSN-UHFFFAOYSA-N boron;2,3-dimethylbutane-2,3-diol Chemical compound [B].[B].CC(C)(O)C(C)(C)O UNXISIRQWPTTSN-UHFFFAOYSA-N 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 239000011259 mixed solution Substances 0.000 description 15
- QEDCHCLHHGGYBT-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1h-indole Chemical compound BrC1=CC=C2NCCC2=C1 QEDCHCLHHGGYBT-UHFFFAOYSA-N 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 14
- 238000002953 preparative HPLC Methods 0.000 description 13
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 13
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 12
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 11
- 125000000304 alkynyl group Chemical group 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- 239000012312 sodium hydride Substances 0.000 description 11
- 229910000104 sodium hydride Inorganic materials 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 229910001873 dinitrogen Inorganic materials 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 150000002431 hydrogen Chemical class 0.000 description 9
- 239000005457 ice water Substances 0.000 description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 125000001931 aliphatic group Chemical group 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- 125000003367 polycyclic group Chemical group 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 125000003003 spiro group Chemical group 0.000 description 7
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 230000033616 DNA repair Effects 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- MCZYEFODKAZWIH-UHFFFAOYSA-N 3-(chloromethyl)-3-methyloxetane Chemical compound ClCC1(C)COC1 MCZYEFODKAZWIH-UHFFFAOYSA-N 0.000 description 5
- VXWVFZFZYXOBTA-UHFFFAOYSA-N 5-bromo-1h-indole Chemical compound BrC1=CC=C2NC=CC2=C1 VXWVFZFZYXOBTA-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 101100388059 Drosophila melanogaster PolQ gene Proteins 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 238000002390 rotary evaporation Methods 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- FRACPXUHUTXLCX-BELIEFIBSA-N tert-butyl N-{1-[(1S)-1-{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}-2-cyclopropylethyl]-2-oxopyridin-3-yl}carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CN(C1=O)[C@@H](CC2CC2)C(=O)N[C@@H](C[C@@H]3CCNC3=O)[C@H](C(=O)NCC4=CC=CC=C4)O FRACPXUHUTXLCX-BELIEFIBSA-N 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 239000011592 zinc chloride Substances 0.000 description 5
- 235000005074 zinc chloride Nutrition 0.000 description 5
- QUYJEYSRBCLJIZ-UHFFFAOYSA-N 1-methylpyrazole-3-carbaldehyde Chemical compound CN1C=CC(C=O)=N1 QUYJEYSRBCLJIZ-UHFFFAOYSA-N 0.000 description 4
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 210000003722 extracellular fluid Anatomy 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 4
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- JTPXVCKCLBROOJ-UHFFFAOYSA-N 2-amino-6-chloropyrazine Chemical compound NC1=CN=CC(Cl)=N1 JTPXVCKCLBROOJ-UHFFFAOYSA-N 0.000 description 3
- DUQGFIKXKISULR-UHFFFAOYSA-N 3-methyloxetane-3-carbaldehyde Chemical compound O=CC1(C)COC1 DUQGFIKXKISULR-UHFFFAOYSA-N 0.000 description 3
- STVHMYNPQCLUNJ-UHFFFAOYSA-N 5-bromo-1h-indazole Chemical compound BrC1=CC=C2NN=CC2=C1 STVHMYNPQCLUNJ-UHFFFAOYSA-N 0.000 description 3
- KGGYMBKTQCLOTE-UHFFFAOYSA-N 6-chloropyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC(Cl)=N1 KGGYMBKTQCLOTE-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102000004257 Potassium Channel Human genes 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 108020001213 potassium channel Proteins 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- KSOVGRCOLZZTPF-QMKUDKLTSA-N (1s,2s,3r,4r)-3-[[5-fluoro-2-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@H]1[C@H]([C@@]2([H])C[C@@]1(C=C2)[H])C(N)=O)C(C(=CN=1)F)=NC=1NC(C=C1C)=CC=C1N1CCN(C)CC1 KSOVGRCOLZZTPF-QMKUDKLTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- WGABOZPQOOZAOI-UHFFFAOYSA-N 2-[4-[[(3,5-dimethoxy-4-methylbenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]acetic acid Chemical compound COC1=C(C)C(OC)=CC(C(=O)N(CCCC=2C=CC=CC=2)CC=2C=CC(CC(O)=O)=CC=2)=C1 WGABOZPQOOZAOI-UHFFFAOYSA-N 0.000 description 2
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 2
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-oxetanone Chemical group O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 2
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 2
- PCHYYOCUCGCSBU-UHFFFAOYSA-N 4-bromo-2-methylaniline Chemical compound CC1=CC(Br)=CC=C1N PCHYYOCUCGCSBU-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- NELWQUQCCZMRPB-UBPLGANQSA-N [(2r,3r,4r,5r)-4-acetyloxy-5-(4-amino-5-ethenyl-2-oxopyrimidin-1-yl)-2-methyloxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](C)O[C@H]1N1C(=O)N=C(N)C(C=C)=C1 NELWQUQCCZMRPB-UBPLGANQSA-N 0.000 description 2
- NBGXGDBTUJNTKJ-JEDNCBNOSA-N [(2s)-morpholin-2-yl]methanol;hydrochloride Chemical compound Cl.OC[C@@H]1CNCCO1 NBGXGDBTUJNTKJ-JEDNCBNOSA-N 0.000 description 2
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 2
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- 125000004452 carbocyclyl group Chemical group 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940126212 compound 17a Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229940125873 compound 60b Drugs 0.000 description 2
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 2
- 125000000532 dioxanyl group Chemical group 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- JLPJFSCQKHRSQR-UHFFFAOYSA-N oxolan-3-one Chemical compound O=C1CCOC1 JLPJFSCQKHRSQR-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000002053 thietanyl group Chemical group 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- AEVBPXDFDKBGLT-YOUFYPILSA-N (2s,3s,4r,5r)-n-[2-[4-(diethoxyphosphorylmethyl)anilino]-2-oxoethyl]-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolane-2-carboxamide Chemical compound C1=CC(CP(=O)(OCC)OCC)=CC=C1NC(=O)CNC(=O)[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 AEVBPXDFDKBGLT-YOUFYPILSA-N 0.000 description 1
- NLQMSBJFLQPLIJ-UHFFFAOYSA-N (3-methyloxetan-3-yl)methanol Chemical compound OCC1(C)COC1 NLQMSBJFLQPLIJ-UHFFFAOYSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- NXILIHONWRXHFA-QMMMGPOBSA-N (3s)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H](C(O)=O)C1 NXILIHONWRXHFA-QMMMGPOBSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 description 1
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- RUBQQRMAWLSCCJ-UHFFFAOYSA-N 1,2-difluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(F)=C1 RUBQQRMAWLSCCJ-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- FZTLLUYFWAOGGB-UHFFFAOYSA-N 1,4-dioxane dioxane Chemical compound C1COCCO1.C1COCCO1 FZTLLUYFWAOGGB-UHFFFAOYSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- KEJFADGISRFLFO-UHFFFAOYSA-N 1H-indazol-6-amine Chemical compound NC1=CC=C2C=NNC2=C1 KEJFADGISRFLFO-UHFFFAOYSA-N 0.000 description 1
- ICFGFAUMBISMLR-UHFFFAOYSA-N 1h-pyrazole-5-carbaldehyde Chemical compound O=CC=1C=CNN=1 ICFGFAUMBISMLR-UHFFFAOYSA-N 0.000 description 1
- PQXKWPLDPFFDJP-UHFFFAOYSA-N 2,3-dimethyloxirane Chemical compound CC1OC1C PQXKWPLDPFFDJP-UHFFFAOYSA-N 0.000 description 1
- VUFMJROCMFQILX-UHFFFAOYSA-N 2-(dimethylamino)acetaldehyde;hydrochloride Chemical compound Cl.CN(C)CC=O VUFMJROCMFQILX-UHFFFAOYSA-N 0.000 description 1
- CJLZUKCACMUYFP-GOSISDBHSA-N 2-[(5R)-4-[2-[3-(3-methylbutanoyloxy)phenyl]acetyl]-8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-5-yl]acetic acid Chemical compound CC(C)CC(=O)OC1=CC=CC(CC(=O)N2[C@@H](C3=CC=C(N=C3NCC2)C(F)(F)F)CC(O)=O)=C1 CJLZUKCACMUYFP-GOSISDBHSA-N 0.000 description 1
- DRQWUAAWZFIVTF-UHFFFAOYSA-N 2-amino-5-bromophenol Chemical compound NC1=CC=C(Br)C=C1O DRQWUAAWZFIVTF-UHFFFAOYSA-N 0.000 description 1
- HKOJYPPTIPJZAZ-UHFFFAOYSA-N 2-methoxy-6-methylaniline Chemical compound COC1=CC=CC(C)=C1N HKOJYPPTIPJZAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- MHCWLERQNFATHZ-UHFFFAOYSA-N 2-methylindazol-6-amine Chemical compound C1=CC(N)=CC2=NN(C)C=C21 MHCWLERQNFATHZ-UHFFFAOYSA-N 0.000 description 1
- RAJRANFZSWDUJZ-UHFFFAOYSA-N 2-methylpyrazole-3-carbaldehyde Chemical compound CN1N=CC=C1C=O RAJRANFZSWDUJZ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000001627 3 membered heterocyclic group Chemical group 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 1
- IWJGMJHAIUBWKT-UHFFFAOYSA-N 4-bromo-2-methylphenol Chemical compound CC1=CC(Br)=CC=C1O IWJGMJHAIUBWKT-UHFFFAOYSA-N 0.000 description 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
- FBXGQDUVJBKEAJ-UHFFFAOYSA-N 4h-oxazin-3-one Chemical compound O=C1CC=CON1 FBXGQDUVJBKEAJ-UHFFFAOYSA-N 0.000 description 1
- MBVCESWADCIXJN-UHFFFAOYSA-N 5-Bromoisatin Chemical compound BrC1=CC=C2NC(=O)C(=O)C2=C1 MBVCESWADCIXJN-UHFFFAOYSA-N 0.000 description 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- URDGCPQHZSDBRG-UHFFFAOYSA-N 6-bromo-1,2,3,4-tetrahydroisoquinoline Chemical compound C1NCCC2=CC(Br)=CC=C21 URDGCPQHZSDBRG-UHFFFAOYSA-N 0.000 description 1
- WEHMHBSITKCQBY-UHFFFAOYSA-N 6-bromo-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(Br)=CC=C21 WEHMHBSITKCQBY-UHFFFAOYSA-N 0.000 description 1
- GEDVWGDBMPJNEV-UHFFFAOYSA-N 6-bromo-1h-benzimidazole Chemical compound BrC1=CC=C2N=CNC2=C1 GEDVWGDBMPJNEV-UHFFFAOYSA-N 0.000 description 1
- YLAFBGATSQRSTB-UHFFFAOYSA-N 6-bromo-1h-quinolin-2-one Chemical group N1C(=O)C=CC2=CC(Br)=CC=C21 YLAFBGATSQRSTB-UHFFFAOYSA-N 0.000 description 1
- MQWZSSIUHXNNTM-UHFFFAOYSA-N 6-bromo-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(Br)=CC=C21 MQWZSSIUHXNNTM-UHFFFAOYSA-N 0.000 description 1
- SBBQFRYIMUUNFT-UHFFFAOYSA-N 6-bromopyrazin-2-amine Chemical compound NC1=CN=CC(Br)=N1 SBBQFRYIMUUNFT-UHFFFAOYSA-N 0.000 description 1
- QAJYCQZQLVENRZ-UHFFFAOYSA-N 6-chloropyridin-3-amine Chemical compound NC1=CC=C(Cl)N=C1 QAJYCQZQLVENRZ-UHFFFAOYSA-N 0.000 description 1
- UENBBJXGCWILBM-UHFFFAOYSA-N 6-methylpyridin-3-amine Chemical compound CC1=CC=C(N)C=N1 UENBBJXGCWILBM-UHFFFAOYSA-N 0.000 description 1
- RZOKQIPOABEQAM-UHFFFAOYSA-N 6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC=C(C(O)=O)C=N1 RZOKQIPOABEQAM-UHFFFAOYSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- XONKJZDHGCMRRF-UHFFFAOYSA-N 7-fluoro-1h-indole Chemical compound FC1=CC=CC2=C1NC=C2 XONKJZDHGCMRRF-UHFFFAOYSA-N 0.000 description 1
- KGWPHCDTOLQQEP-UHFFFAOYSA-N 7-methylindole Chemical compound CC1=CC=CC2=C1NC=C2 KGWPHCDTOLQQEP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700040618 BRCA1 Genes Proteins 0.000 description 1
- 108700010154 BRCA2 Genes Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- NZSQBRZWARZNQH-ZWOACCQCSA-N C1(CC1)NC(=O)O[C@H]1C(C2CC[C@]3([C@@]4(CC[C@@]5(C(C4CCC3[C@]2(CC1)C)[C@@H](CC5)[C@H](C)O)C(=O)O)C)C)(C)C Chemical compound C1(CC1)NC(=O)O[C@H]1C(C2CC[C@]3([C@@]4(CC[C@@]5(C(C4CCC3[C@]2(CC1)C)[C@@H](CC5)[C@H](C)O)C(=O)O)C)C)(C)C NZSQBRZWARZNQH-ZWOACCQCSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- WUZBOJXXYMKMMF-UHFFFAOYSA-N COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F Chemical compound COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F WUZBOJXXYMKMMF-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- SBUJJOHVJPCLRS-UHFFFAOYSA-N Cl.Cl.CCN=C=NCCCN(C)C.CCN=C=NCCCN(C)C Chemical compound Cl.Cl.CCN=C=NCCCN(C)C.CCN=C=NCCCN(C)C SBUJJOHVJPCLRS-UHFFFAOYSA-N 0.000 description 1
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 208000025939 DNA Repair-Deficiency disease Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 108010093204 DNA polymerase theta Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-VVKOMZTBSA-N Dideuterium Chemical compound [2H][2H] UFHFLCQGNIYNRP-VVKOMZTBSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitrogen oxide Substances O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 102000015087 Poly (ADP-Ribose) Polymerase-1 Human genes 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- NBGXGDBTUJNTKJ-NUBCRITNSA-N [(2r)-morpholin-2-yl]methanol;hydrochloride Chemical compound Cl.OC[C@H]1CNCCO1 NBGXGDBTUJNTKJ-NUBCRITNSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- CXQGKOICHGQQMF-UHFFFAOYSA-N azido diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(ON=[N+]=[N-])OC1=CC=CC=C1 CXQGKOICHGQQMF-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- SGCLBIRCSTXTIU-UHFFFAOYSA-N boric acid;2,3-dimethylbutane-2,3-diol Chemical compound OB(O)O.CC(C)(O)C(C)(C)O.CC(C)(O)C(C)(C)O SGCLBIRCSTXTIU-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- BZOWIADSJYMJJJ-UHFFFAOYSA-N methyl 6-formylpyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(C=O)N=C1 BZOWIADSJYMJJJ-UHFFFAOYSA-N 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 231100000310 mutation rate increase Toxicity 0.000 description 1
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- JSOMVCDXPUXKIC-UHFFFAOYSA-N tert-butyl 3-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)C1 JSOMVCDXPUXKIC-UHFFFAOYSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000001730 thiiranyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a compound with a novel structure, and a prodrug, a tautomer, an optical isomer, a solvate, an isotopic derivative or a pharmaceutically acceptable salt thereof. The compounds with novel structures designed by the invention provide a new direction for the development of the drugs of the POLQ inhibitors. The research on the in vitro enzyme activity inhibition activity shows that the compounds have stronger inhibition effect on the POLQ enzyme and can be used as prospect compounds for treating diseases mediated by the POLQ inhibitor.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a heterocyclic urea compound serving as a POLQ inhibitor, and a preparation method and application of the compound.
Background
Defects in DNA repair have become an effective strategy against cancer. It has become increasingly apparent over the past decades that selective deletions of the DNA repair pathway occur in a wide variety of tumors from 40% to 50%. DNA repair deletions promote tumor cell proliferation, leading to genetic instability and/or increased mutation rates, driving the evolution of tumors. Cancers deficient in DNA repair often rely on alternate DNA repair pathways, which have been targeted and successful in developing inhibitors of Poly ADP Ribose Polymerase (PARP) for the treatment of BRCA deficient breast and ovarian cancer. However, the need for new therapeutic approaches that exploit other DNA repair deficiencies remains urgent to overcome the acquired and innate resistance to PARP inhibitors (PARPi). DNA polymerase θ (POLQ)) is involved in DNA repair, not only synergizing with PARP inhibitors, but also has broader utility in cancer therapy. POLQ has been the major focus of drug development, and it is also a significant reason that it is not substantially expressed in normal cells, but is increased in many cancers, whether accompanied by a defect in Homologous Recombination (HRD).
POLQ is a key component of the POLQ alt-EJ pathway, also known as the microhomology-mediated end joining (MMEJ) pathway, involved in DNA double strand break repair, and the MMEJ can be paralleled by the HR and NHEJ pathways (Truong et al, PNAS 2003, 110 (19), 7720-7725). POLQ is less expressed in normal tissues but is up-regulated in many tumor types, such as breast, ovary, HNSCC, and lung. POLQ inhibitors have the potential to be used in a wide range of clinical settings, particularly in HR deficient tumors such as breast and ovarian cancers, or in combination with DNA damaging agents (chemotherapy and radiotherapy). Mechanistically, the indications can also be expanded in combination with PARP1 inhibitors.
POLQ overexpression is observed in a number of cancers, and the up-regulated levels correlate with poor prognosis. For example, about 70% of breast cancers show 5-fold or more high expression of POLQ, and this high expression is observed in both normal and deficient HR functioning breast cancers. In addition, POLQ is highly expressed in cancer cells and is resistant to ionizing radiation and chemotherapeutic drugs. Aberrant expression of POLQ also promotes survival of cells deficient in homologous recombination, a feature commonly observed in cells mutated in the BRCA1 or BRCA2 genes. Therefore, POLQ is considered as a promising new cancer target, and novel POLQ inhibitors will become part of new anticancer therapies.
Disclosure of Invention
The invention aims to provide a compound with a heterocyclic urea structure as a POLQ inhibitor, a preparation method of the compound and application of the compound in treating diseases mediated by POLQ.
In a first aspect of the present invention, there is provided a compound represented by the following formula (I), or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof, having the following structure:
wherein X is selected from O and S;
w and V are independently selected from N or C (R) w );R w Represents hydrogen, halogen or C 1-6 An alkyl group;
a is selected from hydrogen, halogen, amino, cyano, hydroxy, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-6 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Hydroxyalkyl, halo C 1-6 Alkyl radical, C 1-6 Alkylamino, -CO-C 1-6 Alkyl, -CO-C 1-6 Haloalkyl, -NHCO-C 1-6 Alkyl, -CH 2 CONR a1 R a2 ;R a1 And R a2 Independently selected from H and C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Hydroxyalkyl, halo C 1-6 An alkyl group;
ring B is selected from C 6-14 Aryl, 5-16 membered heteroaryl and 5-16 membered heterocyclyl, said C 6-14 Aryl, 5-16 membered heteroaryl and 5-16 membered heterocyclyl is optionally substituted with n R b Substituted when multiple R b At the same time, each R b May be the same or different; wherein n is selected from 0, 1,2,3,4 and 5;
R b selected from halogen, cyano, hydroxy, nitro, amino, oxo, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy radical, C 1-6 Alkylthio radical, C 1-6 Hydroxyalkyl, 4-to 10-membered heterocyclic group, C 6-12 Aryl, 5-10 membered heteroaryl, -C 1-6 alkyl-C 3-8 Cycloalkyl, -C 1-6 Alkyl-4-10 membered heterocyclyl, -C 1-6 alkyl-C 6-12 Aryl radical, -C 1-6 Alkyl-5-10 membered heteroaryl, -NH-C 3-8 Cycloalkyl, -NH-4-10 membered heterocyclyl, -NH-C 6-12 Aryl, -NH-5-10 membered heteroaryl, -NH-C 1-6 alkyl-C 3-8 Cycloalkyl, -NH-C 1-6 Alkyl-4-10 membered heterocyclyl, -NH-C 1-6 alkyl-C 6-12 Aryl, -NH-C 1-6 Alkyl-5-10 membered heteroaryl, -O-C 1-6 alkyl-C 3-8 Cycloalkyl, -O-C 1-6 Alkyl-4-10 membered heterocyclyl, -O-C 1-6 alkyl-C 6-12 Aryl and-O-C 1-6 Alkyl-5-10 membered heteroaryl; said C is 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Alkylthio radical, C 1-6 Hydroxyalkyl, 4-to 10-membered heterocyclyl, C 6-12 Aryl, 5-10 membered heteroaryl, -C 1-6 alkyl-C 3-8 Cycloalkyl, -C 1-6 Alkyl-4-10 membered heterocyclyl, -C 1-6 alkyl-C 6-12 Aryl radical, -C 1-6 Alkyl-5-10 membered heteroaryl, -NH-C 3-8 Cycloalkyl, -NH-4-10 membered heterocyclyl, -NH-C 6-12 Aryl, -NH-5-10 membered heteroaryl, -NH-C 1-6 alkyl-C 3-8 Cycloalkyl, -NH-C 1-6 Alkyl-4-10 membered heterocyclyl, -NH-C 1-6 alkyl-C 6-12 Aryl, -NH-C 1-6 Alkyl-5-10 membered heteroaryl, -O-C 1-6 alkyl-C 3-8 Cycloalkyl, -O-C 1-6 Alkyl-4-10 membered heterocyclyl, -O-C 1-6 alkyl-C 6-12 Aryl and-O-C 1-6 Alkyl-5-10 membered heteroaryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, nitro, oxo, -NH (C) 1-3 Alkyl), -N (C) 1-3 Alkyl) (C 1-3 Alkyl), -C 1-3 alkyl-NH 2 、-NH-C(O)C 1-3 Alkyl, -C (O) C 1-3 Alkyl, halo C 1-6 Alkyl radical, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Alkylthio radical, C 1-6 Hydroxyalkyl, 4-to 10-membered heterocyclic group, C 6-12 Aryl, 5-10 membered heteroaryl;
R 1 is selected from C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Hydroxyalkyl, halo C 1-6 Alkyl radical, C 1-6 Alkylamino radical, -CO-C 1-6 Alkyl, -CO-C 1-6 Haloalkyl, -NHCO-C 1-6 Alkyl, 4-12 membered heterocyclyl, 5-12 membered heteroaryl, C 6-12 An aryl group; said C is 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Hydroxyalkyl, halogeno C 1-6 Alkyl radical, C 1-6 Alkylamino radical, -CO-C 1-6 Alkyl, -CO-C 1-6 Haloalkyl, -NHCO-C 1-6 Alkyl, 4-12 membered heterocyclyl, 5-12 membered heteroaryl, C 6-12 Aryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, nitro, oxo, -NH (C) 1-3 Alkyl), -N (C) 1-3 Alkyl) (C 1-3 Alkyl), -C 1-3 alkyl-NH 2 、-NH-C(O)C 1-3 Alkyl, -C (O) C 1-3 Alkyl, halo C 1-6 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl, -C 1-3 alkyl-N (C) 1-3 Alkyl) C 1-3 Alkyl radical, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy radical, C 1-6 Alkylthio radical, C 1-6 Hydroxyalkyl, 4-to 10-membered heterocyclyl, C 6-12 Aryl, 5-10 membered heteroaryl;
R 2 and R 3 Independently selected from H, C 1-4 Alkyl radical, C 1-4 Haloalkyl, C 1-4 Alkoxy radical, C 1-4 Halogenoalkoxy, C 3-8 A cycloalkyl group; or R 2 And R 3 Together with the atoms to which they are attached form a 5-or 6-membered heterocyclic ring;
unless otherwise specified, the heteroatoms in the heterocyclic groups and heteroaryl groups are independently selected from O, N or S, and the number of heteroatoms is 1,2,3 or 4.
In a first aspect of the present invention, there is provided a compound represented by the following formula (I), or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof, having the following structure:
wherein X is selected from O and S;
w and V are independently selected from N or C (R) w );R w Represents hydrogen, halogen or C 1-6 An alkyl group;
a is selected from hydrogen, halogen, amino, cyano, hydroxy, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-6 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Hydroxyalkyl, halo C 1-6 Alkyl radical, C 1-6 Alkylamino, -CO-C 1-6 Alkyl, -CO-C 1-6 Haloalkyl, -NHCO-C 1-6 Alkyl, -CH 2 CONR a1 R a2 ;R a1 And R a2 Independently selected from H and C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Hydroxyalkyl, halo C 1-6 An alkyl group;
ring B is selected from C 6-12 Aryl, 5-16 membered heteroaryl and 5-16 membered heterocyclyl, C 6-12 Aryl, 5-16 membered heteroaryl and 5-16 membered heterocyclyl are optionally substituted with n R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different; wherein n is selected from 0, 1,2,3,4 and 5;
R b selected from halogen, cyano, hydroxy, nitro, amino, oxo, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Alkylthio radical, C 1-6 Hydroxyalkyl, 4-to 10-membered heterocyclic group, C 6-12 Aryl, 5-10 membered heteroaryl, -C 1-6 alkyl-C 3-8 Cycloalkyl, -C 1-6 Alkyl-4-10 membered heterocyclyl, -C 1-6 alkyl-C 6-12 Aryl radical, -C 1-6 Alkyl-5-10 membered heteroaryl, -NH-C 3-8 Cycloalkyl, -NH-4-10 membered heterocyclyl, -NH-C 6-12 Aryl, -NH-5-10 membered heteroaryl, -NH-C 1-6 alkyl-C 3-8 Cycloalkyl, -NH-C 1-6 Alkyl-4-10 membered heterocyclyl, -NH-C 1-6 alkyl-C 6-12 Aryl, -NH-C 1-6 Alkyl-5-10 membered heteroaryl, -O-C 1-6 alkyl-C 3-8 Cycloalkyl, -O-C 1-6 Alkyl-4-10 membered heterocyclyl, -O-C 1-6 alkyl-C 6-12 Aryl and-O-C 1-6 Alkyl-5-10 membered heteroaryl; said C is 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy radical, C 1-6 Alkylthio radical, C 1-6 Hydroxyalkyl, 4-to 10-membered heterocyclic group, C 6-12 Aryl, 5-10 membered heteroaryl, -C 1-6 alkyl-C 3-8 Cycloalkyl, -C 1-6 Alkyl-4-10 membered heterocyclyl, -C 1-6 alkyl-C 6-12 Aryl radical, -C 1-6 Alkyl-5-10 membered heteroaryl, -NH-C 3-8 Cycloalkyl, -NH-4-10 membered heterocyclyl, -NH-C 6-12 Aryl, -NH-5-10 membered heteroaryl, -NH-C 1-6 alkyl-C 3-8 Cycloalkyl, -NH-C 1-6 Alkyl-4-10 membered heterocyclyl, -NH-C 1-6 alkyl-C 6-12 Aryl, -NH-C 1-6 Alkyl-5-10 membered heteroaryl, -O-C 1-6 alkyl-C 3-8 Cycloalkyl, -O-C 1-6 Alkyl-4-10 membered heterocyclyl, -O-C 1-6 alkyl-C 6-12 Aryl and-O-C 1-6 Alkyl-5-10 membered heteroaryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, nitro, oxo, -NH (C) 1-3 Alkyl), -N (C) 1-3 Alkyl) (C 1-3 Alkyl), -C 1-3 alkyl-NH 2 、-NH-C(O)C 1-3 Alkyl, -C (O) C 1-3 Alkyl, halo C 1-6 Alkyl radical, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy radical, C 1-6 Alkylthio radical, C 1-6 Hydroxyalkyl, 4-to 10-membered heterocyclic group, C 6-12 Aryl, 5-10 membered heteroaryl;
R 1 is selected from C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Hydroxyalkyl, halogeno C 1-6 Alkyl radical, C 1-6 Alkylamino, -CO-C 1-6 Alkyl, -CO-C 1-6 Haloalkyl, -NHCO-C 1-6 Alkyl, 4-12 membered heterocyclyl, 5-12 membered heteroaryl, C 6-12 An aryl group; said C is 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Hydroxyalkyl, halo C 1-6 Alkyl radical, C 1-6 Alkylamino, -CO-C 1-6 Alkyl, -CO-C 1-6 Haloalkyl, -NHCO-C 1-6 Alkyl, 4-12 membered heterocyclyl, 5-12 membered heteroaryl, C 6-12 Aryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, nitro, oxo, -NH (C) 1-3 Alkyl), -N (C) 1-3 Alkyl) (C 1-3 Alkyl), -C 1-3 alkyl-NH 2 、-NH-C(O)C 1-3 Alkyl, -C (O) C 1-3 Alkyl, halo C 1-6 Alkyl radical, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Alkylthio radical, C 1-6 Hydroxyalkyl, 4-to 10-membered heterocyclic group, C 6-12 Aryl, 5-10 membered heteroaryl;
R 2 and R 3 Independently selected from H, C 1-4 Alkyl radical, C 1-4 Haloalkyl, C 1-4 Alkoxy radical, C 1-4 Halogenoalkoxy, C 3-8 A cycloalkyl group; or R 2 And R 3 Together with the atoms to which they are attached form a 5-or 6-membered heterocyclic ring;
unless otherwise specified, the heteroatoms in the heterocyclic groups and heteroaryl groups are independently selected from O, N or S, and the number of heteroatoms is 1,2,3 or 4.
In a preferred embodiment of the invention, W and V are both selected from N.
In a preferred embodiment of the invention, A is selected from hydrogenHalogen, amino, cyano, hydroxy, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-6 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Hydroxyalkyl, halo C 1-6 An alkyl group; more preferably, a is selected from hydrogen, halogen, amino, cyano, hydroxy, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, cyclopropyl, methoxy; most preferably, a is selected from hydrogen.
In a preferred embodiment of the invention, ring B is selected from C 6-14 Aryl, 5-14 membered heteroaryl and 5-14 membered heterocyclyl, said C 6-14 Aryl, 5-14 membered heteroaryl and 5-14 membered heterocyclyl is optionally substituted with n R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different; wherein n is selected from 0, 1,2,3 and 4; more preferably, ring B is selected from C 6 Aryl, 6-14 membered heteroaryl and 6-14 membered heterocyclyl, said C 6 Aryl, 6-14 membered heteroaryl and 6-14 membered heterocyclyl is optionally substituted with n R b Substituted when multiple R b At the same time, each R b May be the same or different; wherein n is selected from 0, 1,2 and 3.
In a preferred embodiment of the invention, ring B is selected from C 6-10 Aryl, 5-12 membered heteroaryl and 5-14 membered heterocyclyl, said C 6-10 Aryl, 5-12 membered heteroaryl and 5-14 membered heterocyclyl are optionally substituted with n R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different; wherein n is selected from 0, 1,2,3 and 4; more preferably, ring B is selected from phenyl, 8-10 membered heteroaryl and 9-14 membered heterocyclyl, the heteroatoms in the heteroaryl, heterocyclyl being independently selected from O or N, the number of heteroatoms being 1,2 or 3, the phenyl, 8-10 membered heteroaryl and 9-14 membered heterocyclyl being optionally substituted by N R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different, wherein n is selected from 0, 1,2 and 3; more preferably, ring B is selected from phenyl, 9-10 membered bicyclic heterocyclyl wherein the heteroatom is N, the number of heteroatoms is 1 or 2, said phenyl, 9-10 membered bicyclic heterocyclyl optionally substituted with N R b The substitution is carried out by the following steps,when a plurality of R b When occurring simultaneously, each R b Which may be the same or different, wherein n is selected from 0, 1 and 2.
In a preferred embodiment of the present invention, ring B is selected from the group consisting of 6-12 membered bicyclic heteroaryl, 6-14 membered bicyclic heterocyclyl and 12-14 membered tricyclic heterocyclyl, said 6-12 membered bicyclic heteroaryl, 6-14 membered bicyclic heterocyclyl and 12-14 membered tricyclic heterocyclyl being optionally substituted with n R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different, wherein n is selected from 0, 1,2,3 and 4; more preferably, ring B is selected from 9-10 membered bicyclic heteroaryl, 9-10 membered bicyclic heterocyclyl and 14 membered tricyclic heterocyclyl, the heteroatoms in the heteroaryl, heterocyclyl are independently selected from O or N, the number of heteroatoms is 1,2 or 3, the 9-10 membered bicyclic heteroaryl, 9-10 membered bicyclic heterocyclyl and 14 membered tricyclic heterocyclyl are optionally substituted with N R b Substituted when multiple R b At the same time, each R b May be the same or different, wherein n is selected from 0, 1,2 and 3; more preferably, ring B is selected from 9-10 membered bicyclic heteroaryl and 9-10 membered bicyclic heterocyclyl, wherein the heteroatom in the heteroaryl or heterocyclyl is O or N and the number of heteroatoms is 1,2 or 3, wherein the 9-10 membered bicyclic heteroaryl and 9-10 membered bicyclic heterocyclyl are optionally substituted with N R b Substituted when multiple R b At the same time, each R b May be the same or different, wherein n is selected from 1,2 and 3; more preferably, ring B is selected from 9-10 membered bicyclic heterocyclic group, wherein the heteroatom in said heterocyclic group is N and the number of heteroatoms is 1, said 9-10 membered bicyclic heterocyclic group being optionally substituted by N R b Substituted when multiple R b When occurring simultaneously, each R b Which may be the same or different, wherein n is selected from 1 and 2.
In a preferred embodiment of the invention ring B is selected from 9-10 membered bicyclic heteroaryl, wherein the heteroatoms in said heteroaryl are independently selected from O or N, the number of heteroatoms is 1,2 or 3, said 9-10 membered bicyclic heteroaryl is optionally substituted by N R b Substituted when multiple R b At the same time, each R b Which may be the same or different, wherein n is selected from 1,2 and 3.
In a preferred embodiment of the invention, the ringB is selected from the group consisting of 5-membered/6-membered bicyclic fused heteroaryl, 6-membered/5-membered bicyclic fused heteroaryl, 6-membered/6-membered bicyclic fused heteroaryl, 5-membered/6-membered bicyclic fused heterocyclyl, 6-membered/5-membered bicyclic fused heterocyclyl, 6-membered/6-membered bicyclic fused heterocyclyl, wherein the heteroatom in the heteroaryl or heterocyclyl is O or N, the number of heteroatoms is 1,2 or 3, and the 5-membered/6-membered bicyclic fused heteroaryl, 6-membered/5-membered bicyclic fused heteroaryl, 6-membered/6-membered bicyclic fused heteroaryl, 5-membered/6-membered bicyclic fused heterocyclyl, 6-membered/5-membered bicyclic fused heterocyclyl, 6-membered/6-membered bicyclic fused heterocyclyl is optionally substituted with N R b Substituted when multiple R b At the same time, each R b Which may be the same or different, wherein n is selected from 1,2 and 3.
In a preferred embodiment of the invention, ring B is selected from C 6-10 Aryl radical, said C 6-10 Aryl is optionally substituted by n R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different; wherein n is selected from 1,2,3 and 4; more preferably, ring B is selected from phenyl optionally substituted by n R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different, wherein n is selected from 1,2 and 3; more preferably, ring B is selected from phenyl optionally substituted by n R b Substituted when more than one R b When occurring simultaneously, each R b Which may be the same or different, wherein n is selected from 1 and 2.
Preferably, ring B is monocyclic, bicyclic or tricyclic, including spiro, fused and bridged rings; more preferably, ring B is monocyclic or bicyclic; more preferably, ring B is bicyclic.
Preferably, ring B is selected from phenyl, 5-7 membered monocyclic heteroaryl, 5-7 membered monocyclic heterocyclyl, naphthyl, phenanthryl, anthracyl, 8-14 membered bicyclic heteroaryl, 8-14 membered bicyclic heterocyclyl, 9-14 membered tricyclic heteroaryl, 9-14 membered tricyclic heterocyclyl.
Preferably, ring B is selected from 8-14 membered bicyclic fused ring heteroaryl, 8-14 membered bicyclic fused ring heterocyclyl, 9-14 membered fused ring tricyclic heteroaryl, 9-14 membered fused ring tricyclic heterocyclyl.
Further preferably, ring B is selected from C 6 Aryl, 5-membered monocyclic heteroaryl, 6-membered monocyclic heteroaryl, 7-membered monocyclic heteroaryl<xnotran> ,5 ,6 ,7 ,6 /6 ,4 /4 ,4 /5 ,5 /4 ,5 /5 ,5 /6 ,6 /5 ,4 /6 ,6 /4 ,6 /6 ,4 /4 ,4 /5 ,5 /4 ,5 /5 ,5 /6 ,6 /5 ,4 /6 ,6 /4 ,6 /6 ,5 /6 /6 ,6 /5 /6 ,6 /6 /5 ,5 /5 /6 ,5 /6 /5 ,6 /5 /5 ,6 /6 /6 ,5 /6 /6 ,6 /5 /6 ,6 /6 /5 ,5 /5 /6 ,5 /6 /5 , </xnotran> 6-membered/5-membered tricyclic fused heterocyclic group, 6-membered/6-membered tricyclic fused aryl group, wherein hetero atoms in the heterocyclic group and the heteroaryl group are independently selected from O, N or S, and the number of hetero atoms is 1,2 or 3; the above groups are optionally substituted by n R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different; wherein n is selected from 0, 1,2 and 3.
Preferably, ring B is selected from the following structures, optionally substituted by n R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different, wherein n is selected from 0, 1,2 and 3:
even more preferably, ring B is selected from the following structures, optionally substituted by n R b Substituted when multiple R b Go out at the same timeAt the occurrence of each R b May be the same or different, wherein n is selected from 0, 1,2 and 3:
even more preferably, ring B is selected from the following structures optionally substituted by n R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different, wherein n is selected from 1,2 and 3:
even more preferably, ring B is selected fromSaid structure is optionally substituted by n R b Substituted when more than one R b At the same time, each R b May be the same or different, wherein n is selected from 1 or 2.
Preferably, R b -ring B is selected from the following structures:
even more preferably, R b -ring B is selected from the following structures:
in a preferred embodiment of the invention, R b Selected from halogen, cyano, hydroxy, nitro, amino, oxo, C 1-4 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-6 Cycloalkyl radical, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-to 10-membered heterocyclic group, C 6-12 Aryl, 5-10 membered heteroaryl, -C 1-4 alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-4-10 membered heterocyclyl, -C 1-4 alkyl-C 6-12 Aryl radical, -C 1-4 Alkyl-5-10 membered heteroaryl, -NH-C 3-8 Cycloalkyl, -NH-4-10 membered heterocyclyl, -NH-C 6-12 Aryl, -NH-5-10 membered heteroaryl, -NH-C 1-4 alkyl-C 3-8 Cycloalkyl, -NH-C 1-4 Alkyl-4-10 membered heterocyclyl, -NH-C 1-4 alkyl-C 6-12 Aryl, -NH-C 1-4 Alkyl-5-10 membered heteroaryl, -O-C 1-4 alkyl-C 3-8 Cycloalkyl, -O-C 1-4 Alkyl-4-10 membered heterocyclyl, -O-C 1-4 alkyl-C 6-12 Aryl and-O-C 1-4 Alkyl-5-10 membered heteroaryl; said C is 1-4 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-6 Cycloalkyl radical, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-to 10-membered heterocyclyl, C 6-12 Aryl, 5-10 membered heteroaryl, -C 1-4 alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-4-10 membered heterocyclyl, -C 1-4 alkyl-C 6-12 Aryl radical, -C 1-4 Alkyl-5-10 membered heteroaryl, -NH-C 3-8 Cycloalkyl, -NH-4-10 membered heterocyclyl, -NH-C 6-12 Aryl, -NH-5-10 membered heteroaryl, -NH-C 1-4 alkyl-C 3-8 Cycloalkyl, -NH-C 1-4 Alkyl-4-10 membered heterocyclyl, -NH-C 1-4 alkyl-C 6-12 Aryl, -NH-C 1-4 Alkyl-5-10 membered heteroaryl, -O-C 1-4 alkyl-C 3-8 Cycloalkyl, -O-C 1-4 Alkyl-4-10 membered heterocyclyl, -O-C 1-4 alkyl-C 6-12 Aryl and-O-C 1-4 Alkyl-5-10 membered heteroaryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, nitro, oxo, -NH (C) 1-3 Alkyl), -N (C) 1-3 Alkyl) (C) 1-3 Alkyl), -C (O) C 1-3 Alkyl, halo C 1-6 Alkyl radical, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Alkylthio radical, C 1-6 A hydroxyalkyl group.
Further preferably, R b Selected from halogen, cyano, hydroxy, nitro, amino, oxo, C 1-4 Alkyl radical, C 3-6 Cycloalkyl, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-10 membered heterocyclyl, -C 1-4 alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-4-10 membered heterocyclyl, -C 1-4 Alkyl-5-10 membered heteroaryl, -NH-C 3-8 Cycloalkyl, -NH-4-10 membered heterocyclyl, -NH-5-10 membered heteroaryl, -NH-C 1-4 alkyl-C 3-8 Cycloalkyl, -NH-C 1-4 Alkyl-4-10 membered heterocyclyl, -NH-C 1-4 Alkyl-5-10 membered heteroaryl, -O-C 1-4 alkyl-C 3-8 Cycloalkyl, -O-C 1-4 Alkyl-4-10 membered heterocyclyl and-O-C 1-4 Alkyl-5-10 membered heteroaryl; said C is 1-4 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-10 membered heterocyclyl, -C 1-4 alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-4-10 membered heterocyclyl, -C 1-4 Alkyl-5-10 membered heteroaryl, -NH-C 3-8 Cycloalkyl, -NH-4-10 membered heterocyclyl, -NH-5-10 membered heteroaryl, -NH-C 1-4 alkyl-C 3-8 Cycloalkyl, -NH-C 1-4 Alkyl-4-10 membered heterocyclyl, -NH-C 1-4 Alkyl-5-10 membered heteroaryl, -O-C 1-4 alkyl-C 3-8 Cycloalkyl, -O-C 1-4 Alkyl-4-10 membered heterocyclyl and-O-C 1-4 Alkyl-5-10 membered heteroaryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, nitro, oxo, -NH (C) 1-3 Alkyl), -N (C) 1-3 Alkyl) (C 1-3 Alkyl), -C (O) C 1-3 Alkyl radical, C 1-6 Alkyl radical, C 1-6 A hydroxyalkyl group.
Further preferably, R b Selected from halogen, cyano, hydroxy, nitro, amino, oxo, C 1-4 Alkyl radical, C 5-6 Cycloalkyl radical, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-6 membered heterocycloalkyl, 4-6 membered heterocycloalkenyl, 7-8 membered bicyclic heterocyclyl, -C 1-4 alkyl-C 3-6 Cycloalkyl, -C 1-4 Alkyl-4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkenyl, -NH-C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl; the heteroatom in the heterocycloalkyl, heterocycloalkenyl, heterocyclyl or heteroaryl is O or N, and the number of heteroatoms is 1,2 or 3; said C is 1-4 Alkyl radical, C 5-6 Cycloalkyl radical, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-6 membered heterocycloalkyl, 4-6 membered heterocycloalkenyl, 7-8 membered bicyclic heterocyclyl, -C 1-4 alkyl-C 3-6 Cycloalkyl, -C 1-4 Alkyl-4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkenyl, -NH-C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, nitro, oxo, -NH (C) 1-3 Alkyl), -N (C) 1-3 Alkyl) (C 1-3 Alkyl), -C (O) C 1-3 Alkyl radical, C 1-4 Alkyl radical, C 1-3 A hydroxyalkyl group.
Further preferably, R b Selected from halogen, cyano, hydroxy, nitro, amino, oxo, C 1-4 Alkyl radical, C 5-6 Cycloalkyl radical, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-6 membered heterocycloalkyl, 4-6 membered heterocycloalkenyl, 7-8 membered bicyclic heterocyclyl, -C 1-4 alkyl-C 3-6 Cycloalkyl, -C 1-4 Alkyl-4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkenyl, -NH-C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl; the heteroatom in the heterocycloalkyl, the heterocycloalkenyl, the heterocyclyl and the heteroaryl is O or N, and the number of the heteroatoms is 1 or 2; said C is 1-4 Alkyl radical、C 5-6 Cycloalkyl radical, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-6 membered heterocycloalkyl, 4-6 membered heterocycloalkenyl, 7-8 membered bicyclic heterocyclyl, -C 1-4 alkyl-C 3-6 Cycloalkyl, -C 1-4 Alkyl-4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkenyl, -NH-C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, nitro, oxo, -NHCH 3 、-N(CH 3 )(CH 3 )、-C(O)CH 3 Methyl, ethyl, hydroxymethyl.
Further preferably, R b Selected from the group consisting of halogen, cyano, hydroxy, nitro, amino, oxo, methyl, ethyl, n-propyl, isopropyl, methoxy, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-10 membered heterocyclyl, -CH 2 -cyclopropyl, -CH 2 -cyclobutyl, -CH 2 -cyclopentyl, -CH 2 -4-6 membered heterocyclyl, -CH 2 -5-6 membered heteroaryl, -NHCH 2 -cyclopropyl, -NHCH 2 -cyclobutyl, -NHCH 2 -cyclopentyl, -NHCH 2 -4-6 membered heterocyclyl, -NHCH 2 -5-6 membered heteroaryl, -NH-cyclopropyl, -NH-cyclobutyl, -NH-cyclopentyl, -NH-4-6 membered heterocyclyl, -NH-5-6 membered heteroaryl, -OCH 2 -cyclopropyl, -OCH 2 -cyclobutyl, -OCH 2 -cyclopentyl, -OCH 2 -4-6 membered heterocyclyl and-OCH 2 -5-6 membered heteroaryl, said methyl, ethyl, n-propyl, isopropyl, methoxy, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-10 membered heterocyclyl, -CH 2 -cyclopropyl, -CH 2 -cyclobutyl, -CH 2 -cyclopentyl, -CH 2 -4-6 membered heterocyclyl, -CH 2 -5-6 membered heteroaryl, -NHCH 2 -cyclopropyl, -NHCH 2 -cyclobutyl, -NHCH 2 -cyclopentyl, -NHCH 2 -4-6 membered heterocyclyl, -NHCH 2 -5-6 membered heteroaryl, -NH-cyclopropyl, -NH-cyclobutanRadical, -NH-cyclopentyl, -NH-4-6 membered heterocyclyl, -NH-5-6 membered heteroaryl, -OCH 2 -cyclopropyl, -OCH 2 -cyclobutyl, -OCH 2 -cyclopentyl, -OCH 2 -4-6 membered heterocyclyl and-OCH 2 -5-6 membered heteroaryl is unsubstituted or substituted by one or more of the following substituents, respectively: halogen, cyano, hydroxy, nitro, oxo, -NHCH 3 、-N(CH 3 )(CH 3 )、-C(O)CH 3 Methyl, ethyl, hydroxymethyl.
Preferably, R b Selected from the following structures: halogen, cyano, hydroxy, nitro, amino, oxo, methyl, ethyl, n-propyl, isopropyl, methoxy, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
Said above structure being unsubstituted or substituted by one or more of the following substituents, respectively: halogen, cyano, hydroxy, nitro, oxo, -NHCH 3 、-N(CH 3 )(CH 3 )、-C(O)CH 3 Methyl, ethyl, hydroxymethyl.
Further preferably, R b Selected from halogen, cyano, hydroxy, nitro, amino, oxo, methyl ethyl, n-propyl, isopropyl methoxy, methylthio, methoxy-N-methyl,
Further preferably, R b Selected from the group consisting of halogen, cyano, hydroxy, nitro, amino, oxo, methyl ethyl, n-propyl, isopropyl, methoxy, methylthio, methyl,
Most preferably, R b Selected from the group consisting of halogen, cyano, hydroxy, nitro, amino, oxo, methyl ethyl, n-propyl, isopropyl, methoxy, methylthio, methyl,
In a preferred embodiment of the invention, ring B is selected from 9-10 membered bicyclic heteroaryl and 9-10 membered bicyclic heterocyclyl, said 9-10 membered bicyclic heteroaryl and 9-10 membered bicyclic heterocyclyl being optionally substituted by n R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different, wherein n is selected from 1 or 2; r b Selected from halogen, oxo, C 1-6 Alkyl, -C 1-4 Alkyl-4-6 membered heterocycloalkyl, C 5-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl, said C 1-6 Alkyl, -C 1-4 Alkyl-4-6 membered heterocycloalkyl, C 5-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, C 1-4 An alkyl group; the heteroatom in the heterocycloalkyl and heteroaryl is O or N, and the number of the heteroatoms is 1 or 2.
In a preferred embodiment of the invention, ring B is selected from 9-10 membered bicyclic heteroaryl and 9-10 membered bicyclic heterocyclyl, said 9-10 membered bicyclic heteroaryl and 9-10 membered bicyclic heterocyclyl being optionally substituted by n R b Substituted when multiple R b At the same time, each R b May be the same or different, wherein n is selected from 1 or 2; r b Selected from halogen, oxo, C 1-4 Alkyl, -C 1-4 Alkyl-4-6 membered heterocycloalkyl, C 5-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl, said C 1-6 Alkyl, -C 1-4 Alkyl-4-6 membered heterocycloalkyl, C 5-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, methyl; the heteroatom in the heterocycloalkyl and heteroaryl is O or N, and the number of the heteroatoms is 1 or 2.
In a preferred embodiment of the invention, R 1 Selected from 4-12 membered heterocyclyl, 5-12 membered heteroaryl; the 4-12 membered heterocyclyl, 5-12 membered heteroaryl are unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, -NH-C (O) C 1-3 Alkyl, halo C 1-6 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl, -C 1-3 alkyl-N (C) 1-3 Alkyl) C 1-3 Alkyl radical, C 1-6 Alkyl radical, C 3-8 Cycloalkyl, C 1-6 Alkoxy radical, C 1-6 A hydroxyalkyl group.
Preferably, R 1 Selected from 5-10 membered heterocyclyl, 6-10 membered heteroaryl; the 5-10 membered heterocyclyl, 6-10 membered heteroaryl are unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, -NH-C (O) C 1-3 Alkyl, halo C 1-6 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl, -C 1-3 alkyl-N (C) 1-3 Alkyl) C 1-3 Alkyl radical, C 1-3 Alkyl radical, C 3-6 Cycloalkyl, C 1-3 Alkoxy radical, C 1-3 A hydroxyalkyl group.
Further preferably, R 1 Selected from the group consisting of 5-6 membered heterocycloalkyl, 9-10 membered bicyclic heterocyclyl, 6 membered monocyclic heteroaryl, 9-10 membered bicyclic heteroaryl; the heteroatom in the heterocycloalkyl, the heterocyclic group and the heteroaryl is O or N, and the number of the heteroatoms is 1,2 or 3; the 5-6 membered heterocycloalkyl, 9-10 membered bicyclic heterocyclyl, 6 membered monocyclic heteroaryl, 9-10 membered bicyclic heteroaryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, -NH-C (O) C 1-3 Alkyl, halo C 1-3 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl, -C 1-3 alkyl-N (C) 1-3 Alkyl) C 1-3 Alkyl radical, C 1-3 Alkyl radical, C 3-6 Cycloalkyl, C 1-3 Alkoxy radical, C 1-3 A hydroxyalkyl group.
Further preferably, R 1 Selected from the group consisting of 5-6 membered heterocycloalkyl, 5-membered/6-membered bicyclic fused heterocyclyl, 6-membered/5-membered bicyclic fused heterocyclyl, 6-membered/6-membered bicyclic fused heterocyclyl, 6-membered monocyclic heteroaryl, 5-membered/6-membered bicyclic fused heteroaryl, 6-membered/5-membered bicyclic fused heteroaryl, 6-membered/6-membered bicyclic fused heteroaryl; the heteroatom in the heterocycloalkyl, the heterocyclic group and the heteroaryl is O or N, and the number of the heteroatoms is 1,2 or 3; the 5-6 membered heterocycloalkyl group, the 5-membered/6-membered bicyclic fused heterocyclic group, the 6-membered/5-membered bicyclic fused heterocyclic group, the 6-membered/6-membered bicyclic fused heterocyclic group, the 6-membered monocyclic heteroaryl group, the 5-membered/6-membered bicyclic fused heteroaryl group, the 6-membered/5-membered bicyclic fused heteroaryl group, the 6-membered/6-membered bicyclic fused heteroaryl group are unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methoxy, -NH-C (O) CH 3 、-CH 2 NHCH 3 Trifluoromethyl, difluoromethyl, monofluoromethyl, hydroxymethyl.
In a preferred embodiment of the invention, R 1 Selected from the group consisting of 4-12 membered heterocyclyl, 5-12 membered heteroaryl, and C 6-12 An aryl group; the 4-12 membered heterocyclic group, 5-12 membered heteroaryl group and C 6-12 Aryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, amino, hydroxy, nitro, oxo, -NH (C) 1-3 Alkyl), -N (C) 1-3 Alkyl) (C 1-3 Alkyl), -C 1-3 alkyl-NH 2 、-NH-C(O)C 1-3 Alkyl, -C (O) C 1-3 Alkyl, halo C 1-3 Alkyl radical, C 1-3 Alkyl radical, C 3-8 Cycloalkyl radical, C 1-3 Alkoxy radical, C 1-3 Alkylthio radical, C 1-3 A hydroxyalkyl group.
Preferably, R 1 Selected from the group consisting of 5-10 membered heterocyclyl, 6-10 membered heteroaryl and C 6-10 An aryl group; the 5-to 10-membered heterocyclic group, 6-to 10-membered heteroaryl group and C 6-10 Aryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, nitro, oxo, -NHCH 3 、-N(CH 3 )(CH 3 )、-NH-C(O)CH 3 、-C(O)CH 3 Methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methoxy, methylthio, trifluoromethyl, difluoromethyl, monofluoromethyl.
Preferably, R 1 Is monocyclic, bicyclic or tricyclic, including spiro and fused rings; more preferably, ring B is monocyclic or bicyclic.
Preferably, R 1 Selected from phenyl, 5-7 membered monocyclic heteroaryl, 5-7 membered monocyclic heterocyclyl, naphthyl, 8-14 membered bicyclic heteroaryl, 8-14 membered bicyclic heterocyclyl.
Preferably, R 1 Selected from phenyl, 5-7 membered monocyclic heteroaryl, 5-7 membered monocyclic heterocyclyl, naphthyl, 8-14 membered bicyclic fused ring heteroaryl, 8-14 membered bicyclic fused ring heterocyclyl.
Further preferably, R 1 Is selected from C 6 Aryl, 5-membered monocyclic heteroaryl, 6-membered monocyclic heteroaryl, 7-membered monocyclic heteroaryl, 5-membered monocyclic heterocyclyl, 6-membered monocyclic heterocyclyl, 7-membered monocyclic heterocyclyl, 6/6-membered bicyclic fused aryl, 4-membered/4-membered bicyclic fused heteroaryl, 4-membered/5-membered bicyclic fused heteroaryl, 5-membered/4-membered bicyclic fused heteroaryl, 5-membered/5-membered bicyclic fused heteroaryl, 5-membered/6-membered bicyclic fused heteroaryl, 6-membered/5-membered bicyclic fused heteroaryl, 4-membered/6-membered bicyclic fused heteroaryl, 6-membered/4-membered bicyclic fused heteroaryl, 6-membered/6-membered bicyclic fused heteroaryl, 4-membered/4-membered bicyclic fused heterocyclyl, 4-membered/5-membered bicyclic fused heterocyclyl, 5-membered/4-membered bicyclic fused heterocyclyl, 5-membered/6-membered bicyclic fused heterocyclyl, 6-membered/5-membered bicyclic fused heterocyclyl, 4-membered/6-membered bicyclic fused heterocyclyl, 6-membered/6-membered bicyclic fused heterocyclyl, heteroaryl, O, N is 1 heteroatom selected from 1 or N is 3; r is as defined above 1 The group is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, nitro, oxo, -NHCH 3 、-N(CH 3 )(CH 3 )、-NH-C(O)CH 3 、-C(O)CH 3 Methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methoxy, methylthio, trifluoromethyl, difluoromethyl, monofluoromethyl.
Even more preferably, R 1 Selected from the following structures, which are unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, nitro, oxo, -NHCH 3 、-N(CH 3 )(CH 3 )、-NH-C(O)CH 3 、-C(O)CH 3 Methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methoxy, methylthio, trifluoromethyl, difluoromethyl, monofluoromethyl:
even more preferably, R 1 Selected from the following structures:
most preferably, R 1 Selected from the following structures:
in a preferred embodiment of the invention, R 1 Selected from 6-membered monocyclic heteroaryl, 9-10-membered bicyclic heteroaryl; the heteroatom in the heteroaryl is O or N, and the number of the heteroatoms is 1,2 or 3; the 6-membered monocyclic heteroaryl and the 9-10-membered bicyclic heteroaryl are unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, -NH-C (O) C 1-3 Alkyl, halo C 1-3 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl, -C 1-3 alkyl-N (C) 1-3 Alkyl) C 1-3 Alkyl radical, C 1-3 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-3 Alkoxy radical, C 1-3 A hydroxyalkyl group.
Preference is given toOf (A) R 1 Selected from 6-membered monocyclic heteroaryl, 9-membered bicyclic heteroaryl; the heteroatom in the heteroaryl is N, and the number of the heteroatoms is 1 or 2; the 6-membered monocyclic heteroaryl and the 9-membered bicyclic heteroaryl are unsubstituted or substituted by one or more of the following substituents, respectively: which is unsubstituted or substituted, respectively, by one or more of the following substituents: halogen, hydroxy, halogeno C 1-3 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl radical, C 1-3 Alkyl radical, C 1-3 A hydroxyalkyl group.
Further preferably, R 1 Selected from 6-membered monocyclic heteroaryl, 5-membered/6-membered bicyclic fused heteroaryl, 6-membered/5-membered bicyclic fused heteroaryl, 6-membered/6-membered bicyclic fused heteroaryl; the heteroatom in the heteroaryl is N, and the number of the heteroatoms is 1 or 2; the 5-membered/6-membered bicyclic fused heteroaryl, 6-membered/5-membered bicyclic fused heteroaryl, 6-membered/6-membered bicyclic fused heteroaryl is unsubstituted or substituted with one or more of the following substituents, respectively: which is unsubstituted or substituted, respectively, by one or more of the following substituents: halogen, -C 1-3 alkyl-NH-C 1-3 Alkyl radical, C 1-3 Alkyl radical, C 1-3 A hydroxyalkyl group.
Further preferably, R 1 Selected from the following structuresWhich is unsubstituted or substituted, respectively, by one or more of the following substituents: fluorine, chlorine, bromine, -CH 2 NHCH 3 Methyl, hydroxymethyl.
Further preferably, R 1 Selected from the following structures:
in a preferred embodiment of the invention, R 2 And R 3 Independently selected from hydrogen, methyl; or R 2 And R 3 Together with the atoms to which they are attached form a 5-or 6-membered heterocyclic ring.
Preferably, the first and second liquid crystal materials are,R 2 and R 3 Independently selected from hydrogen, methyl; or R 2 And R 3 Together with the atoms to which they are attached form a 5-membered heterocycloalkyl group in which the heteroatom is N, or a 6-membered heterocycloalkyl group, the number of heteroatoms being 2.
Further preferably, R 2 And R 3 Independently selected from hydrogen, methyl; or R 2 And R 3 Together with the atoms to which they are attached form a 5-membered heterocycloalkyl or a 6-membered heterocycloalkyl in which the heteroatom is N, the number of heteroatoms is 2, and X is S.
In a preferred embodiment of the invention, ring B is selected from phenyl optionally substituted by n R b Substituted when more than one R b When occurring simultaneously, each R b May be the same or different, wherein n is selected from 1,2 and 3; r is 1 Selected from 5-10 membered bicyclic heterocyclyl, 6-10 membered bicyclic heteroaryl; the 5-10 membered bicyclic heterocyclyl, 6-10 membered bicyclic heteroaryl are unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, -NH-C (O) C 1-3 Alkyl, halo C 1-6 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl, -C 1-3 alkyl-N (C) 1-3 Alkyl) C 1-3 Alkyl radical, C 1-6 Alkyl radical, C 3-8 Cycloalkyl, C 1-6 Alkoxy radical, C 1-6 A hydroxyalkyl group.
Preferably, ring B is selected from phenyl optionally substituted by n R b Substituted when more than one R b At the same time, each R b May be the same or different, wherein n is selected from 1,2 and 3; r is 1 Selected from 9-10 membered bicyclic heterocyclyl, 9-10 membered bicyclic heteroaryl; the 9-10 membered bicyclic heterocyclic group, 9-10 membered bicyclic heteroaryl group are unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, -NH-C (O) C 1-3 Alkyl, halo C 1-6 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl, -C 1-3 alkyl-N (C) 1-3 Alkyl) C 1-3 Alkyl radical, C 1-3 Alkyl radical, C 3-6 Cycloalkyl, C 1-3 Alkoxy radical, C 1-3 A hydroxyalkyl group.
Further preferably, ring B is selected from phenyl optionally substituted by n R b Substituted when more than one R b At the same time, each R b May be the same or different, wherein n is selected from 1,2 and 3; r 1 Selected from the group consisting of 5-membered/6-membered bicyclic fused heterocyclic group, 6-membered/5-membered bicyclic fused heterocyclic group, 6-membered/6-membered bicyclic fused heterocyclic group, 5-membered/6-membered bicyclic fused heteroaryl group, 6-membered/5-membered bicyclic fused heteroaryl group, 6-membered/6-membered bicyclic fused heteroaryl group; the heteroatom in the heterocyclic group and the heteroaryl group is O or N, and the number of the heteroatoms is 1,2 or 3; the 5-membered/6-membered bicyclic fused heterocyclic group, the 6-membered/5-membered bicyclic fused heterocyclic group, the 6-membered/6-membered bicyclic fused heterocyclic group, the 5-membered/6-membered bicyclic fused heteroaryl group, the 6-membered/5-membered bicyclic fused heteroaryl group, the 6-membered/6-membered bicyclic fused heteroaryl group are unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methoxy, -NH-C (O) CH 3 、-CH 2 NHCH 3 Trifluoromethyl, difluoromethyl, monofluoromethyl, hydroxymethyl.
In a preferred embodiment of the invention ring B is selected from phenyl optionally substituted with 2R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different; r b Selected from methyl,R 1 Is selected from C 1-3 And (b) one or more optionally substituted pyridyl groups in the alkyl group.
Preferably, R b -ring B is selected from the following structures:
In a preferred embodiment of the present invention, the compound represented by formula (I), or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof, is selected from the group consisting of:
the invention also aims to provide a method for preparing the compound shown in the formula (I) or a prodrug, a tautomer, a stereoisomer, a solvate, an isotopic derivative or a pharmaceutically acceptable salt thereof.
The compounds can be prepared by the following procedure.
The method comprises the following general steps:
a general step two:
a third general step:
wherein, in the preparation method, each substituent group in the compound is defined as the above.
The invention also provides a pharmaceutical composition which comprises the compound shown in the formula (I) shown in the invention, or a prodrug, a tautomer, a stereoisomer, a solvate, an isotopic derivative or a pharmaceutically acceptable salt thereof.
The invention also provides a medicinal composition which comprises the compound shown in the formula (I) shown in the invention, or a prodrug, a tautomer, a stereoisomer, a solvate, an isotope derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary material.
Administration of a compound of the present invention or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative or pharmaceutically acceptable salt thereof, can be carried out in pure form or in the form of a suitable pharmaceutical composition by any acceptable mode of administration which provides the drug for analogous use. The pharmaceutical compositions of the present invention may be prepared by combining a compound of the present invention with suitable pharmaceutically acceptable excipients. The pharmaceutical compositions of the present invention may be formulated as solid, semi-solid, liquid or gaseous formulations.
The invention also aims to provide the application of the compound shown in the formula (I) in the invention, or a prodrug, a tautomer, a stereoisomer, a solvate, an isotopic derivative or a pharmaceutically acceptable salt thereof in preparing medicines for treating diseases mediated by the POLQ.
In some embodiments, the POLQ-mediated disease is cancer or a tumor-associated disease.
Further, the present invention provides the use wherein the cancer or tumor comprises a solid tumor and a hematological tumor; the solid tumors comprise breast cancer, colorectal cancer, cervical cancer, ovarian cancer, prostatic cancer, gastric cancer (comprising gastrointestinal junction cancer), esophageal cancer, head and neck cancer and lung cancer; the hematologic tumors include lymphomas and leukemias.
An object of the present invention also includes providing a method for preventing and/or treating a disease mediated by POLQ, which comprises administering to a patient a therapeutically effective dose of a compound represented by the general formula (I), or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to the present invention; further, the POLQ-mediated disease is cancer or a tumor-related disease; further, the present invention provides the use wherein the cancer or tumor comprises a solid tumor and a hematological tumor; the solid tumors comprise breast cancer, colorectal cancer, cervical cancer, ovarian cancer, prostatic cancer, gastric cancer (comprising gastrointestinal junction cancer), esophageal cancer, head and neck cancer and lung cancer; the hematologic tumors include lymphomas and leukemias.
The compound represented by the general formula (I) of the present invention, or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof, may be administered in combination with one, two, or more additional anticancer agents or immune checkpoint modulators for treating cancer or tumor.
Further, the additional anti-cancer agents or immune checkpoint modulators for the treatment of cancer or tumor comprise PARP inhibitors, ATR inhibitors, ATM inhibitors, WEE1 inhibitors, topoisomerase inhibitors and DNA damaging chemotherapeutic agents.
Further, the DNA damage chemotherapeutic drug comprises cisplatin, bleomycin, gemcitabine and docetaxel; the topoisomerase inhibitor comprises etoposide and irinotecan.
The compound shown in the general formula (I) or a prodrug, a tautomer, a stereoisomer, a solvate, an isotope derivative or a pharmaceutically acceptable salt thereof can be used in combination with one or two or more other treatment means (such as radiotherapy) for treating cancer or tumors.
When the compound of the present invention, or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof, is administered in combination with another anticancer agent or immune checkpoint inhibitor for the treatment of cancer or tumor, the compound of the present invention, or a pharmaceutically acceptable salt thereof, may provide enhanced anticancer effects.
Definition of
The terms "optional," "any," "optionally," or "optionally" refer to a subsequently described event or circumstance which may, but need not, occur, and include instances where said event or circumstance occurs and instances where it does not.
The term "oxo" means that two hydrogen atoms at the same substitution position are replaced by the same oxygen atom to form a double bond, i.e. = O.
Unless otherwise specified, the term "alkyl" refers to a monovalent saturated aliphatic hydrocarbon group, a straight or branched chain group containing 1-20 carbon atoms, preferably 1-10 carbon atoms (i.e., C) 1-10 Alkyl group), further preferably containing 1 to 8 carbon atoms (C) 1-8 Alkyl), more preferably containing 1 to 6 carbon atoms (i.e., C) 1-6 Alkyl) such as "C 1-6 By alkyl is meant that the group is alkyl and the number of carbon atoms in the carbon chain is between 1 and 6 (specifically 1,2,3,4, 5 or 6). Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, neopentyl, 1-dimethylpropyl, 1, 2-dimethylpropyl, 2-dimethylpropylAlkyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, n-heptyl, n-octyl and the like.
Unless otherwise specified, the term "alkenyl" refers to a straight or branched chain unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms having at least one double bond. The alkenyl group may contain 2 to 20 carbon atoms, preferably 2 to 10 carbon atoms (i.e., C) 2-10 Alkenyl), further preferably containing 2 to 8 carbon atoms (C) 2-8 Alkenyl), more preferably containing 2 to 6 carbon atoms (i.e., C) 2-6 Alkenyl), 2-5 carbon atoms (i.e., C) 2-5 Alkenyl), 2-4 carbon atoms (i.e., C) 2-4 Alkenyl), 2-3 carbon atoms (i.e., C) 2-3 Alkenyl), 2 carbon atoms (i.e., C) 2 Alkenyl) such as "C 2-6 By alkenyl "is meant that the group is alkenyl and the number of carbon atoms in the carbon chain is between 2 and 6 (specifically 2,3,4, 5 or 6). Non-limiting examples of alkenyl groups include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl, and 1, 3-butadienyl, and the like.
Unless otherwise specified, the term "alkynyl" refers to a straight or branched chain unsaturated aliphatic hydrocarbon group having at least one triple bond consisting of carbon atoms and hydrogen atoms. Alkynyl groups may contain 2-20 carbon atoms, preferably 2-10 carbon atoms (i.e., C) 2-10 Alkynyl) and further preferably contains 2 to 8 carbon atoms (C) 2-8 Alkynyl) and more preferably contains 2 to 6 carbon atoms (i.e., C) 2-6 Alkynyl), 2-5 carbon atoms (i.e., C) 2-5 Alkynyl), 2-4 carbon atoms (i.e., C) 2-4 Alkynyl), 2-3 carbon atoms (i.e., C) 2-3 Alkynyl), 2 carbon atoms (i.e., C) 2 Alkynyl), for example "C 2-6 Alkynyl "means that the group is alkynyl and the number of carbon atoms in the carbon chain is between 2 and 6 (specifically 2,3,4, 5 or 6). Non-limiting examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, and the like.
Unless otherwise specified, the term "cycloalkyl" refers to a monocyclic saturated aliphatic radical having the specified number of carbon atoms, preferably comprising 3 to 12 carbon atoms (i.e., C) 3-12 Cycloalkyl), more preferably containing 3 to 10 carbon atoms (C) 3-10 Cycloalkyl radicals) Further, 3 to 6 carbon atoms (C) are preferable 3-6 Cycloalkyl), 4 to 6 carbon atoms (C) 4-6 Cycloalkyl), 5 to 6 carbon atoms (C) 5-6 Cycloalkyl). Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methylcyclopropyl, 2-ethyl-cyclopentyl, dimethylcyclobutyl, and the like.
Unless otherwise specified, the term "alkoxy" refers to an-O-alkyl group, as defined above, i.e. containing 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, preferably 1 to 8 carbon atoms, more preferably 1 to 6 carbon atoms (specifically 1,2,3,4, 5 or 6). Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, tert-butoxy, pentyloxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 1-dimethylpropoxy, 1, 2-dimethylpropoxy, 2-dimethylpropoxy, 1-ethylpropoxy, and the like.
Unless otherwise specified, the term "alkylthio" refers to the replacement of the oxygen in the above-mentioned "alkoxy" by sulfur, i.e., -S-alkyl, which is as defined above, i.e., contains 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, preferably 1 to 8 carbon atoms, more preferably 1 to 6 carbon atoms (specifically 1,2,3,4, 5 or 6). Representative examples include, but are not limited to, methylthio, ethylthio, propylthio, isopropylthio, butylthio, 1-methylpropylthio, tert-butylthio, pentylthio, 1-dimethylpropylthio, 1, 2-dimethylpropylthio, and the like. .
The term "halogen" or "halo" means, unless otherwise specified, F, cl, br, I. The term "haloalkyl" means an alkyl group as defined above wherein one, two or more hydrogen atoms or all hydrogen atoms are replaced by halogen. Representative examples of haloalkyl groups include CCl 3 、CF 3 、CHCl 2 、CH 2 Cl、CH 2 Br、CH 2 I、CH 2 CF 3 、CF 2 CF 3 And the like.
Unless otherwise specified, the term "heterocyclyl" means a saturated or partially unsaturated monocyclic, bicyclic or polycyclic cyclic hydrocarbon substituent, which isA non-aromatic structure comprising 3 to 20 ring atoms, wherein 1,2,3 or more ring atoms are selected from N, O or S, the remaining ring atoms being C. Preferably 3 to 12 ring atoms, further preferably 3 to 10 ring atoms, or 3 to 8 ring atoms, or 3 to 6 ring atoms, or 4 to 6 ring atoms, or 5 to 6 ring atoms. The heteroatoms are preferably 1-4, more preferably 1-3 (i.e. 1,2 or 3). Examples of monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, dihydropyrrolyl, piperidinyl, piperazinyl, pyranyl, and the like. Bicyclic or polycyclic heterocyclic groups include heterocyclic groups that are spiro, fused, and bridged. "Heterocyclyl" bicyclic or polycyclic rings include those wherein one ring is aromatic and the other ring is non-aromatic, including spiro, fused and bridged rings. Heterocyclyl groups may be monocyclic (monocyclic heterocyclyl) ring systems, or fused (fused or heterofused ring groups), bridged (heterobridged or bridged heterocyclyl) or spiro-connected (heterospiro or spiroheterocyclyl) ring systems, such as bicyclic ring systems (bicyclic heterocyclyl), and may be saturated or partially unsaturated. Bicyclic heterocyclic groups may contain one or more heteroatoms in one or both rings. In some embodiments, heterocyclyl also includes ring systems in which heterocyclyl as defined above is fused to one or more carbocyclyl groups, wherein the point of attachment is on the carbocyclyl or heterocyclyl ring; alternatively, in some embodiments, heterocyclyl further includes a ring system wherein heterocyclyl is fused to one or more aryl/heteroaryl groups as defined above, wherein the point of attachment is on the aryl/heteroaryl or heterocyclyl ring; alternatively, in some embodiments, a heterocyclyl group as defined above is a fused ring system of one or more heterocyclyl groups as defined above wherein the point of attachment is on any heterocyclyl ring. In the above case, the number of elements of the heterocyclic ring system is the number of ring atoms of the ring system after fusion. In some embodiments, a heterocyclyl is optionally substituted, e.g., unsubstituted (unsubstituted heterocyclyl) or substituted (substituted heterocyclyl) with one or more substituents. Exemplary 3-membered heterocyclic groups containing 1 heteroatom include, but are not limited to, aziridinyl (aziridyl), oxacyclopropaneyl (oxarenyl), and thiacyclopropanyl (thiorenyl). Containing 1 hetero atomExemplary 4-membered heterocyclic groups of (a) include, but are not limited to, azetidinyl, oxetanyl and thietanyl. Exemplary 5-membered heterocyclic groups containing 1 heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, pyrrolidinyl, dihydropyrrolyl, and 2, 5-dioxopyrrolidinyl. Exemplary 5-membered heterocyclic groups containing 2 heteroatoms include, but are not limited to, dioxolanyl, oxathiacyclopentane, dithiolane, each 2-oxooxazolidinyl. Exemplary 5-membered heterocyclic groups containing 3 heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl and thiadiazolinyl. Exemplary 6-membered heterocyclic groups containing 1 heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and tetrahydrothiopyranyl (thianyl). Exemplary 6-membered heterocyclic groups containing 2 heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclic groups containing 3 heteroatoms include, but are not limited to, triazinylalkyl (triazinanyl), oxadiazinylalkyl (oxadiazinanyl), thiadiazinylalkyl (thiadiazinanyl), oxathiazinoalkyl (oxathiazinanyl), and dioxazinylalkyl (dioxazinanyl). Exemplary 7-membered heterocyclic groups containing 1 heteroatom include, but are not limited to, azepanyl, oxepinyl, and thiepanyl. Exemplary 8-membered heterocyclic groups containing 1 heteroatom include, but are not limited to, azacyclooctyl, oxocyclooctyl, and thiacyclooctyl. Condensed to a C 6 Exemplary 5-membered heterocyclic groups on the aryl ring (also referred to herein as 5, 6-bicyclic heterocyclic groups) include, but are not limited to, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolonyl, and the like. Condensed to a C 6 Exemplary 6-membered heterocyclyl groups on the aryl ring (also referred to herein as 6, 6-bicyclic heterocyclyl groups) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
Unless otherwise specified, the terms "fused ring group" and "fused ring" refer to aromatic, nonaromatic, saturated or partially unsaturated ring systems formed from two or more ring structures that share two adjacent atoms with each other. Illustrative examples of "fused rings" include (but are not limited to)And the like.
Unless otherwise specified, the terms "fused heterocyclic group", "fused ring heterocyclic group", and "fused ring heterocyclic group" refer to a non-aromatic, saturated, or partially unsaturated ring system formed by two or more ring structures sharing two adjacent atoms with each other, the ring atoms containing one or more heteroatoms independently selected from oxygen, nitrogen, and sulfur, the number of heteroatoms being 1,2,3, or more. Illustrative examples of "fused ring heterocyclyl" include (but are not limited to) And the like.
Unless otherwise specified, the terms "fused ring heteroaryl", "fused heteroaryl group" and "fused heteroaryl group" refer to an aromatic ring system formed by two or more ring structures sharing two adjacent atoms with each other, the ring atoms containing one or more heteroatoms independently selected from oxygen, nitrogen and sulfur, the number of heteroatoms being 1,2,3 or more. Illustrative examples of "fused ring heteroaryl" include (but are not limited to)And the like.
Unless otherwise specified, the terms "spirocyclic group", "spirocyclic ring" and "spirocyclic ring" refer to a saturated, monovalent aliphatic hydrocarbon group containing only one spiro carbon atom, which may contain from 6 to 14, preferably from 7 to 10, ring carbon atoms. Spiro ring groups include 3-membered/5-membered, 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, and 5-membered/6-membered spiro ring groups, etc., in which spiro atoms are respectively counted as the number of elements in each ring. Illustrative examples of spiro ring groups include (but are not limited to)And so on.
Unless otherwise specifiedThe terms "heterospirocyclic group", "spirocyclic heterocyclyl" refer to a saturated, monovalent aliphatic group containing only one spiro carbon atom, which may contain 6 to 14 ring atoms, preferably 7 to 10 ring atoms, of which 1 to 4 ring heteroatoms, preferably 1 to 3 (i.e. 1,2 or 3) ring heteroatoms, are included, and the heteroatoms are independently selected from N, O and S. Heterospirocyclic groups include 3-membered/5-membered, 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, and 5-membered/6-membered heterospirocyclic groups, etc., in which the number of spiro atoms is counted individually for each ring. Illustrative examples of heterocyclic groups include (but are not limited to)And so on.
Unless otherwise specified, the terms "bridged ring group", "bridged ring" refer to a polycyclic, monovalent aliphatic hydrocarbon group in which any two rings share two ring carbon atoms not directly connected, which may contain from 5 to 20 ring carbon atoms, preferably from 6 to 14 ring carbon atoms, more preferably from 7 to 10 ring carbon atoms, and may contain one or more double bonds, but none of the rings has a completely conjugated pi-electron system. The bridged ring group includes a bicyclic, tricyclic, tetracyclic or polycyclic bridged ring group, preferably a bicyclic, tricyclic or tetracyclic bridged ring group, more preferably a bicyclic or tricyclic bridged ring group. Illustrative examples of bridge ring groups include (but are not limited to)
Unless otherwise specified, the terms "heterobridged cyclic group", "bridged heterocyclic group" refer to a polycyclic, monovalent aliphatic group in which any two rings share two ring atoms which are not directly connected, which may contain 5 to 14 ring atoms, preferably 6 to 14 ring atoms, more preferably 7 to 10 ring atoms, of which 1 to 4 ring heteroatoms, preferably 1 to 3 (i.e., 1,2, or 3) ring heteroatoms, are independently selected from N, O, and S, and may contain one or more double bonds, but none of the rings have a completely conjugated pi-electron system. Heterobridged ring groups include bicyclic, tricyclic, tetracyclic or polycyclic heterobridged ring groups, preferably bicyclic, tricyclic or tetracyclic heterobridged ring groups, more preferably bicyclic or tricyclicHeterobridged ring radicals. Illustrative examples of heterobridged ring groups include (but are not limited to)
Unless otherwise specified, "heterocycloalkyl" means a monocyclic, saturated "heterocyclyl" or "heterocycle" as defined above, the ring atoms being as defined above, i.e. comprising from 3 to 20 ring atoms ("3-20 membered heterocycloalkyl"), the number of heteroatoms being from 1 to 4 (1, 2,3 or 4), preferably from 1 to 3 (1, 2 or 3), wherein the heteroatoms are each independently selected from N, O or S. Preferably 3 to 12 ring atoms ("3-12 membered heterocycloalkyl"), more preferably 3 to 10 ring atoms ("3-10 membered heterocycloalkyl"), even more preferably 3 to 8 ring atoms ("3-8 membered heterocycloalkyl"), even more preferably 4 to 7 ring atoms ("4-7 membered heterocycloalkyl"), even more preferably 5 to 10 ring atoms ("5-10 membered heterocycloalkyl"), even more preferably 5 to 6 ring atoms ("5-6 membered heterocycloalkyl"). In certain embodiments, each instance of heterocycloalkyl is independently optionally substituted, e.g., unsubstituted (an "unsubstituted heterocycloalkyl") or substituted (a "substituted heterocycloalkyl") with one or more substituents. The "heterocyclyl" or "heterocyclic" moieties above have given some exemplary "heterocycloalkyl" and also include, but are not limited to, aziridinyl, oxacyclopropaneyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, tetrahydrofuranyl, oxacyclohexylyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, oxathiacyclohexyl, oxazolidinyl, dioxanyl, dithiacyclohexyl, thiazolidinyl, pyrrolidinyl, pyrazolidinyl, imidazolinidinyl, and the like.
Unless otherwise specified, the term "aryl" denotes monocyclic, bicyclic and tricyclic aromatic carbocyclic ring systems containing from 6 to 16 carbon atoms, or from 6 to 14 carbon atoms, or from 6 to 12 carbon atoms, or from 6 to 10 carbon atoms, preferably from 6 to 10 carbon atoms, and the term "aryl" may be used interchangeably with the term "aromatic ring". Examples of the aryl group may include, but are not limited to, phenyl, naphthyl, anthryl, phenanthryl, pyrenyl, or the like.
Unless otherwise specified, the term "heteroaryl" denotes an aromatic monocyclic, bicyclic or polycyclic ring system containing a 5-16 membered structure, preferably a 5-14 membered structure, a 5-12 membered structure, a 5-10 membered structure, a 5-8 membered structure, more preferably a 5-6 membered structure, wherein 1,2,3 or more ring atoms are heteroatoms and the remaining atoms are carbon, the heteroatoms are independently selected from O, N or S, the number of heteroatoms being preferably 1,2 or 3. Bicyclic or polycyclic heterocyclic groups include fused ring heteroaryl groups. Examples of heteroaryl groups include, but are not limited to, furyl, thienyl, oxazolyl, thiazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiadiazolyl, triazinyl, phthalazinyl, quinolinyl, isoquinolinyl, pteridinyl, purinyl, indolyl, isoindolyl, indazolyl, benzofuranyl, benzothienyl, benzopyridyl, benzopyrimidinyl, benzopyrazinyl, benzimidazolyl, phthalizinyl, pyrrolo [2,3-b ] pyridyl, imidazo [1,2-a ] pyridyl, pyrazolo [1,5-a ] pyrimidinyl, imidazo [1,2-b ] pyridazinyl, [1,2,4] triazolo [4,3-b ] pyridazinyl, [1,2,4] triazolo [1,5-a ] pyrimidinyl, [1,2,4] triazolo [1,5-a ] pyridyl, and the like.
Unless otherwise specified, the term "pharmaceutically acceptable salt" or "pharmaceutically acceptable salt" refers to salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of mammals, particularly humans, without excessive toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio, such as the medically acceptable salts of amines, carboxylic acids, and other types of compounds, are well known in the art. The salts may be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base or free acid with a suitable reagent.
The term "isotopic derivative" means, unless otherwise specified, that a compound of the present invention can exist in an isotopically labeled or enriched form, containing one or more atoms having an atomic mass or mass number different from the most naturally found atomThe atomic mass or mass number of a plurality of atoms. The isotope may be a radioactive or non-radioactive isotope. Isotopes commonly used as isotopic labels are: an isotope of hydrogen, 2 h and 3 h; carbon isotope: 13 c and 14 c; chlorine isotope: 35 cl and 37 cl; fluorine isotope: 18 f; iodine isotope: 123 i and 125 i; nitrogen isotope: 13 n and 15 n; oxygen isotope: 15 O, 17 o and 18 isotopes of O and sulfur 35 And S. These isotopically labeled compounds can be used to study the distribution of pharmaceutically acceptable molecules in tissues. In particular to 3 H and 13 c, because they are easy to label and convenient to detect, they are more widely used. Certain heavy isotopes, such as heavy hydrogen (c: (b)) 2 H) The substitution of (2) can enhance the metabolic stability and prolong the half-life period, thereby achieving the aim of reducing the dosage and providing the curative effect advantage. Isotopically-labeled compounds are generally synthesized by known synthetic techniques as are non-isotopically-labeled compounds, starting from a starting material which has been labeled.
Unless otherwise specified, the terms "solvate," "solvate," and "solvate" mean a physical association of a compound of the invention with one or more solvent molecules (whether organic or inorganic). The physical association includes hydrogen bonding. In certain instances, the solvate will be able to be isolated, for example, when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid. The solvent molecules in the solvate may be present in a regular arrangement and/or a disordered arrangement. Solvates may comprise stoichiometric or non-stoichiometric amounts of solvent molecules. "solvate" encompasses both solution phase and isolatable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Solvation methods are well known in the art.
Unless otherwise specified, the term "stereoisomers" refers to compounds having the same chemical structure, but differing in the arrangement of atoms or groups in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric isomers (cis/trans), atropisomers, and the like. Any resulting mixture of stereoisomers may be separated into pure or substantially pure geometric isomers, enantiomers, diastereomers, for example, by chromatography and/or fractional crystallization, depending on the differences in the physicochemical properties of the components.
Unless otherwise specified, the term "tautomer" refers to structural isomers that have different energies that can interconvert through a low energy barrier. If tautomerism is possible (e.g., in solution), then the chemical equilibrium of the tautomer can be reached. For example, proton tautomers (also referred to as proton transfer tautomers) include interconversions by proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions by recombination of some of the bonding electrons.
Unless otherwise indicated, the structural formulae depicted herein include all isomeric forms (e.g., enantiomeric, diastereomeric, and geometric (or conformational) isomers): such as R, S configuration containing asymmetric centers, (Z), (E) isomers of double bonds, and conformational isomers of (Z), (E). Thus, individual stereochemical isomers of the compounds of the present invention or mixtures of enantiomers, diastereomers, or geometric isomers (or conformers) thereof are within the scope of the present invention.
The term "prodrug" refers to a drug that is converted in vivo to the parent drug, unless otherwise specified. Prodrugs are often useful, which may improve some determined, undesirable physical or biological property. Physical properties are often associated solubility (too high or insufficient lipid or water solubility) or stability, while problematic biological properties include too rapid metabolism or poor bioavailability, which may itself be associated with physicochemical properties. For example, they can be bioavailable by oral administration, whereas the parent cannot. The prodrug also has improved solubility in pharmaceutical compositions compared to the parent drug. An example, without limitation, of a prodrug would be any compound of the invention administered as an ester ("prodrug") to facilitate transport across a cell membrane, where water solubility is detrimental to mobility, but once intracellular water solubility is beneficial, it is subsequently metabolically hydrolyzed to the carboxylic acid, the active entity. Another example of a prodrug may be a short peptide (polyamino acid) bound to an acid group, where the peptide is metabolized to show an active moiety.
The term "optionally substituted" means, unless otherwise specified, that the hydrogen of the substitutable site of the group is unsubstituted or substituted with one or more substituents, preferably selected from the group consisting of: halogen, hydroxy, mercapto, cyano, nitro, amino, azido, oxo, carboxy, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-10 Cycloalkyl radical, C 3-10 Cycloalkylsulfonyl, 3-10 membered heterocycloalkyl, C 6-14 Aryl or 5-to 10-membered heteroaromatic ring group, wherein, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 3-10 Cycloalkyl, C 3-10 Cycloalkylsulfonyl, 3-10 membered heterocycloalkyl, C 6-14 Aryl or 5-to 10-membered heteroaromatic ring radicals optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl or C 1-6 Alkoxy, said oxo means that two H at the same substitution position are replaced by the same O to form a double bond.
Unless otherwise specified, the term "treatment" encompasses any treatment of a disease, disorder, or condition in a patient, including: (a) Inhibiting the symptoms of, i.e., arresting the development of, diseases, disorders, and conditions; or (b) alleviating the symptoms of the disease, disorder, and condition, i.e., causing regression of the disease or symptoms; or (c) ameliorating or eliminating a disease, disorder, and condition or one or more symptoms associated with the disease.
The beneficial effects of the invention are as follows:
the invention designs a compound with a novel structure, and provides a new direction for the development of the drugs of the POLQ inhibitor class. The research on the in vitro enzyme activity inhibition activity shows that the compound has stronger inhibition effect on the POLQ enzyme and can be used as a prospect compound for treating the POLQ-mediated diseases. The hERG test shows that the compound has no obvious inhibition effect on hERG channel and has relatively low cardiac toxicity. In addition, the invention researches a specific synthesis method, and the synthesis method has the advantages of simple process and convenient operation, and is beneficial to large-scale industrial production and application.
The abbreviations used in the preparation examples, examples and elsewhere herein are:
DPPA Azidophosphoric acid Diphenyl ester
TEA Triethylamine
DCM dichloromethane
TFA trifluoroacetic acid
XPhos 2-dicyclohexylphos-2 ',4',6' -triisopropylbiphenyl
DMF N, N' -dimethylformamide
B 2 Pin 2 Biboric acid pinacol ester
Pd(dppf)Cl 2 [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride
Dioxane Dioxane
MsCl methanesulfonyl chloride
Boc 2 Di-tert-butyl O dicarbonate
DCE 1, 2-Dichloroethane
THF tetrahydrofuran
TBDPSCl tert-butyldiphenylchlorosilane
DMP dimethyl phthalate
TBAF tetrabutylammonium fluoride
DMSO dimethyl sulfoxide
NBS N-bromosuccinimide
Tert-Butyl Tert-Butyl Tert-Butyl ester
DMAP N, N-dimethylpyridin-4-amine
EDCl 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
LAH lithium aluminum hydride
Detailed Description
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Experimental procedures without specific conditions noted in the following examples are generally performed under conventional conditions or conditions recommended by the manufacturers. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials are described herein for illustrative purposes only.
The structure of the compounds of the invention is determined by Nuclear Magnetic Resonance (NMR) or/and liquid mass spectrometry (LC-MS) or/and liquid chromatography (HPLC). NMR was measured using a Wuhan Zhongke Niujin Magnetic Resonance Technigy Co., ltd Quan tum-I,400MHz; the instrument used for LC-MS was Agilent,1290Infinity II; the instrument used for HPLC was Thermo, ultimate 3000.
Preparative HPLC condition one (ammonium bicarbonate as additive): the instrument comprises the following steps: a SHIMADZU; a pump: LC-20AP; a detector: SPD-20A; wavelength: 214nm and 254nm; column type: ultimate XB-C18, 50 × 250mm,10um (PARP-05); mobile phase: a:10mM ammonium bicarbonate, B: acetonitrile; operating time: 30min; flow rate: 70mL/min.
Preparative HPLC condition two (formic acid as additive): the instrument comprises the following steps: a SHIMADZU; a pump: LC-20AP; a detector: SPD-20A; wavelength: 214nm and 254nm; column type: ultimate XB-C18, 50 × 250mm,10um (PARP-05); mobile phase: a:0.1% formic acid, B: acetonitrile; operating time: 30min; flow rate: 70mL/min.
The starting materials in the examples of the present invention are known and commercially available or may be synthesized using or according to methods known in the art.
Preparation of an intermediate:
an intermediate A: preparation of 1- (6-chloropyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea
The first step is as follows: 6-methylpyridine-3-carboxylic acid (10.00g, 72.9mmol, 1.0eq) was dissolved in dichloromethane (500 mL), and triethylamine (22.08g, 218.7mmol, 3.0eq) and cascade were added in this orderDiphenyl azophoshate (26.60g, 109.4mmol, 1.5eq), reacted at room temperature overnight, diluted with ethyl acetate (200 mL), the organic phase washed with saturated aqueous ammonium chloride (60mL. Times.3), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was subjected to flash silica gel column chromatography (PE: EA =4:1 to 1) to obtain compound A1 (9.78 g, yield: 100%). MS (ESI): M/z 135.1 (M + H) + .
The second step is that: compound A1 (5.00g, 37.27mmol, 1.0eq) and 6-chloropyrazine-2-amine (5.30g, 41.00mmol, 1.1eq) were dissolved in toluene (200 mL), argon was replaced, and the reaction mixture was heated to 110 ℃ and stirred for 6 hours. The reaction mixture was cooled to room temperature, concentrated under reduced pressure to remove toluene, washed with ethyl acetate, filtered, and dried to give intermediate A1- (6-chloropyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea (6.23 g, yield: 63.4%). MS (ESI) M/z 264.0 (M + H) + .
An intermediate B: preparation of 6- (3-methyl-4- ((3-methyloxetan-3-yl) methoxy) phenyl) pyrazin-2-amine
The first step is as follows: 4-bromo-2-methylphenol (1.00g, 5.35mmol, 1.0eq) was dissolved in N, N' -dimethylformamide (20 mL), sodium hydride (235mg, 9.63mmol,60% pure, 1.0eq) was slowly added at 0 ℃, and after stirring for 10 minutes, 3- (chloromethyl) -3-methyloxetane (709mg, 5.89mmol, 1.1eq) was added, and the mixture was heated to 100 ℃ and stirred overnight. The reaction was cooled to room temperature, quenched with ice water (50 mL), the aqueous phase extracted with ethyl acetate, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was subjected to flash silica gel column chromatography (PE 100% to PE: EA = 4). MS (ESI) M/z 271.1 (M + H) + .
The second step is that: compound B1 (2.20g, 8.11mmol, 1.0eq), pinacol diboron ester (3.09g, 12.2mmol, 1.5eq), potassium acetate (2.39g, 24.3mmol, 3.0eq) and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (290mg, 0.4mmol, 0.05eq) was added to dioxane (40 mL) and stirred at 100 ℃ under argon. Concentrating the reaction mixture under reduced pressure, separating the residue by flash silica gel column chromatography (PE)100% to PE: EA = 10) to obtain compound B2 (2.58 g, yield: 100.0%). MS (ESI) M/z 319.2 (M + H) + .
The third step: compound B2 (4.69g, 14.77mmol, 1.0eq), 6-chloropyrazin-2-amine (1.91g, 14.77mmol, 1.0eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (1.08g, 1.48mmol, 0.1eq) and anhydrous sodium carbonate (3.13g, 29.54mmol, 2.0eq) were sequentially added to a mixed solution of dioxane/water (200 mL/50 mL), replaced with argon for 3 times, and the mixture was heated to 90 ℃ and stirred for 6 hours. After the reaction was cooled to room temperature, water (30 mL) was added, the aqueous phase was extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was separated by flash silica gel chromatography (PE: EA =4:1 to 1) to give intermediate B6- (3-methyl-4- ((3-methyloxetan-3-yl) methoxy) phenyl) pyrazin-2-amine (2.80 g, yield: 66.6%). MS (ESI): M/z 286.2 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ8.22(s,1H),7.86–7.74(m,3H),7.05(d,J=9.2Hz,1H),6.42(s,2H),4.54(d,J=6.0Hz,2H),4.33(d,J=5.6Hz,2H),4.08(s,2H),2.22(s,3H),1.39(s,3H).
An intermediate C: preparation of 6- (3-methyl-4- ((3-methyloxetan-3-yl) methoxy) phenyl) pyrazine-2-carboxylic acid
6-chloropyrazine-2-carboxylic acid (249mg, 1.57mmol, 1eq) and compound B2 (5009 mg,1.57mmol, 1eq), sodium carbonate (332mg, 3.14mmol, 2eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (57mg, 0.079mmol, 0.05eq) was added to a mixed solution of dioxane (10 mL) and water (1 mL), nitrogen gas was replaced, and the reaction solution was heated to 100 ℃ and stirred for 16 hours. The reaction was cooled to room temperature, concentrated under reduced pressure, and the residue was subjected to flash silica gel column chromatography (DCM: meOH = 1) to give intermediate C6- (3-methyl-4- ((3-methyloxetan-3-yl) methoxy) phenyl) pyrazine-2-carboxylic acid (200 mg, yield: 40.8%). MS (ESI) M/z 315.1 (M + H) + .
Example 1
Synthesis of 1- (6- (1- ((3-methyloxetan-3-yl) methyl) -1H-indol-5-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 5-bromo-1H-indole (534mg, 2.72mmol, 1eq) was dissolved in N, N-dimethylformamide (20 mL), cooled in an ice water bath to 0 ℃ and sodium hydride (131mg, 3.27mmol,60% pure, 1.2eq) was added. After 30 minutes of reaction in an ice bath, 3- (chloromethyl) -3-methyloxetane (361mg, 3.00mmol, 1.1eq) was added thereto, and after the addition, the reaction mixture was heated to 90 ℃ and stirred for 18 hours. The reaction solution was poured into 100mL of ice water, extracted with ethyl acetate, and the organic phases were combined. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was subjected to flash silica gel column chromatography (PE: EA =10:1 to 5). MS (ESI) M/z 280.0 (M + H) + .
The second step is that: compound 1a (310mg, 1.11mmol, 1eq), potassium acetate (327mg, 3.33mmol, 3eq), pinacol ester diboron (423mg, 1.67mmol, 1.5eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (40mg, 0.055mmol, 0.05eq) was added to dioxane (10 mL) in sequence, replaced with argon three times and heated to 100 deg.C for reaction overnight. The reaction solution was concentrated, and the residue was subjected to flash silica gel column chromatography (PE: EA = 3). MS (ESI) M/z 328.2 (M + H) + .
The third step: intermediate A (285mg, 1.08mmol, 1eq), compound 1b (354mg, 1.08mmol, 1eq), potassium carbonate (299mg, 2.16mmol, 2eq) were added in this order to a mixed solution of dioxane (5 mL) and water (0.5 mL), and [1,1' -bis (diphenylphosphino) ferrocene ] was added]Palladium dichloride (35mg, 0.11mmol, 0.1eq) was replaced with argon three times, and then the temperature was raised to 100 ℃ to react for 18 hours. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (20 mL), washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was refluxed with 3mL of ethanol for 30 minutes, slowly cooled to room temperature, filtered and dried to give the title compound, 1- (6- (1- ((3-methyloxetan-3-yl) methyl) -1H-indol-5-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea (55 mg, yield: 11.9%). MS (ESI):m/z 429.2(M+H) + . 1 H NMR(400MHz,DMSO-d 6 )δ9.96(s,1H),9.77(s,1H),8.87(s,1H),8.85(s,1H),8.53(d,J=2.4Hz,1H),8.34(s,1H),7.94–7.89(m,2H),7.73(d,J=8.4Hz,1H),7.51(d,J=3.2Hz,1H),7.23(d,J=8.4Hz,1H),6.62(d,J=3.2Hz,1H),4.62(d,J=6.0Hz,2H),4.46(s,2H),4.23(d,J=5.6Hz,2H),2.43(s,3H),1.21(s,3H).
example 2
Synthesis of 1- (6- (1- ((3-methyloxetan-3-yl) methyl) -1H-indazol-5-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 3-methyl-3-oxetanylmethanol (4 g,39.17mmol, 1eq) and triethylamine (5.95g, 58.76mmol,1.5 eq) were dissolved in dichloromethane (50 mL), methanesulfonyl chloride (4.71g, 41.13mmol, 1.05eq) was slowly added dropwise at 0 ℃ and reacted at 25 ℃ for 2 hours after completion of the addition. The reaction mixture was spun and pumped to dryness by an oil pump to obtain Compound 2a (5.6 g,31.07mmol, 79.3%). 1 HNMR(400MHz,CDCl 3 )δ4.52(d,J=6.4Hz,2H),4.43(d,J=6.4Hz,2H),4.32(s,2H),3.08(s,3H),1.40(s,3H).
The second step: 5-bromoindazole (1g, 5.08mmol, 1eq), compound 2a (1.01g, 5.58mmol, 1.1eq) and potassium carbonate (2.1g, 15.23mmol, 3eq) were dissolved in N, N-dimethylformamide (20 mL), and the reaction mixture was heated to 50 ℃ for 16 hours. The reaction mixture was diluted with water (100 mL), the aqueous phase was extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated by column chromatography (PE: EA = 10). MS (ESI) M/z 281.0 (M + H) + . 1 HNMR(400MHz,CDCl 3 )δ7.86(s,1H),7.78(d,J=1.2Hz,1H),7.78(d,J=1.2Hz,1H),7.37(dd,J=8.8,1.6Hz,1H),7.20(d,J=8.8Hz,1H),4.70(d,J=6.0Hz,2H),4.45(s,2H),4.34(d,J=6.0Hz,2H),1.15(s,3H).
The third step: compound 2b (100mg, 0.35mmol, 1eq) was dissolved in dioxane (5 mL), and potassium acetate (70mg, 0.71mmol, 2eq) and pinacol diboron (18 mg,0.71mmol, 2eq) were added in that order0mg,0.71mmol, 2eq) and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (13mg, 0.018mmol, 0.05eq) was purged with nitrogen, and the reaction mixture was heated to 90 ℃ and stirred for 16 hours. The reaction solution was concentrated under reduced pressure, and the residue was subjected to flash silica gel chromatography (PE: EA = 5. MS (ESI): M/z 329.2 (M + H) + .
The fourth step: compound 2c (120mg, 0.37mmol, 0.8eq), intermediate A (120mg, 0.46mmol, 1eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (1695g, 0.02mmol, 0.05eq) and sodium carbonate (97mg, 0.91mmol, 2eq) were sequentially added to a mixed solvent of dioxane (5 mL) and water (0.5 mL), nitrogen gas was replaced, and the reaction solution was heated to 100 ℃ and stirred for 16 hours. The reaction liquid was concentrated under reduced pressure, and the residue was subjected to flash silica gel chromatography (DCM: meOH = 10. MS (ESI) M/z 430.2 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ9.76–9.75(m,2H),8.95(s,1H),8.92(s,1H),8.54–8.52(m,2H),8.26(d,J=0.8Hz,1H),8.15(dd,J=8.8,1.6Hz,1H),7.92–7.89(m,2H),7.24(d,J=8.4Hz,1H),4.71–4.70(m,4H),4.28(d,J=6.0Hz,2H),2.43(s,3H),1.15(s,3H).
Example 3
Synthesis of 1- (6- (1- ((3-methyloxetan-3-yl) methyl) -1,2,3, 4-tetrahydroquinolin-6-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 6-bromo-1, 2,3, 4-tetrahydroquinoline (1.00g, 4.71mmol, 1eq) was dissolved in N, N' -dimethylformamide (10 mL), sodium hydride (302mg, 7.54mmol,60% by volume purity,1.6 eq) was added to the above solution, and after stirring at room temperature for 30 minutes, 3- (chloromethyl) -3-methyloxyethane (852mg, 7.07mmol, 1.5eq) was added, and the mixture was stirred at room temperature overnight. The reaction was quenched by slowly adding 25mL of ice water. Extracted with ethyl acetate, washed once with brine (15 mL), once with water (15 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the desired compoundCompound 3a (1.39 g, yield: 99.6%). MS (ESI) M/z 296.0 (M + H) + .
The second step is that: compound 3a (1.38g, 4.66mmol, 1eq), pinacol diboron diborate (1.77g, 6.99mmol, 1.5eq), 1' -bis (diphenylphosphino) ferrocene palladium dichloride (205mg, 0.28mmol, 0.06eq) and potassium acetate (1.37g, 13.98mmol, 3eq) were added in sequence to anhydrous dioxane (25 mL), replaced with argon three times, and the reaction solution was warmed to 80 ℃ and stirred overnight. The reaction solution was directly concentrated under reduced pressure, and the residue was subjected to flash silica gel column chromatography (PE: EA = 6. MS (ESI) M/z 344.2 (M + H) + .
The third step: compound 3b (200mg, 0.58mmol, 1eq), intermediate A (184.35mg, 0.7mmol, 1.2eq), potassium carbonate (161.05mg, 1.17mmol, 2eq) and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (42mg, 0.058mmol, 0.1eq) was added in this order to a mixed solution of dioxane (5 mL) and water (1 mL), and the mixture was heated to 90 ℃ under argon and stirred overnight. After the reaction mixture was cooled, water (5 mL) was added, the aqueous phase was extracted with dichloromethane, and the organic phase was concentrated under reduced pressure. The residue was separated by flash silica gel chromatography (DCM: meOH = 10). MS (ESI) M/z 445.3 (M + H) + . 1 HNMR(400MHz,DMSO-d 6 )δ9.95(s,1H),9.64(s,1H),8.67(s,1H),8.66(s,1H),8.49(d,J=2.4Hz,1H),7.88(dd,J=8.4,2.8Hz,1H),7.74–7.62(m,2H),7.20(d,J=8.4Hz,1H),6.70(d,J=8.8Hz,1H),4.53(d,J=5.6Hz,2H),4.18(d,J=6.0Hz,2H),3.50(s,2H),3.28–3.21(m,2H),2.77(t,J=6.2Hz,2H),2.40(s,3H),1.90–1.85(m,2H),1.29(s,3H).
Example 4
Synthesis of 1- (6- (1- ((3-methyloxetan-3-yl) methyl) indolin-5-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 5-bromo-2, 3-dihydro-1H-indole (1.00g, 5.05mmol, 1.0eq) was dissolved in methylene chloride (10 mL), 3-methyl-3-formyl-1-oxetane (606 mg,6.05mmol, 1.2eq) and acetic acid (1 mL) were sequentially added, and after the reaction solution was stirred at room temperature for 30 minutes, sodium borohydride acetate (2.14g, 10.10mmol, 2.0eq) was added, and stirring was continued at room temperature overnight. The reaction mixture was washed with a saturated sodium bicarbonate solution (20 mL) and a saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was subjected to flash silica gel column chromatography (PE: DCM = 3. MS (ESI) M/z 282.0 (M + H) + .
The second step is that: compound 4a (480mg, 1.71mmol, 1.0eq), pinacol diboron ester (651mg, 2.56mmol, 1.5eq), potassium acetate (419mg, 4.27mmol, 2.5eq) and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (125mg, 0.17mmol, 0.1eq) was added to dioxane (4 mL) in sequence and heated to 100 ℃ under argon atmosphere and stirred for 3 hours. After the reaction solution was cooled to room temperature, it was filtered through celite, and concentrated under reduced pressure. The residue was separated by preparative thin layer chromatography (PE: EA = 4. MS (ESI) M/z 330.2 (M + H) + .
The third step: compound 4b (213mg, 0.65mmol,1.0 eq), intermediate A (188mg, 0.71mmol, 1.1eq), sodium carbonate (137mg, 1.29mmol,2.0 eq) and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (47mg, 0.06mmol, 0.1eq) was sequentially added to a mixed solution of dioxane/water (5mL, 4/1), replaced with argon gas 3 times, heated to 90 ℃ and stirred for 3 hours. Ethyl acetate (20 mL) was added for dilution, celite was filtered, and the filtrate was concentrated under reduced pressure. Washed with ethyl acetate (15 mL) and dried to give compound 4- (6- (1- ((3-methyloxetan-3-yl) methyl) indolin-5-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea (32.71 mg, yield: 11.7%). MS (ESI) M/z 431.2 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ10.36(s,1H),9.83(s,1H),8.81(d,J=1.6Hz,1H),8.69(s,1H),8.54(d,J=2.8Hz,1H),7.89(dd,J=8.4,2.8Hz,1H),7.81–7.78(m,2H),7.22(d,J=8.4Hz,1H),6.62(d,J=9.2Hz,1H),4.49(d,J=6.0Hz,2H),4.28(d,J=5.6Hz,2H),3.45(t,J=8.8Hz,2H),3.36(s,2H),3.04(t,J=8.4Hz,2H),2.42(s,3H),1.34(s,3H).
Examples 5 and 6
Synthesis of 1- (6- (1- ((3-methyloxetan-3-yl) methyl) -1H-benzo [ d ] imidazol-5-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea (compound 5):
synthesis of 1- (6- (1- ((3-methyloxetan-3-yl) methyl) -1H-benzo [ d ] imidazol-6-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea (compound 6):
synthesis of Compounds 5 and 6 As in example 1, the first step was performed using 5-bromo-1H-benzimidazole in place of 5-bromo-1H-indole to give two isomers, and the last step was purified by reverse phase preparative chromatography pre-HPLC (0.01% FA in water, meCN) to give the title compounds 5 and 6.
Compound 5: MS (ESI) M/z 430.2 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ9.85(s,1H),9.77(s,1H),8.93(d,J=0.4Hz,1H),8.92(s,1H),8.55–8.51(m,1H),8.42(d,J=1.6Hz,2H),8.04(dd,J=8.4,1.6Hz,1H),7.92(dd,J=8.4,2.4Hz,1H),7.89–7.83(m,1H),7.23(d,J=8.4Hz,1H),4.61(d,J=6.0Hz,2H),4.55(s,2H),4.26(d,J=6.0Hz,2H),2.43(s,3H),1.25(s,3H).
Compound 6: MS (ESI): M/z 430.2 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ9.77(s,1H),9.72(s,1H),8.97(s,1H),8.95(s,1H),8.54(d,J=2.4Hz,1H),8.44(s,2H),7.98(dd,J=8.4,1.6Hz,1H),7.90(dd,J=8.4,2.4Hz,1H),7.82(d,J=8.4Hz,1H),7.23(d,J=8.4Hz,1H),4.62(d,J=6.0Hz,2H),4.58(s,2H),4.27(d,J=6.0Hz,2H),2.43(s,3H),1.25(s,3H).
Example 7
Synthesis of 1- (6- (1- ((3-methyloxetan-3-yl) methyl) -2-carbonyl-1, 2,3, 4-tetrahydroquinolin-6-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
synthesis of Compound 7 the same procedure as in example 1 was used, substituting 6-bromo-1, 2,3, 4-tetrahydro-2-quinolinone for 5-bromo-1H-indole in the first step. Compound 7: MS (ESI) M/z 459.2 (M + H) + . 1 H NMR(400MHz,DMSO-d6)δ9.72(s,2H),8.93(s,1H),8.84(s,1H),8.52(s,1H),8.01–7.87(m,3H),7.40(d,J=8.4Hz,1H),7.22(d,J=8.4Hz,1H),4.53(d,J=5.6Hz,2H),4.16(s,2H),4.06(d,J=5.6Hz,2H),3.02–2.92(m,2H),2.71–2.60(m,2H),2.43(s,3H),1.27(s,3H).
Example 8
Synthesis of 1- (6- (1- ((3-methyloxetan-3-yl) methyl) -2-carbonyl-1, 2-dihydroquinolin-6-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the synthesis of compound 8 was performed as in example 1, substituting 6-bromoquinolin-2-one for 5-bromo-1H-indole in the first step. Compound 8: MS (ESI) M/z 457.3 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ9.76(s,1H),9.67(s,1H),9.02(s,1H),8.94(s,1H),8.53(d,J=2.8Hz,1H),8.50(d,J=2.0Hz,1H),8.28(dd,J=8.8,2.0Hz,1H),8.06(d,J=9.6Hz,1H),7.90(dd,J=8.4,2.4Hz,1H),7.75(d,J=9.2Hz,1H),7.23(d,J=8.4Hz,1H),6.76(d,J=9.6Hz,1H),4.57(d,J=6.4Hz,2H),4.40(s,2H),4.09(d,J=6.0Hz,2H),2.43(s,3H),1.38(s,3H).
Example 9
Synthesis of 1- (6-methylpyridin-3-yl) -3- (6- (2- (tetrahydrofuran-3-yl) -1,2,3, 4-tetrahydroisoquinolin-6-yl) pyrazin-2-yl) urea:
the first step is as follows: 6-bromo-1, 2,3, 4-tetrahydroisoquinoline (400mg, 1.89mmol, 1eq), dihydro-3 (2H) -furanone (195mg, 2.27mmol, 1.2eq), zinc chloride (26mg, 0.189mmol, 0.1eq) were added to methanol (15 mL), and sodium cyanoborohydride was added thereto at room temperature(226mg, 3.78mmol, 2eq) and stirring continued at room temperature for 1 hour. The reaction was poured into saturated sodium bicarbonate solution (100 mL), the aqueous phase was extracted with ethyl acetate, the organic phases were combined, dried over sodium sulfate and concentrated. The residue was subjected to flash silica gel chromatography (PE/EA = 3/1) to give compound 9a (570 mg, yield: 106.9%). MS (ESI) M/z 282.1 (M + H) + . 1 H NMR(400MHz,CDCl 3 )δ7.26–7.19(m,2H),6.89(d,J=7.9Hz,1H),4.05–3.94(m,2H),3.83(dd,J=16.0,8.1Hz,1H),3.73(dd,J=8.6,6.8Hz,1H),3.65(d,J=14.9Hz,1H),3.54(d,J=14.9Hz,1H),3.23–3.10(m,1H),2.88(t,J=5.8Hz,2H),2.83–2.74(m,1H),2.71–2.62(m,1H),2.21–2.08(m,1H),2.01–1.87(m,1H).
The second step: to 1,4-dioxane (10 mL) was added at room temperature the compound 9a (580mg, 2.06mmol, 1eq), pinacol diboron (0.78g, 3.08mmol, 1.5eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (150mg, 0.21mmol, 0.1eq) and potassium acetate (610mg, 6.17mmol, 3eq). The mixture was heated to 100 ℃ under nitrogen and stirred for 2 hours. The reaction solution was concentrated, and the residue was subjected to flash silica gel chromatography (PE/EA = 3/1) to obtain compound 9b (500 mg, yield: 73.7%). MS (ESI) M/z 330.2 (M + H) + .
The third step: intermediate A (150mg, 0.54mmol, 1eq), compound 9b (225mg, 0.68mmol, 1.2eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (40mg, 0.054mmol, 0.1eq) and sodium carbonate (180.88mg, 1.71mmol, 3eq) were dissolved in dioxane (4 mL) and water (2 mL) and stirred at 100 ℃ for 2 hours under nitrogen. Water (200 mL) was poured into the reaction mixture, extracted with ethyl acetate, and the organic phase was dried over sodium sulfate and concentrated. The residue was subjected to flash silica gel column chromatography (DCM/MeOH = 10/1) to give a crude product, which was further purified by preparative reverse-HPLC (0.01% FA in water, meCN) to give the title compound 9 (10 mg, yield: 4.1%). MS (ESI) M/z 431.3 (M + H) + . 1 H NMR(400MHz,MeOD)δ8.73(s,2H),8.57(d,J=2.5Hz,1H),8.04(dd,J=8.5,2.6Hz,1H),7.93–7.88(m,2H),7.37–7.30(m,2H),4.15–3.94(m,5H),3.83(dd,J=16.0,8.1Hz,1H),3.64–3.56(m,1H),3.24–3.11(m,4H),2.53(s,3H),2.41–2.32(m,1H),2.17–2.07(m,1H).
Example 10
1- (6-methylpyridin-3-yl) -3- (6- (2- (oxetan-3-yl) -1,2,3, 4-tetrahydroisoquinolin-6-yl) pyrazin-2-yl) urea
The synthesis of compound 10 was performed as in example 9, substituting 3-oxetanone for dihydro-3 (2H) -furanone in the first step. Compound 10: MS (ESI) M/z 417.3 (M + H) + . 1 H NMR(400MHz,MeOD)δ8.71(s,1H),8.69(s,1H),8.59(d,J=2.5Hz,1H),8.03(dd,J=8.5,2.6Hz,1H),7.90–7.82(m,2H),7.34–7.26(m,2H),4.83(t,J=6.7Hz,2H),4.75(t,J=6.3Hz,2H),3.83–3.76(m,1H),3.67(s,2H),3.09(t,J=6.0Hz,2H),2.76(t,J=6.0Hz,2H),2.53(s,3H).
Example 11
Synthesis of (R) -1- (6-methylpyridin-3-yl) -3- (6- (1, 2,4a, 5-tetrahydro-4H-benzo [ b ] [1,4] oxadiazyl [4,3-d ] [1,4] oxazin-8-yl) pyrazin-2-yl) urea:
the first step is as follows: (S) -2-hydroxymethylmorpholine hydrochloride (900mg, 5.86mmol, 1eq), 1, 2-difluoro-4-nitrobenzene (932mg, 5.86mmol, 1eq) were dissolved in dimethyl sulfoxide (100 mL), and potassium hydroxide (1.64g, 29.29mmol, 4eq) was added. The mixture was stirred at room temperature for 3 hours and then warmed to 60 ℃ for 18 hours. The reaction mixture was cooled, poured into water (300 mL), and extracted with ethyl acetate. The combined organic phases were washed with water, brine (100 mL), dried over anhydrous sodium sulfate and concentrated. The residue was subjected to flash silica gel column chromatography (PE: EA = 20. MS (ESI) M/z 237.1 (M + H) + .
The second step is that: compound 11a (560mg, 2.37mmol, 1eq) and di-tert-butyl dicarbonate (776mg, 3.56mmol, 1.5eq) were sequentially added to methanol (20 mL), palladium on carbon (60mg, 10%) was added, hydrogen gas was substituted three times, and the mixture was reacted at room temperature overnight. The reaction mixture was filtered and concentrated to give compound 11b (660 mg, yield: 90.9%)。MS(ESI):m/z 307.2(M+H) + .
The third step: compound 11b (720mg, 2.35mmol, 1eq) was dissolved in methylene chloride (3 mL), trifluoroacetic acid (3 mL) was added dropwise, and the mixture was stirred at room temperature for 2 hours. The solvent was dried and then dissolved in dichloromethane (30 mL), a saturated sodium bicarbonate solution (50 mL) was added, the mixture was stirred for half an hour and then the layers were separated, the organic phase was dried and then dried, and the crude product was separated by flash chromatography on silica gel (PE: EA =5:1 to 1) to obtain compound 11c (360 mg, yield: 74.3%). MS (ESI): M/z 207.2 (M + H) + . 1 HNMR(400MHz,DMSO-d 6 )δ6.49(d,J=8.4Hz,1H),6.30–5.93(m,2H),4.45(s,1H),4.05(d,J=10.4Hz,1H),3.85(d,J=11.2Hz,1H),3.74(d,J=9.4Hz,1H),3.59–3.44(m,1H),3.35(d,J=12.4Hz,2H),3.09(t,J=10.5Hz,1H),2.82(d,J=9.2Hz,1H).
The fourth step: compound 11c (360mg, 1.75mmol, 1eq) was added to water (10 mL), hydrobromic acid (0.6 mL,48% aqueous solution) was added, and the mixture was cooled to 0 ℃ in an ice bath and stirred for 0.5 hour. An aqueous solution (0.5 mL) of sodium nitrite (133mg, 1.92mmol, 1.05eq) was added dropwise. After 0 ℃ reaction for 0.5 hour, cuprous bromide (751mg, 5.24mmol, 3eq) was added and the reaction was carried out at 0 ℃ for 2 hours. Saturated sodium bicarbonate solution (50 mL) was added, extracted with ethyl acetate, the organic phases combined, dried over anhydrous sodium sulfate and concentrated. The residue was subjected to flash silica gel column chromatography (PE: EA =10:1 to 5). MS (ESI) M/z 270.0 (M + H) + .
The fifth step: compound 11d (75mg, 0.28mmol, 1eq), potassium acetate (55mg, 0.56mmol, 2eq), pinacol diboron (106mg, 0.42mmol, 1.5eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (8mg, 0.03mmol, 0.1eq) was sequentially added to dioxane (2 mL), replaced with argon three times, and then heated to 100 ℃ for reaction overnight. The reaction solution was concentrated, and the residue was subjected to flash silica gel column chromatography (PE: EA = 4). MS (ESI) M/z 318.2 (M + H) + .
And a sixth step: intermediate A (53mg, 0.2mmol, 1eq), compound 11e (63mg, 0.2mmol, 1eq), and sodium carbonate (43mg, 0.4mmol, 2eq) were added to a mixed solvent of dioxane (1 mL) and water (0.2 mL) in this order, and [1,1' -bis (diphenylphosphino) ferrocene was added]Palladium dichloride (5mg, 0.02mm)ol,0.1 eq), replacement with argon three times, and reaction at 100 ℃ for 18 hours. After the reaction mixture was cooled, ethyl acetate (20 mL) was added, and the mixture was washed once with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was isolated and purified by preparative thin layer chromatography (EA/PE = 9). MS (ESI): M/z 419.2 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ10.32(s,1H),9.88(s,1H),8.91(s,1H),8.74(s,1H),8.55–8.49(m,1H),7.93–7.85(m,1H),7.60(dd,J=8.4,2.0Hz,1H),7.47(d,J=2.0Hz,1H),7.21(d,J=8.4Hz,1H),7.01(d,J=8.8Hz,1H),4.30–4.27(m,1H),4.00–3.96(m,1H),3.95–3.85(m,2H),3.73(d,J=11.6Hz,1H),3.66–3.56(m,1H),3.27–3.14(m,2H),2.79(dd,J=12.0,3.6Hz,1H),2.42(s,3H).
Example 12
Synthesis of (S) -1- (6-methylpyridin-3-yl) -3- (6- (1, 2,4a, 5-tetrahydro-4H-benzo [ b ] [1,4] oxadiazanyl [4,3-d ] [1,4] oxazin-8-yl) pyrazin-2-yl) urea:
synthesis of Compound 12 the same procedure as in example 11 was used, except that in the first step, (R) -2-hydroxymethylmorpholine hydrochloride was used instead of (S) -2-hydroxymethylmorpholine hydrochloride. Compound 12: MS (ESI): M/z 419.2 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ10.41(s,1H),9.91(s,1H),8.93(s,1H),8.74(s,1H),8.54(d,J=2.4Hz,1H),7.88(dd,J=8.4,2.8Hz,1H),7.60(dd,J=8.4,2.0Hz,1H),7.47(d,J=2.0Hz,1H),7.21(d,J=8.4Hz,1H),7.01(d,J=8.4Hz,1H),4.30–4.26(m,1H),4.00–3.96(m,1H),3.95–3.87(m,2H),3.77–3.68(m,1H),3.64–3.58(m,1H),3.25–3.16(m,2H),2.83–2.76(m,1H),2.42(s,3H).
Example 13
Synthesis of 1- (6- (3-methyl-4- ((3-methyloxetan-3-yl) methoxy) phenyl) pyrazin-2-yl) -3- (pyrazolo [1,5-a ] pyridin-6-yl) urea:
the first step is as follows: reacting 6-bromopyrazolo [1,5-a ]]Pyridine (500mg, 2.5mmol, 1eq) was dissolved in toluene (4 mL), and tert-butyl carbamate (2.6 g,22mmol, 8.7eq), palladium acetate (62mg, 0.28mmol, 0.1eq), cesium carbonate (1.6 g,5mmol, 2eq) and XPhos (120mg, 0.25mmol, 0.1eq) were added. The nitrogen gas was replaced three times, and the reaction mixture was heated to 110 ℃ and stirred for 16 hours. The reaction was concentrated, and the residue was separated by flash column chromatography on silica gel (DCM: meOH = 10) to give compound 13a (873 mg, yield: 100%). MS (ESI) M/z 234.1 (M + H) + .
The second step is that: compound 13a (873mg, 3.73mmol, 1eq) was added to trifluoroacetic acid (3 mL), and the reaction was stirred at room temperature for 1 hour. The reaction was concentrated, and the residue was separated by flash silica gel column chromatography (DCM: meOH = 10) to obtain compound 13b (100 mg, yield: 20%). MS (ESI) M/z 134.1 (M + H) + .
The third step: intermediate C (157mg, 0.5mmol, 1eq) was dissolved in toluene (5 mL), and compound 13b (100mg, 0.75mmol, 1.5eq), triethylamine (152mg, 1.5mmol, 3eq), and diphenylphosphorylazide (275.2mg, 1.0mmol, 2eq) were added. The mixture was heated to 100 ℃ and stirred for 5 hours. The reaction solution was concentrated, and the residue was purified by preparative reverse phase chromatography pre-HPLC (0.01% FA in water, meCN) to give the title compound 13 (8 mg, yield: 3.6%). MS (ESI) M/z 445.1 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ9.81–9.79(m,2H),9.15–9.14(m,1H),8.90(s,1H),8.81(s,1H),7.97–7.92(m,3H),7.71(dd,J=9.6,0.8Hz,1H),7.18–7.14(m,1H),7.12(dd,J=9.2,2.0Hz,1H),6.60(dd,J=2.2,1.0Hz,1H),4.56(d,J=5.6Hz,2H),4.35(d,J=6.0Hz,2H),4.14(s,2H),2.27(s,3H),1.41(s,3H).
Example 14
Synthesis of 1- (imidazo [1,2-a ] pyridin-6-yl) -3- (6- (3-methyl-4- ((3-methyloxetan-3-yl) methoxy) phenyl) pyrazin-2-yl) urea:
reacting imidazo [1,2-a ]]Pyridine-6-carboxylic acid (100mg, 0.62mmol, 1eq), intermediate B (194mg, 0.68mmol, 1.1eq),diphenyl azidophosphate (339mg, 1.24mmol, 2eq) and triethylamine (187mg, 1.85mmol, 3eq) were added to toluene (5 mL) and stirred at 90 ℃ for 5 h. The reaction was concentrated, and the residue was separated by flash column chromatography on silica gel (DCM: meOH = 10) to give the title compound 14 (7.8 mg, yield: 3.2%). MS (ESI): M/z 445.2 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ9.78(s,1H),9.76(s,1H),9.09–9.07(m,1H),8.91(s,1H),8.81(s,1H),8.03(s,1H),7.96–7.94(m,2H),7.59–7.57(m,1H),7.54–7.53(m,1H),7.17–7.15(m,1H),7.10(dd,J=9.6,2.0Hz,1H),4.56(d,J=5.6Hz,2H),4.35(d,J=5.6Hz,2H),4.14(s,2H),2.27(s,3H),1.41(s,3H).
Example 15
Synthesis of 1- (imidazo [1,2-a ] pyridin-7-yl) -3- (6- (3-methyl-4- ((3-methyloxetan-3-yl) methoxy) phenyl) pyrazin-2-yl) urea:
synthesis of Compound 15 the same as in example 14, using imidazo [1,2-a ]]Pyridine-7-carboxylic acid instead of imidazo [1,2-a ]]Pyridine-6-carboxylic acid. Compound 15: MS (ESI) M/z 445.1 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ10.01(s,1H),9.84(s,1H),8.92(s,1H),8.80(s,1H),8.47(d,J=7.2Hz,1H),7.98–7.92(m,2H),7.85–7.80(m,2H),7.44(s,1H),7.14(d,J=9.2Hz,1H),6.90(d,J=7.2Hz,1H),4.54(d,J=5.6Hz,2H),4.33(d,J=6.0Hz,2H),4.12(s,2H),2.26(s,3H),1.40(s,3H).
Example 16
Synthesis of 1- (2-methyl-2H-indazol-6-yl) -3- (6- (3-methyl-4- ((3-methyloxetan-3-yl) methoxy) phenyl) pyrazin-2-yl) urea:
compound 16 was synthesized according to the same procedure as in example 13, except that 2-methyl-6-amino-2H-indazole was used instead of compound 13b in the third step. Compound 16: MS (ESI) M/z 459.2 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ10.42(s,1H),9.93(s,1H),9.02(s,1H),8.78(s,1H),8.25(s,1H),7.96–7.92(m,3H),7.66–7.62(m,1H),7.15(d,J=9.2Hz,1H),7.02(dd,J=8.8,1.6Hz,1H),4.56(d,J=5.6Hz,2H),4.35(d,J=5.6Hz,2H),4.13(s,2H),4.12(s,3H),2.28(s,3H),1.41(s,3H).
Example 17
Synthesis of 1- (6- (4- ((3-methyloxyethan-3-yl) methyl) -3, 4-dihydro-2H-benzo [ b ] [1,4] oxazin-7-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 2-amino-5-bromophenol (2.00g, 10.64mmol, 1.0eq) was dissolved in 1, 2-dichloroethane (50 mL), and 3-methoxyethane-3-carbaldehyde (1.06g, 10.64mmol, 1.0eq) and sodium cyanoborohydride (2.00g, 31.91mmol, 3.0eq) were added and stirred at room temperature for 8 hours. The system was poured into ice water, extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and the residue was separated by flash silica gel column chromatography (100% PE-PE: EA = 10) to obtain compound 17a (1.29 g, yield: 44.6%). MS (ESI) M/z 272.0 (M + H) + .
The second step is that: compound 17a (1g, 3.67mmol, 1eq) was dissolved in N, N-dimethylformamide (50 mL), and potassium carbonate (1.50g, 11.02mmol, 3eq) was added at room temperature, followed by 1, 2-dibromoethane (2.0g, 11.02mmol, 3eq). The mixture was heated to 100 ℃ and stirred overnight. The mixture was cooled to room temperature, diluted with ethyl acetate (200 mL), washed with water, brine and the organic phase was dried over anhydrous sodium sulfate. After concentration, the residue was separated by flash silica gel chromatography (PE: EA = 9). MS (ESI) M/z 298.0 (M + H) + .
The third step: the compound 17b (483mg, 1.62mmol, 1.0eq), pinacol diboron ester (617mg, 2.43mmol, 1.5eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (118mg, 0.16mmol, 0.1eq) and potassium acetate (3970 mg,4.05mmol, 2.5eq) were sequentially added to dioxane (5 mL), replaced with argon gas for 3 times, and the temperature was raised toAfter stirring at 100 ℃ for 2 hours, the mixture was filtered through celite, concentrated under reduced pressure, and the residue was chromatographed on flash silica gel (PE: EA = 10. MS (ESI): M/z 346.2 (M + H) + .
The fourth step: compound 17c (227mg, 0.66mmol, 1.0eq), intermediate A (191mg, 0.72mmol, 1.1eq), cesium carbonate (428mg, 1.315mmol, 2.0eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (48mg, 0.07mmol, 0.1eq) was sequentially added to a mixed solution of dioxane-water (4, 1,5mL), replaced with argon gas 3 times, and heated to 100 ℃ for reaction for 2 hours. After the system was cooled to room temperature, extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, washed with methanol, filtered, the cake was collected, and dried under vacuum to give the title compound 17 (177.77 mg, yield: 60.3%). MS (ESI) M/z 447.2 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ9.86(s,1H),9.65(s,1H),8.75(s,1H),8.70(s,1H),8.50(s,1H),7.90(d,J=8.4Hz,1H),7.53(d,J=8.0Hz,1H),7.44(s,1H),7.22(d,J=8.0Hz,1H),6.87(d,J=8.8Hz,1H),4.55(d,J=5.2Hz,2H),4.23(d,J=6.0Hz,4H),3.53(s,2H),3.36(s,2H),2.43(s,3H),1.32(s,3H).
Example 18
Synthesis of 1- (6- (4- ((3-methyloxyethan-3-yl) methyl) -3-oxo-3, 4-dihydro-2H-benzo [ b ] [1,4] oxazin-7-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 7-bromo-2H-benzo [ b ]][1,4]Oxazin-3 (4H) -one (301mg, 1.32mmol, 1eq) was dissolved in N, N-dimethylformamide (10 mL), sodium hydride (60%, 106mg,2.64mmol, 2eq) was added under ice-bath, and after 30 minutes of incubation, 3- (chloromethyl) -3-methyloxetane (175mg, 1.45mmol, 1.1eq) was added, and after completion of the addition, the temperature was raised to 80 ℃ for 18 hours. The reaction was cooled and poured into ice water (50 mL), the aqueous phase was extracted with ethyl acetate, and the organic phases were combined. The organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was chromatographed on flash silica gel (PE: EA =10:1 to 5)19a (160 mg, yield: 38.8%). MS (ESI) M/z 312.0 (M + H) + .
The second step is that: compound 19a (160mg, 0.51mmol, 1eq), potassium acetate (100mg, 1.02mmol, 2eq), pinacol ester diboron (194mg, 0.77mmol, 1.5eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (15mg, 10%) was sequentially added to dioxane (5 mL), replaced with argon three times, and heated to 100 ℃ for reaction overnight. The reaction solution was subjected to flash silica gel chromatography (EA: PE = 3. MS (ESI): M/z 360.2 (M + H) + .
The third step: intermediate A (74mg, 0.28mmol, 1eq), compound 19b (151mg, 0.42mmol, 1.5eq), and sodium carbonate (60mg, 0.56mmol, 2eq) were sequentially added to a mixed solvent of dioxane (5 mL) and water (0.5 mL), and [1,1' -bis (diphenylphosphino) ferrocene was added]Palladium dichloride (15mg, 10%) was substituted with argon three times, and then the mixture was heated to 100 ℃ to react for 3 hours. The reaction solution was cooled, ethyl acetate (20 mL) was added, the organic phase was washed once with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and spun dry, and the crude product was purified by flash chromatography on silica gel (EA) to give a crude product, which was further purified by preparative Pre-HPLC (C18, 0.01% HCOOH in water, meCN) to give the title compound 19 (30 mg, yield: 23.3%). MS (ESI) M/z 461.2 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ9.74(s,1H),9.71(s,1H),8.97(s,1H),8.87(s,1H),8.52(d,J=2.4Hz,1H),7.89(dd,J=8.4,2.8Hz,1H),7.79(dd,J=8.4,2.0Hz,1H),7.76(d,J=2.0Hz,1H),7.50(d,J=8.8Hz,1H),7.23(d,J=8.4Hz,1H),4.77(s,2H),4.54(d,J=6.0Hz,2H),4.17(s,2H),4.10(d,J=6.0Hz,2H),2.43(s,3H),1.30(s,3H).
Example 19
Synthesis of 1- (6- {1- [ trans-2-hydroxychloropentyl ] -2, 3-dihydro-1H-indol-5-yl } pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: zinc chloride (1.62g, 11.89mmol, 2eq) was dissolved in water (20 mL), and 5-bromo-2, 3-indoline (1.77g, 8.92mmol,1.5 eq) and 1, 2-cyclopentane oxide were slowly added(500mg, 5.94mmol, 1equiv) in acetonitrile (10 mL), heating to 90 ℃ under nitrogen, and stirring for 2 hours. Ethyl acetate (50 mL) was added to dilute the reaction mixture, the layers were separated by extraction, the organic phase was concentrated to give a crude product, which was purified by flash chromatography on silica gel (EA% = 0-30%) to give compound 49a (900 mg, yield: 53.7%). MS (ESI) M/z 282.1 (M + H) + . 1 H NMR(400MHz,CDCl 3 )δ7.16–7.09(m,2H),6.41(d,J=8.9Hz,1H),4.24(q,J=6.8Hz,1H),3.70(dd,J=15.3,8.2Hz,1H),3.48–3.31(m,2H),2.95(t,J=8.3Hz,2H),2.05–1.76(m,4H),1.71–1.58(m,3H).
The second step is that: in a 100mL flask, compound 49a (900mg, 3.19mmol, 1eq), pinacoldiboron diborate (1.21g, 4.78mmol, 1.5eq), potassium acetate (939mg, 9.57mmol, 3eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (233mg, 0.32mmol, 0.1eq) and dioxane (20 mL) were heated to 100 ℃ under nitrogen and stirred for 2 hours. The reaction mixture was diluted with water (100 mL) and ethyl acetate (300 mL), the layers were separated, and the organic layer was dried over anhydrous sodium sulfate and concentrated. Flash chromatography on silica gel (EA% = 0-70%) gave compound 49b (500 mg, yield: 47.6%). MS (ESI): M/z 330.2 (M + H) + .
The third step: compound 49b (100mg, 0.304mmol, 1eq), intermediate A (160.17mg, 0.608mmol, 2eq), sodium carbonate (64.12mg, 0.608mmol, 2eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (44.59mg, 0.0609mmol, 0.2eq) was added to a mixed solution of dioxane (5 mL) and water (0.5 mL), nitrogen gas was replaced, and the reaction solution was heated to 100 ℃ and stirred for 16 hours. The reaction solution was cooled to room temperature, filtered, and the filtrate was concentrated by rotary evaporation, dissolved in 10mL of N, N-dimethylformamide, and filtered again, and sent to preparative treatment. The residue was purified by reverse phase preparative chromatography Prep-HPLC to give the title compound 49 (18.80 mg, yield: 14.4%). MS (ESI) M/z 430.5 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ10.05(s,1H),9.72(s,1H),8.73(s,1H),8.72(s,1H),8.59(d,J=2.4Hz,1H),7.98–7.95(m,1H),7.84–7.76(m,2H),7.32(d,J=8.4Hz,1H),6.66(d,J=8.4Hz,1H),4.93(s,1H),4.17–4.10(m,1H),3.81–3.75(m,1H),3.64–3.57(m,2H),3.04(t,J=8.4Hz,2H),2.49(s,3H),1.96–1.84(m,2H),1.80–1.73(m,1H),1.69–1.53(m,3H)
Example 20
Synthesis of 1- (6- {1- [ trans-4-hydroxypyrrolidin-3-yl ] -2, 3-dihydro-1H-indol-5-yl } pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 5-Bromoindoline (1.00g, 5.05mmol, 1eq) and THF (20 mL) were charged in a 50mL single-neck flask, sodium hydride (60%, 404mg,10.10mmol, 2eq) was added under ice-cooling, and t-butyl 6-oxa-3-azabicyclo [3.1.0 ] was added under stirring for 20 minutes]Hexane-3-carboxylate (1.40g, 7.57mmol, 1.5eq) was reacted at 95 ℃ for 6 hours. The reaction was quenched with water, extracted with ethyl acetate, and the organic phases were combined, washed with saturated brine, dried over sodium sulfate, filtered, and the filtrate was concentrated and separated by flash silica gel chromatography (PE: EA =10, 1 to 4. MS (ESI) M/z 383.1 (M + H) + . 1 H NMR(400MHz,CDCl 3 )δ7.15(s,2H),6.37(d,J=8.9Hz,1H),4.39(dd,J=10.7,5.2Hz,1H),3.90(dd,J=11.7,5.5Hz,1H),3.73–3.69(m,2H),3.55–3.21(m,4H),2.96(t,J=8.3Hz,2H),2.35(s,1H),1.46(s,9H).
The second step is that: in a 100mL single-neck flask, compound 50a (500mg, 1.30mmol, 1eq), pinacol diboron (398mg, 1.57mmol, 1.2eq), pd (dppf) Cl 2 (191mg, 0.26mmol, 0.2eq), potassium acetate (512mg, 5.22mmol, 4eq) and 1,4-dioxane (30 mL). The reaction system was purged with nitrogen three times and stirred at 90 ℃ for 8 hours. Diluted with water, filtered, the filtrate was extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the residue was separated by flash silica gel chromatography (PE: EA = 4. MS (ESI): M/z 431.4 (M + H) + .
The third step: the compound 50b (279mg, 0.65mmol, 1eq), the intermediate A (167.2mg, 0.65mmol, 1eq), and the [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (92.83mg, 0.13mmol, 0.2eq) and anhydrous sodium carbonate (137.73mg, 1.3mmol, 2eq) were added sequentially to a mixture of dioxane/water (15 mL/1.5 mL)Mixing the solution, heating to 100 ℃ under the protection of nitrogen, and stirring for 16 hours. The organic layer was washed with saturated brine (30 mL), and then dried over anhydrous sodium sulfate. Filtering to remove insoluble substances, and concentrating the organic phase under reduced pressure to obtain a crude product. The crude product was separated by flash chromatography on silica gel (PE: EA =4: 1), and the resulting fraction was subjected to rotary evaporation under reduced pressure to remove the solvent, to obtain compound 50c (200 mg, yield: 57.9%). MS (ESI): M/z 531.8 (M + H) + .
The fourth step: 4M dioxane hydrochloride (4 mL,1mmol, 2.63eq) was added to a solution of compound 50c (200mg, 0.38mmol, 1eq) in dichloromethane (5 mL) with nitrogen and stirring at 25 ℃ for 2 h. The reaction solution was concentrated, and the residue was purified by reverse phase preparative chromatography Prep-HPLC to give the title compound 50 (59 mg, yield: 36.0%). MS (ESI) M/z 432.2 (M + H) + . 1 H NMR(400MHz,MeOD)δ8.55(s,1H),8.52–8.49(m,2H),8.43(s,1H),8.07–8.04(m,1H),7.79–7.76(m,2H),7.29(d,J=8.4Hz,1H),6.74(d,J=8.4Hz,1H),4.61–4.60(m,1H),4.11–4.08(m,1H),3.74–3.69(m,1H),3.58–3.47(m,4H),3.28(d,J=2.4Hz,1H),3.09(t,J=8.4Hz,2H),2.50(s,3H).
Example 21
Synthesis of 1- (6- (1- ((3-hydroxyoxetan-3-yl) methyl) indol-5-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: a solution of 3-oxetanone (2.1g, 29.1mmol) in dry tetrahydrofuran (100 mL) was cooled to 0 ℃ under nitrogen, maintaining the internal temperature below 10 ℃, and vinylmagnesium bromide (1M in THF,50mL,50.0 mmol) was added dropwise. The reaction mixture was stirred for 10 minutes, then allowed to warm to room temperature and stirred for 2 hours. The reaction mixture was poured into saturated ammonium chloride (200 mL). The mixture was stirred for 5 minutes, and the layers were separated and extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to give the crude product. The crude product was separated by flash chromatography on silica gel (PE/EA = 3/2) to obtain compound 52a (600 mg, yield: 20.6%). 1 H NMR(400MHz,CDCl 3 )δ6.36–6.26(m,1H),5.47–5.40(m,1H),5.30–5.27(m,1H),4.74–4.68(m,4H),3.55(s,1H).
The second step: a solution of compound 52a (450mg, 4.49mmol) in dichloromethane (5 mL) and methanol (45 mL) was bubbled with a stream of ozone at-78 deg.C for 20 minutes, after which triphenylphosphine (3.0 g) was added and the mixture was stirred at-78 deg.C for 6 hours. After completion of the reaction, the temperature was raised to room temperature, filtered, and the filtrate was concentrated under reduced pressure to remove the excess reagent to give compound 52b (3.2 g, crude) which was used directly in the next step.
The third step: to a 100mL flask were added compound 52b (2.06g, 20.2mmol, 20.0eq), 5-bromo-2, 3-dihydro-1H-indole (200mg, 1.01mmol, 1.0eq), dichloromethane (30 mL) and glacial acetic acid (0.2 mL) in this order, followed by stirring at room temperature for 30 minutes. Sodium triacetoxyborohydride (428.03mg, 2.02mmol,2.0 eq) was added to the reaction solution, followed by stirring at room temperature for 30 minutes. After the reaction was completed, water (2 mL) was added to quench the reaction, and the reaction was concentrated under reduced pressure to remove excess reagents to obtain a crude product. The crude product was separated by flash chromatography on silica gel (PE/EA = 3/2) to obtain compound 52c (180 mg, yield: 62%). MS (ESI) M/z 283.8 (M + H) + . 1 H NMR(400MHz,CDCl 3 )δ7.27–7.15(m,2H),6.46(d,J=8.4Hz,1H),4.73(d,J=7.2Hz,2H),4.57(d,J=7.2Hz,2H),3.43(s,2H),3.37(t,J=8.4Hz,2H),3.10(s,1H),3.00(t,J=8.4Hz,2H).
The fourth step: under nitrogen protection, compound 52c (198mg, 0.7mmol, 1.0eq), 4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-ylboronic acid (265.42mg, 1.05mmol, 1.5eq), potassium acetate (136.77mg, 1.39mmol, 2.0eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (51.57mg, 0.105mmol, 0.1eq) and dioxane (5 mL). The mixture was stirred at 100 ℃ for 3 hours. After the reaction is finished, cooling to room temperature, and carrying out reduced pressure concentration to remove redundant reagents to obtain a crude product. The crude product was separated by flash chromatography on silica gel (PE/EA = 1/1) to obtain compound 52d (150 mg, yield: 64%). MS (ESI) M/z 332.0 (M + H) + . 1 H NMR(400MHz,CDCl 3 )δ7.59(d,J=8.0Hz,1H),7.57(s,1H),6.59(d,J=8.0Hz,1H),4.74(d,J=7.2Hz,2H),4.59(d,J=7.2Hz,2H),3.51(s,2H),3.39(t,J=8.4Hz,2H),3.08(s,1H),3.02(t,J=8.4Hz,2H),1.33(s,12H).
The fifth step: to compound 52d (129.17mg, 0.39mmol, 1.0eq), intermediate A (92.55mg, 0.35mmol, 0.9eq) and [1,1' -bis (diphenylphosphino) ferrocene, under nitrogen protection]To a solution of palladium dichloride (20.43mg, 0.035mmol, 0.01eq) in dioxane (3 mL) and water (0.3 mL) was added sodium carbonate (82.67mg, 0.79mmol,2.0 eq). The resulting mixture was reacted at 100 ℃ for 3 hours. After the reaction was complete, it was cooled to room temperature. The reaction mixture was diluted with water (50 mL), and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine (150 mL), followed by drying over anhydrous sodium sulfate. Filtering to remove insoluble substances, and concentrating the organic phase under reduced pressure to obtain a crude product. The crude product was chromatographed on flash silica gel (DCM/MeOH = 10/1) to give the title compound 52 (80 mg, yield: 45%). MS (ESI) M/z 432.8 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ9.98(s,1H),9.70(s,1H),8.72(d,J=8.8Hz,2H),8.53(d,J=2.4Hz,1H),7.94–7.89(m,1H),7.83–7.79(m,2H),7.25(d,J=8.4Hz,1H),6.70(d,J=8.4Hz,1H),5.95(s,1H),4.53–4.43(m,4H),3.61(t,J=8.4Hz,2H),3.46(s,2H),3.04(t,J=8.4Hz,2H),2.45(s,3H).
Example 22
Synthesis of 1- [6- (1- { [3- (hydroxymethyl) oxetan-3-yl ] methyl } -2, 3-dihydro-1H-indol-5-yl) pyrazin-2-yl ] -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 3, 3-bis-hydroxymethyl-1-oxetane (1g, 8.46mmol, 1eq) was dissolved in tetrahydrofuran (60 mL), stirred at 0 ℃, sodium hydrogen (60%, 338mg,8.46mmol, 1eq) was added, stirred at room temperature for 30 minutes under nitrogen protection, tert-butyldiphenylchlorosilane (2.33g, 8.46mmol, 1.0eq) was added at 0 ℃, and stirred at room temperature for 1 hour. Quenched with water, extracted 3 times with dichloromethane and concentrated under reduced pressure. The residue was chromatographed on flash silica gel (100% PE to PE: EA = 63) to give compound 53a (2.0 g, yield: 66.2%). 1 H NMR(400MHz,CDCl 3 )δ7.71–7.65(m,4H),7.40–7.47(m,6H),4.50–4.39(m,4H),3.95(s,4H),2.46(s,1H),1.09(s,9H).
The second step is that: compound 53a (1.0 g,0.28mmol, 1eq) was dissolved in dichloromethane (5 mL), and dessimutan reagent (2.37g, 5.60mmol, 2eq) was added thereto, and the reaction was stirred at 0 ℃ for 1 hour. The reaction mixture was transferred with methylene chloride, and rotary evaporation was carried out to obtain compound 53b (0.90 g). 1 H NMR(400MHz,DMSO-d 6 )δ9.84(s,1H),7.65–7.61(m,5H),7.51–7.47(m,5H),4.68(d,J=6.4Hz,2H),4.45(d,J=6.4Hz,2H),4.17(s,2H),1.00(s,9H).
The third step: 5-bromo-2, 3-dihydro-1H-indole (335mg, 1.69mmol, 1eq) was dissolved in methylene chloride (6 mL), and compound 53b (0.90g, 2.54mmol, 1.5eq) and acetic acid (0.6 mL) were added at 0 ℃ to replace nitrogen and stirred at 30 ℃ for 30 minutes, and sodium borohydride acetate (716mg, 3.38mmol, 2eq) was added and stirred at 30 ℃ for 17 hours. The reaction solution was filtered, concentrated, and sampled, and separated by flash chromatography on silica gel (PE: EA = 79. MS (ESI): M/z 535.8 (M + H) + .
The fourth step: compound 53c (800mg, 1.49mmol, 1eq), pinacol diboron (757mg, 2.98mmol, 2eq), potassium acetate (366mg, 3.74mmol, 2.5eq) and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (218mg, 0.299mmol, 0.2eq) was dissolved in 1,4-dioxane (8 mL), and the mixture was stirred at 100 ℃ for 4 hours while displacing nitrogen gas. Celite filtration, and the filtrate was separated by flash silica gel chromatography (PE: EA = 4). MS (ESI) M/z 583.8 (M + H) + .
The fifth step: compound 53d (300mg, 0.51mmol, 1eq), intermediate A (135mg, 0.51mmol, 1eq), sodium carbonate (109mg, 1.028mmol, 2eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (75mg, 0.103mmol, 0.2eq) was added to a mixed solution of dioxane (10 mL) and water (1 mL), nitrogen gas was replaced, and the reaction solution was heated to 100 ℃ and stirred for 16 hours. The reaction solution was cooled to room temperature, filtered, and rotary-distilled to dryness to give compound 53e (300 mg, yield: 85.2%) which was used directly in the next reaction. MS (ESI) M/z 684.8 (M + H) + .
And a sixth step: compound 53e (250mg, 0.365mmol, 1eq) and tetrabutylammonium fluoride (0.73mL, 0.73mmol, 2eq) were dissolved in tetrahydrofuran (1)0 mL) was stirred at room temperature under a nitrogen blanket for 2 hours. Concentration, dissolution in 10mL of N, N-dimethylformamide, filtration and purification by reverse phase preparative chromatography Pre-HPLC gave the title compound 53 (61.19 mg, yield: 37.0%). MS (ESI) M/z 447.2 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ9.93(s,1H),9.67(s,1H),8.72(s,1H),8.69(s,1H),8.51(d,J=2.4Hz,1H),7.90–7.88(m,1H),7.80–7.77(m,2H),7.23(d,J=8.4Hz,1H),6.63(d,J=8.8Hz,1H),5.02–4.98(m,1H),4.42–4.37(m,4H),3.67(d,J=5.2Hz,2H),3.49(t,J=8.4Hz,2H),3.41(s,2H),3.03(t,J=8.4Hz,2H),2.43(s,3H).
Example 23
Synthesis of 1- (6- (1- ((3-methyloxoalk-3-yl) methyl) -2, 3-dihydro-1H-indol-5-yl) pyrazin-2-yl) -3- (pyrazolo [1,5-a ] pyridin-6-yl) urea:
the first step is as follows: to 1.4-dioxane (30 mL) of compound 4b (2.5g, 7.59mmol, 1.0eq) and water (3 mL) were added 6-chloropyrazine-2-carboxylic acid (1.44g, 9.11mmol, 1.2eq), sodium carbonate (2.01g, 18.9mmol, 2.5eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride dichloromethane complex (648mg, 0.8mmol, 0.1eq). Stirring for 3 hours at 100 ℃ under the protection of nitrogen, filtering, and concentrating. The residue was chromatographed on flash silica gel (DCM/MeOH = 10/1) to give compound 59a (1.1 g, yield: 44.5%). MS (ESI): M/z 326.0 (M + H) + .
The second step is that: to toluene (10 mL) containing compound 59a (110mg, 0.34mmol,1.0 eq) was added compound 13b (50mg, 0.37mmol, 1.1eq), triethylamine (105mg, 1.03mmol,3.0 eq), diphenyl phosphorazidate (189mg, 0.69mmol,2.0 eq). Stirring was carried out at 100 ℃ for 15 hours under nitrogen. The reaction solution was concentrated, and the residue was purified by reverse phase preparative chromatography Prep-HPLC to give the title compound 59 (15 mg, yield: 9.7%). MS (ESI) M/z 456.3 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ9.93(s,1H),9.74(s,1H),9.16(s,1H),8.76(s,1H),8.72(s,1H),7.95(d,J=2.4Hz,1H),7.82–7.81(m,2H),7.73(d,J=9.6Hz,1H),7.12(dd,J=9.6,2.0Hz,1H),6.65–6.63(m,1H),6.62–6.61(m,1H),4.51(d,J=5.6Hz,2H),4.31(d,J=5.6Hz,2H),3.48(t,J=8.4Hz,2H),3.39(s,2H),3.07(t,J=8.4Hz,2H),1.36(s,3H).
Example 24
Synthesis of 1- (6- (1- ((3-methyloxoalk-3-yl) methyl) -2, 3-dihydro-1H-indol-5-yl) pyrazin-2-yl) -3- (4, 5,6, 7-tetrahydropyrazol [1,5-a ] pyridin-6-yl) urea:
the first step is as follows: to 6-bromopyrazolo [1,5-a ]]To a solution of pyridine (2.5g, 12.69mmol, 1.0eq), dimethyl sulfoxide (1.66g, 21.19mmol, 1.67eq) and triethylamine (3.85g, 38.07mmol, 3.0eq) in methanol (50 mL) was added bis-triphenylphosphine palladium dichloride (891mg, 3.807mmol, 0.1eq). The reaction mixture was stirred at 100 ℃ under carbon monoxide (16 atm) for 16 hours. After completion of the reaction, the reaction solution was cooled to 25 ℃. The reaction solution was concentrated and then separated by flash silica gel chromatography (PE/EA = 1/1) to obtain compound 60a (2.0 g, yield: 89%). MS (ESI): M/z 177.0 (M + H) + . 1 H NMR(400MHz,CDCl 3 )δ9.20(s,1H),8.22(d,J=2.0Hz,1H),7.79(d,J=8.0Hz,1H),7.62–7.55(m,1H),6.76(s,1H),3.90(s,3H).
The second step: to a solution of compound 60a (700mg, 3.97mmol,1.0 eq) in methanol (5 mL) was added a solution of sodium hydroxide (794.69mg, 19.87mmol,3.0 eq) in water (5 mL). The reaction mixture was stirred at 110 ℃ for 1 hour. After completion of the reaction, the reaction solution was cooled to 25 ℃. Methanol was removed by rotary evaporation under reduced pressure, and diluted with water (20 mL), the reaction solution pH =4 was adjusted with 1M dilute hydrochloric acid, the precipitate was filtered, the cake was washed with water, and the cake was dried by rotary drying to give compound 60b (500 mg, yield: 77%). 1 H NMR(400MHz,DMSO-d 6 )δ13.29(s,1H),9.15(s,1H),8.19(d,J=2.0Hz,1H),7.77(d,J=4.0Hz,1H),7.60–7.55(m,1H),6.74(s,1H).
The third step: to a solution of compound 60b (500mg, 3.08mmol,1.0 eq) in methanol (5 mL) was added palladium on carbon (140mg, 10% wet palladium on carbon). The reaction solution was stirred and reacted at 40 ℃ for 16 hours under hydrogen conditions. After completion of the reaction, the reaction solution was cooled to 25 ℃. Inverse directionThe reaction solution was filtered through a Celite layer, and the filtrate was spin-dried to give compound 60c (500 mg, yield: 97%). 1 H NMR(400MHz,DMSO-d 6 )δ12.82(s,1H),7.34(d,J=1.6Hz,1H),6.02–5.94(m,1H),4.27–4.20(m,1H),4.15–4.07(m,1H),3.11–3.00(m,1H),2.87–2.69(m,2H),2.17–2.05(m,1H),1.94–1.81(m,1H).
The fourth step: in a 100mL single-neck flask, compound 4b (2g, 6.07mmol, 1eq) was added to a mixed solvent of 1,4-dioxane (30 mL) and water (3 mL), and 6-chloropyrazin-2-amine (1.97g, 15.17mmol, 2.5eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (500mg, 0.60mmol, 0.1eq), sodium carbonate (1.28g, 12.12mmol, 2.0eq), the reaction system was purged with nitrogen and then stirred at 100 ℃ for 16 hours. The reaction solution was filtered, concentrated, and pooled, and separated by flash silica gel chromatography (PE: EA = 1) to obtain compound 60d (1.5 g, yield: 83.4%). MS (ESI): M/z 297.0 (M + H) + .
The fifth step: to a solution of compound 60c (100mg, 0.34mmol, 1.0eq), compound 60d (112.14mg, 0.68mmol, 2.0eq) and triethylamine (102.22mg, 1.02mmol, 3.0eq) in toluene (4 mL) was added diphenylphosphorylazide (112.15mg, 0.68mmol, 2.0eq). The reaction solution was stirred at 100 ℃ under nitrogen for 16 hours. After completion of the reaction, the reaction solution was cooled to 25 ℃. Filtration and spin-drying of the filtrate gave a crude product which was purified by preparative reverse phase preparative chromatography per-HPLC to give the title compound 60 (30 mg, yield: 19.4%). MS (ESI) M/z459.8 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ9.41(s,1H),8.61(s,1H),8.59(s,1H),7.93(d,J=6.0Hz,1H),7.69–7.67(m,1H),7.65–7.60(m,1H),7.40(d,J=2.0Hz,1H),6.56(d,J=8.4Hz,1H),6.05(d,J=1.6Hz,1H),4.48(d,J=5.6Hz,2H),4.36–4.25(m,4H),4.05–4.00(m,1H),3.43(t,J=8.4Hz,2H),3.36–3.34(m,2H),3.01(t,J=8.4Hz,2H),2.92–2.85(m,2H),2.10–2.04(m,1H),2.03–1.93(m,1H),1.32(s,3H).
Example 25
Synthesis of 1- (1H-indazol-6-yl) -3- (6- (3-methyl-4- ((3-methyloxy-3-yl) methoxy) phenyl) pyrazin-2-yl) urea:
compound 70 was synthesized according to the same method as that of example 13, except for using 6-aminoindazole in place of compound 13b in the third step. Compound 70: MS (ESI): M/z 445.2 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ12.89(s,1H),10.02(s,1H),9.73(s,1H),8.90(s,1H),8.80(s,1H),8.06(s,1H),7.98–7.94(m,3H),7.70(d,J=8.4Hz,1H),7.17(d,J=9.2Hz,1H),6.96(dd,J=8.8,1.6Hz,1H),4.56(d,J=5.6Hz,2H),4.35(d,J=5.6Hz,2H),4.14(s,2H),2.28(s,3H),1.42(s,3H).
Example 26
Synthesis of 1- (6- (3-methyl-4- (methyl ((1-methyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl) amino) phenyl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 2-chloropyridine-3-amino-formaldehyde (2.00g, 14.13mmol, 1eq) was dissolved in 3M hydrochloric acid (4 mL), 30% hydrogen peroxide (0.5 mL) was added, stirring was carried out at 100 ℃ under microwave for 2 hours, LCMS indicated that the reaction was complete, the reaction solution was adjusted to pH7 with sodium bicarbonate solid, a solid precipitated, filtered, and recrystallized with a small amount of ethanol to give compound 109a (1.20 g, yield: 69%). MS (ESI) M/z 124.1 (M + H) + .
The second step: compound 109a (1.70g, 13.81mmol, 1eq) was dissolved in N, N-dimethylformamide (20 mL), cesium carbonate (9.00g, 27.62mmol, 2eq) was added, and after stirring for 20 minutes, iodomethane (3.92mL, 27.62mmol, 2eq) was added, and the mixture was stirred at room temperature overnight. LCMS showed the reaction was complete, and the reaction was directly concentrated to dryness under reduced pressure and then stirred with silica gel and chromatographed on flash silica gel (DCM: meOH = 10. MS (ESI) M/z 138.1 (M + H) + .
The third step: compound 109b (1.10g, 8.02mmol, 1eq) and 4-bromo-2-methylaniline (2.98g, 16.04mmol, 2eq) were dissolved in methanol (20 mL), and sodium cyanoborohydride (960mg, 16.04mmol, 2eq) was added in portions, and stirred at room temperature overnight. LCMS shows complete reaction, reaction solution, quick silica gelChromatographic separation (DCM: meOH = 10) gave compound 109c (1.3 g, yield: 52.8%). MS (ESI) M/z 307.0 (M + H) + .
The fourth step: compound 109c (300mg, 0.98mmol, 1eq), cesium carbonate (636mg, 1.95mmol, 2eq) were dissolved in N, N-dimethylformamide (3 mL), stirred at room temperature for 30 minutes, iodomethane (208mg, 1.46mmol, 1.5eq) was added dropwise, and stirred at room temperature overnight. LCMS showed the reaction was complete, and the reaction was directly concentrated to dryness under reduced pressure and separated by flash silica gel chromatography (PE: EA = 10) to obtain compound 109d (150 mg, yield: 45.2%). MS (ESI) M/z 321.0 (M + H) + .
The fifth step: compound 109d (130mg, 0.4mmol, 1eq), pinacol diboron (154mg, 0.61mmol, 1.5eq), potassium acetate (80mg, 0.81mmol, 2eq) and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (30mg, 0.04mmol, 0.1eq) was added to dioxane (5 mL) in sequence and stirred overnight at 100 deg.C under argon. LCMS showed the reaction was complete, and the reaction was directly concentrated to dryness under reduced pressure and directly separated by flash silica gel chromatography (PE: EA = 1) to obtain compound 109e (80 mg, yield: 53.7%). MS (ESI) M/z 369.3 (M + H) + .
And a sixth step: compound 109e (80mg, 0.22mmol, 1eq), intermediate A (52mg, 0.2mmol, 0.9eq), cesium carbonate (142mg, 0.43mmol, 2eq) and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (1695g, 0.022mmol, 0.1eq) was added to a mixed solution of dioxane (5 mL) and water (0.5 mL) in that order, and stirred overnight at 100 ℃ under argon. LCMS showed reaction completion, and the reaction was filtered and purified by silica gel prep plate (EA: PE =9, 1, uv254nm) to give crude product, which was further purified by reverse phase preparative chromatography Pre-HPLC to give the title compound 109 (3.61 mg, yield: 3.5%). MS (ESI) M/z 470.2 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ9.97(s,1H),9.78(s,1H),8.88(s,1H),8.79(s,1H),8.53(d,J=2.4Hz,1H),7.92–7.85(m,3H),7.63(dd,J=6.8,2.0Hz,1H),7.44(dd,J=6.8,2.0Hz,1H),7.23(d,J=8.4Hz,1H),7.18(d,J=8.4Hz,1H),6.24(t,J=6.8Hz,1H),3.97(s,2H),3.46(s,3H),2.71(s,3H),2.43(s,3H),2.34(s,3H).
Example 27
Synthesis of 1- (6- (3-methyl-4- (methyl ((1-methyl-1H-pyrazol-3-yl) methyl) amino) phenyl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 1-methyl-1H-pyrazole-3-carbaldehyde (5.00g, 45.41mmol, 1.0eq) and 4-bromo-2-methylaniline (8.45g, 45.41mmol, 1.0eq) were dissolved in methanol (200 mL), and sodium cyanoborohydride (7.13g, 113.52mmol, 2.5eq) was added in portions under an ice-water bath, warmed to room temperature, and reacted overnight. LCMS monitoring showed the product formed, the reaction was concentrated under reduced pressure and separated by flash silica gel chromatography (PE: EA =10, 1 to 4. MS (ESI) M/z 280.0 (M + H) + .
The second step is that: compound 111a (150mg, 0.54mmol, 1eq) was added to N, N-dimethylformamide (5 mL), replaced with argon, sodium hydride (60%, 43mg,1.087mmol, 2eq) was added while cooling on ice, the reaction was maintained for half an hour, iodomethane (152mg, 1.07mmol, 2eq) was added, the tube sealed, and the temperature was raised to 90 ℃ for 3 hours. The reaction solution was cooled to room temperature, quenched with water (30 mL), extracted with ethyl acetate, washed with water, washed with brine, dried over anhydrous sodium sulfate, filtered and dried, and the crude product was separated by flash chromatography on silica gel (PE: EA =10 1 to 3) to obtain compound 111b (150 mg, yield: 71%). MS (ESI) M/z 294.0 (M + H) + .
The third step: compound 111b (135mg, 0.46mmol, 1eq), potassium acetate (135mg, 1.38mmol, 3eq), pinacol diboron (175mg, 0.69mmol, 1.5eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (14mg, 10%) was added to dioxane (5 mL) in this order, replaced with argon three times, and then heated to 100 ℃ for 18 hours. LCMS monitored the product formation, the reaction was cooled and filtered through celite, and the silica gel was stirred and chromatographed on flash silica gel (PE: EA =3, 20-3. MS (ESI) M/z 342.2 (M + H) + .
The fourth step: intermediate A (61mg, 0.23mmol, 1eq), compound 111c (118mg, 0.35mmol, 1.5eq), and sodium carbonate (73mg, 0.69mmol, 3eq) were added in this order to a mixed solvent of dioxane (1.8 mL) and water (0.2 mL), and [1,1' -bis (diphenylphosphino) ferrocene ] was added]Palladium dichloride (10mg, 10%) was replaced by argon three times and then increasedThe temperature is increased to 100 ℃ and the reaction is carried out for 5 hours. The starting material was reacted completely by LCMS and the reaction was washed once with ethyl acetate (10 mL), saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and spun dry. The crude product was purified by reverse phase preparative chromatography Pre-HPLC to give the title compound 111 (5 mg, yield: 4.9%). MS (ESI) M/z 443.3 (M + H) + . 1 H NMR(400MHz,DMSO-d 6 )δ9.87(s,1H),9.75(s,1H),8.86(s,1H),8.79(s,1H),8.53(s,1H),7.94–7.83(m,3H),7.59(d,J=2.4Hz,1H),7.24(d,J=8.4Hz,1H),7.16(d,J=8.4Hz,1H),6.09(d,J=2.4Hz,1H),4.03(s,2H),3.79(s,3H),2.67(s,3H),2.43(s,6H).
Example 28
Synthesis of 1- (6-methylpyridin-3-yl) -3- {6- [1- (pyrrolidin-3-yl) -2, 3-dihydro-1H-indol-5-yl ] pyrazin-2-yl } urea hydrochloride:
the first step is as follows: 5-Bromobinoindole (2.00g, 10.1mmol, 1equiv.), 1-t-butoxycarbonyl-3-pyrrolidone (2.81g, 15.15mmol, 1.5equiv.) was dissolved in methanol (100 mL). The reaction was stirred at room temperature for 2 hours, acetic acid (3 mL) was added, and then sodium cyanoborohydride (3.02g, 50.49mmol, 5equ.) was added in portions. The reaction was stirred overnight. LCMS showed reaction completion, solvent was spun off, dissolved in water, extracted with ethyl acetate, organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and isolated by flash chromatography on silica gel to give compound 114a (3.3 g, yield: 89%). MS (ESI) M/z 367.19 (M + H) + ; 1 H NMR(400MHz,CDCl 3 )δ7.14(s,2H),6.33(d,J=8.8Hz,1H),4.10–3.93(m,1H),3.76–3.46(m,2H),3.44–3.25(m,4H),2.94(t,J=8.3Hz,2H),2.17–1.96(m,2H),1.44(s,9H).
The second step is that: compound 114a (1.00g, 2.72mmol, 1equiv.), pinacol diboron (830mg, 3.27mmol, 1.2equiv.), pd (dppf) Cl 2 (398mg, 0.55mmol, 0.2equiv.), and potassium acetate (1.069g, 10.89mmol, 4equiv.) were added to 1,4-dioxane (30 mL). The reaction system was purged with nitrogen three times and stirred at 90 ℃ for 8 hours. Spin-drying solvent, dissolving in water, extracting with ethyl acetate, and drying with anhydrous sodium sulfateThen, the mixture was filtered, concentrated, and purified by flash silica gel chromatography (PE: EA =20:1 to 10). MS (ESI) M/z 415.42 (M + H) + ; 1 H NMR(400MHz,CDCl 3 ):δ7.67–7.48(m,2H),6.48(t,J=9.6Hz,1H),4.34–4.14(m,1H),3.75–3.50(m,2H),3.50–3.29(m,4H),2.96(t,J=8.3Hz,2H),2.20–2.05(m,2H),1.45(s,9H),1.35–1.29(m,12H).
The third step: 114b (512mg, 1.24mmol, 1equiv.), intermediate A, pd (dppf) Cl, was added to a 100mL single-neck flask 2 (342mg, 0.12mmol, 0.1equiv.), potassium carbonate (342mg, 2.47mmol, 2equiv.), 1,4-dioxane (20 mL) and water (5 mL). The reaction system was purged with nitrogen three times and stirred at 90 ℃ for 4 hours. The solvent was dried by evaporation, dissolved in water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered, concentrated, and prepared by reverse phase preparative chromatography pre-HPLC to give compound 114c (330 mg, yield: 50%). MS (ESI) M/z 516.38 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ8.54(s,2H),8.39(s,1H),8.02(d,J=8.7Hz,1H),7.80–7.70(m,2H),7.28(d,J=8.6Hz,1H),6.65(d,J=8.3Hz,1H),4.31(d,J=7.7Hz,1H),3.70–3.49(m,4H),3.40(dd,J=11.1,6.4Hz,2H),3.05(t,J=8.1Hz,2H),2.49(d,J=9.1Hz,3H),2.17(d,J=8.6Hz,2H),1.48(d,J=2.3Hz,9H).
The fourth step: compound 114c (100mg, 0.19mmol, 1equiv.) and an ethyl hydrogen chloride acetate solution (4M, 10mL) were added to a 10mL single-necked flask, and stirred at room temperature for 2 hours, LCMS showed completion of the reaction, followed by filtration, washing the filter cake with ethyl acetate (20 mL), and drying to obtain the title compound 114 (39.40 mg, yield: 46%). MS (ESI) M/z 416.39 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ11.25(s,1H),10.07(s,1H),9.51(d,J=31.3Hz,2H),9.07–8.89(m,2H),8.79(s,1H),8.31(dd,J=8.7,2.3Hz,1H),7.85(dd,J=18.3,8.2Hz,3H),6.70(d,J=8.4Hz,1H),4.50–4.45(m,1H),3.64–3.48(m,2H),3.47–3.28(m,2H),3.19(m,2H),3.03(t,J=8.3Hz,2H),2.69(s,3H),2.26–1.97(m,2H).
Example 29
Synthesis of 3- (6-chloropyridin-3-yl) -1- (6- {1- [ (3-methyloxacyclohexan-3-yl) methyl ] -2, 3-dihydro-1H-indol-5-yl } pyrazin-2-yl) urea:
the first step is as follows: to 5-bromo-2, 3-dihydro-1H-indole (1g, 5.05mmol, 1.0equiv.) in dichloromethane (20 mL) was added 3-methyloxetane-3-carbaldehyde (606 mg,6.06mmol, 1.2equiv.), glacial acetic acid (0.1mL, 1.67mmol, 0.33equiv.), sodium triacetoxyborohydride (2.13g, 10.1mmol, 2.0equiv.). Stirring at 25 ℃ for 15 hours under the protection of nitrogen. LCMS showed the reaction was complete and the reaction was quenched by addition of water (30 mL), extracted with ethyl acetate, combined organic phases, dried over anhydrous sodium sulfate, filtered and the filtrate concentrated. The residue was purified by flash chromatography on silica gel (PE/EtOAc = 8/1) to give compound 115a (1.4 g, yield: 98%). MS (ESI) M/z 283.8 (M + H) + ; 1 H NMR(400MHz,CDCl 3 ):δ7.17-7.15(m,2H),6.32(d,J=8.0Hz,1H),4.60(d,J=5.6Hz,2H),4.45(d,J=5.6Hz,2H),3.40(t,J=8.4Hz,2H),3.24(s,2H),3.00(t,J=8.4Hz,2H),1.43(s,3H).
The second step: to a solution of compound 115a (1.4g, 4.96mmol, 1.0equiv.) in 1.4-dioxane (20 mL) were added diboronanol ester (1.9g, 7.44mmol, 1.5equiv.), potassium acetate (1.2g, 12.4mmol, 2.5equiv.), and [1,1' -bis (diphenylphosphine) ferrocene]Palladium dichloride dichloromethane complex (3970 mg,0.49mmol, 0.1equiv.). After stirring at 100 ℃ for 3 hours under nitrogen, LCMS indicated complete reaction, cooling to room temperature, water (30 mL) was added to the reaction, extracted with ethyl acetate, dried over innumerable sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified by flash chromatography on silica gel (PE/EtOAc = 3/1) to give compound 115b (900 mg, yield: 55%). MS (ESI): M/z 330.0 (M + H) + ; 1 H NMR(400MHz,CDCl 3 ):δ7.55(d,J=7.8Hz,1H),7.51(s,1H),6.41(d,J=7.8Hz,1H),4.57(d,J=5.8Hz,2H),4.40(d,J=5.8Hz,2H),3.40(t,J=8.4Hz,2H),3.29(s,2H),3.00(t,J=8.4Hz,2H),1.37(s,3H),1.31(s,12H).
The third step: to 1.4-dioxane (30 mL) of compound 115b (2.5g, 7.59mmol,1.0 equiv.) and water (3 mL) were added 6-chloropyrazine-2-carboxylic acid (1.44g, 9.11mmol,1.2 equiv.), sodium carbonate (2.01g, 18.9mm)ol,2.5 equiv.), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride dichloromethane complex (648mg, 0.8mmol, 0.1equiv.). Stirring was carried out at 100 ℃ for 3 hours under nitrogen. LCMS showed reaction complete, filtered and filtrate concentrated. The residue was purified by flash chromatography on silica gel (DCM/MeOH = 10/1) to give compound 115c (1.1 g, yield: 44.5%). MS (ESI): M/z 326.0 (M + H) + 。
The fourth step: to toluene (Tol, 2 mL) of compound 115c (50mg, 0.15mmol, 1.0equiv.), 6-chloropyridin-3-amine (24mg, 0.18mmol, 1.2equiv.), triethylamine (47mg, 0.46mmol, 3.0equiv.), diphenylphosphorylazide (85mg, 0.31mmol, 2.0equiv.) was added. Stirring is carried out for 15 hours at 100 ℃ under the protection of nitrogen. LCMS showed the reaction was complete, the reaction was concentrated and the residue was purified by reverse phase preparative chromatography Prep-HPLC to give the title compound 115 (12 mg, yield: 17.3%). MS (ESI) M/z 451.2 (M + H) + ; 1 H NMR(400MHz,DMSO):δ10.07(s,1H),9.77(s,1H),8.76(s,1H),8.73(s,1H),8.52(d,J=2.8Hz,1H),8.08(dd,J=8.8,2.8Hz,1H),7.82-7.80(m,2H),7.51(d,J=8.8Hz,1H),6.64(d,J=9.2Hz,1H),4.51(d,J=5.6Hz,2H),4.30(d,J=5.6Hz,2H),3.47(t,J=8.0Hz,2H),3.42(s,2H),3.08(d,J=8.0Hz,2H),1.35(s,3H).
Example 30
Synthesis of 1- (6- { 7-methoxy-1- [ (3-methyloxyethan-3-yl) methyl ] -1H-indazol-5-yl } pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: to acetonitrile (10 mL) containing 2-methoxy-6-methylaniline (1.0 g,7.29mmol,1.0 equiv.) was added N-bromosuccinimide (1.69g, 9.48mmol,1.3 equiv.), and the mixture was stirred at 25 ℃ for 15 hours. LCMS showed reaction completion, water was added to the reaction, extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE/EtOAc = 5/1) to give compound 116a (650 mg, yield 41.3%). MS (ESI): M/z 215.8 (M + H) + ; 1 H NMR(400MHz,CDCl 3 ):δ6.86(d,J=1.2Hz,1H),6.81(d,J=2.0Hz,1H),3.85(s,3H),2.16(s,3H).
The second step is that: glacial acetic acid (972mg, 16.2mmol,7.0 equiv.), potassium acetate (1.8g, 18.5mmol,8.0 equiv.), tert-butyl nitrite (358mg, 3.47mmol,1.5 equiv.) were added to toluene (20 mL) of compound 116a (500mg, 2.31mmol,1.0 equiv.). Stirring was carried out at 25 ℃ for 15 hours under nitrogen. LCMS showed reaction completion, water was added to the reaction, extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE/EtOAc = 3/1) to give compound 116b (200 mg, yield: 38%). MS (ESI) M/z 229.0 (M + H) + ; 1 H NMR(400MHz,CDCl 3 )δ7.96(s,1H),7.47(d,J=1.2Hz,1H),6.82(s,1H),3.97(s,3H).
The third step: to compound 116b (180mg, 0.79mmol,1.0 equiv.) in N, N-dimethylformamide (5 mL) was added sodium hydrogen (80mg, 2.0mmol,2.5equiv., purity 60%), 3- (chloromethyl) -3-methyloxyethane (144mg, 1.19mmol,1.5 equiv.) at 0 ℃. Stirring was carried out at 25 ℃ for 15 hours under nitrogen. LCMS showed reaction completion, water (20 mL) was added to the reaction, extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE/EtOAc = 3/1) to give compound 116c (90 mg, yield: 36.5%). MS (ESI) M/z 310.8 (M + H) + ; 1 H NMR(400MHz,CDCl 3 )δ7.85(s,1H),7.42(d,J=1.2Hz,1H),6.78(d,J=1.2Hz,1H),4.79(s,2H),4.76(d,J=6.0Hz,2H),4.33(d,J=6.0Hz,2H),3.94(s,3H),1.20(s,3H).
The fourth step: to 1.4-dioxane (20 mL) of compound 116c (200mg, 0.64mmol, 1.0equiv.), diboronanol ester (243mg, 0.96mmol, 1.5equiv.), potassium acetate (157mg, 1.6mmol, 2.5equiv.), and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride dichloromethane complex (49mg, 0.06mmol, 0.1equiv.). Stirring is carried out for 3 hours at 100 ℃ under the protection of nitrogen. LCMS showed reaction completion, water (30 mL) was added to the reaction, extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography on silica gel (PE/EtOAc = 3/1) to give compound 116d (190 mg, yield: 82.5%)。MS(ESI):m/z 359.0(M+H) + ; 1 H NMR(400MHz,CDCl 3 )δ7.97(s,1H),7.87(s,1H),7.11(s,1H),4.87(s,2H),4.83(d,J=6.0Hz,2H),4.36(d,J=6.0Hz,2H),4.02(s,3H),1.39(s,12H),1.26(s,3H).
The fifth step: to 1.4-dioxane (10 mL) of compound 116d (190mg, 0.53mmol, 1.0equiv.) and water (2 mL) were added intermediate A (168mg, 0.64mmol, 1.2equiv.), sodium carbonate (140mg, 1.32mmol, 2.5equiv.), and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride dichloromethane complex (40mg, 0.05mmol, 0.1equiv.). Stirring is carried out for 15 hours at 100 ℃ under the protection of nitrogen. LCMS showed reaction complete, filtered and the filtrate concentrated. The residue was purified by reverse phase preparative chromatography Prep-HPLC to give the title compound 116 (45 mg, yield: 18.9%). MS (ESI) M/z 460.3 (M + H) + ; 1 H NMR(EN1079-081-P)(400MHz,DMSO):δ9.66-9.64(m,2H),8.93(s,1H),8.88(s,1H),8.48(d,J=2.8Hz,1H),8.15(s,1H),8.05(s,1H),7.84(dd,J=8.4,2.8Hz,1H),7.50(d,J=1.2Hz,1H),7.20(d,J=8.4Hz,1H),4.78(s,2H),4.60(d,J=6.0Hz,2H),4.18(d,J=6.0Hz,2H),4.00(s,3H),2.38(s,3H),1.09(s,3H).
Example 31
Synthesis of 1- (6- {1- [2- (dimethylamine) ethyl ] -2, 3-dihydro-1H-indol-5-yl } pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea formate:
the first step is as follows: 5-bromo-2, 3-dihydro-1H-indole (500mg, 2.52mmol, 1equiv.), 2- (dimethylamino) acetaldehyde hydrochloride (405.57mg, 3.28mmol, 1.3equiv.), zinc chloride (34.41mg, 0.25mmol, 0.1equiv.) were dissolved in methanol (10 mL NaHCO), stirred at room temperature for 2 hours, LCMS showed completion of the reaction, and the reaction was poured into saturated NaHCO 3 (200 mL), extracted with ethyl acetate, the combined organic phases dried over sodium sulfate, filtered, and the filtrate dried to give the crude product. The crude product was chromatographed on flash silica gel (PE/EtOAc = 3/1-DCM/MeOH = 10/1) to give compound 117a (260 mg, yield: 38.3%). MS (ESI) M/z 269.10 (M + H) + ; 1 H NMR(400MHz,CDCl 3 )δ7.19–7.10(m,2H),6.34(d,J=8.8Hz,1H),3.40(t,J=8.4Hz,2H),3.20(t,J=7.0Hz,2H),2.95(t,J=8.3Hz,2H),2.61(t,J=7.0Hz,2H),2.37(s,6H).
The second step is that: to dioxane (6 mL) was added compound 117a (200mg, 0.74mmol, 1equ.), pinacol diboron (283.02mg, 1.11mmol, 1.5equ.), potassium acetate (218.75mg, 2.23mmol, 3equ.) and Pd (dppf) Cl2 (51.22mg, 0.07mmol, 0.1equ.). Heating to 100 ℃ under the protection of nitrogen, and stirring for 2 hours. The reaction was diluted with 50mL of ethyl acetate, filtered, and the filtrate was concentrated to give a crude product, which was separated by flash chromatography on silica gel (ethyl acetate/petroleum ether = 0-90% first, and methanol/dichloromethane = 0-11%) to give compound 117b (100 mg, crude product). MS (ESI) M/z 317.2 (M + H) + .
The third step: compound 117b (100mg, 0.32mmol, 1equiv.), intermediate a (91.71mg, 0.35mmol, 1.1equiv.), sodium carbonate (67.83mg, 0.64mmol, 2.0eq.) and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (23.39mg, 0.03mmol, 0.1equiv.) was sequentially added to a mixed solution of dioxane and water (5mL, 4. Cooled to room temperature, diluted with ethyl acetate (50 mL), filtered, and the filtrate was concentrated to give a crude product, which was purified by C18 column (acetonitrile/water = 0-80%, aqueous phase containing 0.1 wt% formic acid) to give the title compound 117 (15 mg, yield: 11.2%). MS (ESI): M/z 418.2 (M + H) + ; 1 H NMR(400MHz,MeOD)δ8.56(s,1H),8.53(s,1H),8.52(s,1H),8.44(s,1H),8.03(dd,J=8.4,2.7Hz,1H),7.78(d,J=9.9Hz,2H),7.28(d,J=8.5Hz,1H),6.73(d,J=8.2Hz,1H),3.54(t,J=8.4Hz,2H),3.47(t,J=6.5Hz,2H),3.10(dd,J=10.7,6.7Hz,4H),2.71(s,6H),2.50(s,3H).
Example 32
Synthesis of 1- (6- (1- (2-hydroxypropyl) indol-5-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 5-Bromoindoline (1.00g, 5.0mmol, 1.0equiv.) was dissolved in anhydrous THF (10 mL)) To the solution, sodium hydride (0.4 g,10.0mmol,60% purity, 2equiv.) was added under nitrogen protection at 0 ℃ and after stirring for 10min, propylene oxide (0.44g, 7.5mmol,1.5 equiv.) was slowly added dropwise and allowed to warm to room temperature and stirred for 16 hours. The reaction was cooled to room temperature, quenched with ice water (10 mL), the aqueous phase extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated. The residue was subjected to flash silica gel chromatography (PE: EA = 5) to obtain compound 118a (800 mg, yield: 61.5%). 1 H NMR(400MHz,DMSO-d6)δ7.13(s,1H),7.09(d,J=8.4Hz 1H),6.39(d,J=8.4Hz,1H),4.69(d,J=4.4Hz,1H),3.97–3.78(m,1H),3.55–3.40(m,2H),2.96-2.88(m,4H),1.14–1.07(d,J=6.0Hz,3H).
The second step is that: compound 118a (871mg, 3,43mmol, 1.1equiv.), potassium acetate (611mg, 6.24mmol, 2.0equiv.), and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (226mg, 0.31mmol, 0.1equiv.) was added to a solution of 1,4-dioxane (10 mL) and the reaction stirred at 100 ℃ under nitrogen for 16 h. The reaction solution was concentrated under reduced pressure, and the residue was separated by flash silica gel chromatography (PE: EA = 5. MS (ESI) M/z 304.0 (M + H) + .
The third step: to a solution of compound 118b (200mg, 0.66mmol,1.0 equiv.) in dioxane (10 mL) was added an aqueous solution (2 mL) of intermediate A (192mg, 0.73mmol,1.1 equiv.) and sodium carbonate (140mg, 1.32mmol,2.0 equiv.), and [1,1' -bis (diphenylphosphino) ferrocene ] was added under nitrogen protection]Palladium dichloride (51.2mg, 0.07mmol, 0.1equiv.) was reacted at 100 ℃ with stirring for 16 hours. LCMS showed reaction completion, the reaction was cooled to room temperature, concentrated, the residue was added with water (20 mL), extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was separated by flash chromatography on silica gel (PE/EtOAc = 1/9) to give 100mg of crude title compound 118, which was then isolated and purified by reverse phase preparative chromatography Pre-HPLC to give title compound 118 (42.53mg, 0.105mmol, 16.9% yield). MS (ESI): M/z 405.2 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ9.99(s,1H),9.69(s,1H),8.69(s,1H),8.67(s,1H),8.56(s,1H),7.93(d,J=8.8Hz,1H),7.79-7.71(m,2H),7.30(d,J=8.0Hz,1H),6.55(d,J=8.0Hz,1H),4.73(s,1H),3.93-3.88(m,1H),3.58(t,J=8.4Hz,2H),3.09-3.04(m,2H),3.01(t,J=8.8Hz,2H),2.48(s,3H),1.11(d,J=6.4Hz,3H).
Example 33
Synthesis of (S) -1- (6- (1- ((3-methyloxycyclohexan-3-yl) methyl) indol-5-yl) pyrazin-2-yl) -3- (piperidin-3-yl) urea:
the first step is as follows: in a 100mL single-necked flask, compound 60d (500mg, 1.69mmol, 1equiv.) was added to a solvent of toluene (10 mL), followed by addition of (3S) -1- [ (tert-butoxy) carbonyl group]Piperidine-3-carboxylic acid (580.2mg, 2.53mmol, 1.5eq), diphenylphosphorylazide (927.5mg, 3.37mmol, 2.0eq), triethylamine (511.5mg, 5.05mmol, 3.0eq), the reaction system was purged with nitrogen and then stirred at 100 ℃ for 16 hours. LCMS showed the reaction was complete, the reaction was filtered, concentrated, and chromatographed on flash silica gel (PE: EA = 1) to give compound 119a (370 mg, yield 42.0%). MS (ESI) M/z 523.0 (M + H) + .
The second step is that: in a 100mL single-neck flask, the compound 119a (100mg, 0.19mmol, 1equiv.) was added to a solvent of dichloromethane (10 mL), trifluoroacetic acid (2mL, 17.54mmol, 183.3eq) was further added dropwise, and the reaction system was purged with nitrogen and then stirred at 25 ℃ for 1 hour to obtain a red-brown liquid. LCMS showed reaction completion, which was dried and then dissolved in N, N-dimethylformamide and isolated and purified by reverse phase preparative chromatography Pre-HPLC (formic acid as additive) to give the title compound 119 (54.52 mg, 69.4% yield). MS (ESI) M/z 423.4 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ9.54(s,1H),8.61(s,1H),8.52(s,1H),8.22-8.12(m,1H),7.81-7.74(m,2H),6.61(d,J=8.4Hz,1H),4.50(d,J=5.6Hz,2H),4.30(d,J=5.6Hz,2H),3.90–3.80(m,2H),3.37(s,2H),3.22-3.14(m,2H),3.08–2.92(m,3H),2.83–2.69(m,2H),1.96-1.86(m,1H),1.82-1.71(m,1H),1.66–1.48(m,2H),1.35(s,3H).
Example 34
Synthesis of 1- (6- {1- [ (3-methyloxoalk-3-yl) methyl ] -1H,2H,3H pyrrolo [2,3-b ] pyridin-5-yl ] pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: in the presence of 5-bromo-1H, 2H, 3H-pyrrolo [2,3-b ]]Pyridine (500mg, 2.52mmol,1.0 equiv.) in N, N' -dimethylformamide (10 mL) was added sodium hydride (202 mg, 60% purity, 5.05mmol,2.0 equiv.), stirred at room temperature for 30min, then 3-chloromethyl-3-methyloxetane (454mg, 3.77mmol,1.5 equiv.) was added, and stirred at 25 ℃ for 15 hours. LCMS showed the reaction was complete, and was slowly quenched by addition of ice water (10 mL), extracted with ethyl acetate, and the organic phases were combined, washed successively with saturated sodium chloride solution, water, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the residue was purified by flash chromatography on silica gel (eluent: PE/EA = 3/1) to give compound 120a (450 mg, yield: 63.3%). MS (ESI) M/z 282.9 (M + H) + ; 1 H NMR(400MHz,CDCl 3 )δ7.87(d,J=1.2Hz,1H),7.26(d,J=1.2Hz,1H),4.64(d,J=6.0Hz,2H),4.42(d,J=6.0Hz,2H),3.57–3.53(m,4H),3.03(t,J=8.4Hz,2H),1.39(s,3H).
The second step is that: to 1.4-dioxane (15 mL) of compound 120a (300mg, 1.03mmol, 1.0equiv.) were added diboronanol ester (404mg, 1.59mmol, 1.5equiv.), potassium acetate (260mg, 2.65mmol, 2.5equiv.), and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride dichloromethane complex (80mg, 0.1mmol, 0.1equiv.). Stirring is carried out for 3 hours at 100 ℃ under the protection of nitrogen. LCMS indicated complete reaction, suction filtered and concentrated to give crude compound 120b (310 mg, yield: 70.8%) which was used directly in the next step. MS (ESI) M/z 249.0 (M + H) + .
The third step: to 1.4-dioxane (10 mL) of compound 120b (300mg, 1.21mmol, 1.0equiv.) and water (1 mL), intermediate A (383mg, 1.45mmol, 1.2equiv.), sodium carbonate (320mg, 3.02mmol, 2.5equiv.), and [1,1' -bis (diphenylphosphino) ferrocene were added]Palladium dichloride dichloromethane complex (97mg, 0.12mmol, 0.1equiv.). Stirring is carried out for 15 hours at 100 ℃ under the protection of nitrogen. LCMS showed reaction complete, filtered and the filtrate concentrated. The residue was purified by reverse phase preparative chromatography Prep-HPLC to give the title compound 120 (11 mg, yield: 2.1%). MS (ESI) M/z 432.3 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ11.57(s,1H),9.15(s,1H),8.73(s,1H),8.66(d,J=2.4Hz,1H),8.60(s,1H),8.46(s,1H),8.18(s,1H),7.94(dd,J=8.8,2.4Hz,1H),7.19(d,J=8.4Hz,1H),4.19(d,J=12.8Hz,1H),4.02-3.96(m,3H),3.44-3.43(m,1H),3.40(s,2H),3.35-3.32(m,2H),3.23(d,J=12.8Hz,1H),2.42(s,3H),1.05(s,3H).
Example 35
Synthesis of 3- (6-methylpyridin-3-yl) -1- {6- [1- (oxazolidin-3-yl) -2, 3-dihydro-1H-indol-5-yl ] pyrazin-2-yl } urea:
the first step is as follows: 5-bromo-2, 3-dihydro-1H-indole (500mg, 2.52mmol, 1equv.), oxazolidin-3-one (326mg, 3.79mmol, 1.5equv.), zinc chloride (34mg, 0.24mmol, 0.1equv.), and methanol (10ml, 100.0%) were added, sodium cyanoborohydride (302mg, 4.71mmol, 2equv.) was added at room temperature, and stirring was continued for 1 hour at room temperature. LCMS showed the reaction was complete and the reaction was quenched by pouring into saturated sodium bicarbonate solution (100 mL), extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered and the filtrate was spun dry to give crude product which was chromatographed on flash silica gel (PE/EtOAc = 3/1) to give compound 121a (600 mg, yield: 88.8%). MS (ESI): M/z 268.10 (M + H) + ; 1 H NMR(400MHz,CDCl 3 )δ7.20–7.12(m,2H),6.36(d,J=8.1Hz,1H),4.19(ddd,J=14.9,7.5,4.4Hz,1H),4.24-4.15(m,1H),4.07-3.98(m,1H),3.89–3.84(m,1H),3.79(dd,J=15.7,8.4Hz,1H),3.46(dd,J=16.6,8.2Hz,1H),3.38(dd,J=16.6,8.2Hz,1H),2.94(t,J=8.3Hz,1H),2.25-2.13(m,1H),2.07–1.94(m,1H).
The second step is that: the compound 121a (600mg, 2.24mmol, 1equiv.), the bis-pinacol borate (852.31mg, 3.36mmol, 1.5equiv.), pd (dppf) Cl 2 (80 mg), KOAc (700 mg) was dissolved in 1,4-dioxane (10 ml, 100%), and reacted at 100 ℃ for 2 hours under nitrogen protection. LCMS shows complete reaction, the reaction is poured into water (100 mL), extracted with ethyl acetate, the organic phases are combined, dried over anhydrous sodium sulfate, filtered, the filtrate is spun dry to give the crude product, which is then purified over silica gelChromatography (PE/EtOAc = 3/1) afforded compound 121b (400 mg, yield: 56.7%). MS (ESI) M/z 316.24 (M + H) + ;1H NMR(EN1084-59-P1A,CDCl 3 ,400MHz)δ7.56(d,J=7.9Hz,1H),7.51(s,1H),6.47(d,J=7.9Hz,1H),4.36–4.25(m,1H),4.06-3.96(m,1H),3.93(dd,J=9.4,4.0Hz,1H),3.85(dd,J=9.4,6.6Hz,1H),3.79(dd,J=15.6,8.3Hz,1H),3.52–3.46(m,1H),3.44–3.36(m,1H),2.95(t,J=8.4Hz,2H),2.26-2.13(m,1H),2.09–1.92(m,1H),1.31(s,12H).
The third step: compound 121b (200mg, 0.63mmol, 1eq), intermediate A (167.3mg, 0.63mmol, 1eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (92.7mg, 0.13mmol, 0.2eq) and anhydrous sodium carbonate (134.5mg, 1.27mmol, 2eq) were added in sequence to a mixed solution of dioxane/water (20 mL/2 mL), heated to 100 ℃ under nitrogen protection and stirred for 16 hours. LCMS shows the reaction is complete, the reaction is concentrated and the residue is purified by reverse phase preparative chromatography Prep-HPLC to give the title compound 121 (62.42 mg, yield: 23.6%). MS (ESI) M/z 417.0 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ9.94(s,1H),9.67(s,1H),8.73(s,1H),8.69(s,1H),8.52(d,J=2.4Hz,1H),7.90(dd,J=8.4,2.8Hz,1H),7.80-7.78(m,2H),7.26(d,J=8.4Hz,1H),6.68(d,J=8.4Hz,1H),4.43-4.37(m,1H),3.91–3.89(m,1H),3.83–3.75(m,2H),3.71-3.65(m,1H),3.53–3.44(m,2H),2.98(t,J=8.4Hz,2H),2.43(s,3H),2.19-2.13(m,1H),2.01–1.90(m,1H).
Example 36
Synthesis of (1- {6- [1- (2-methylpropyl) -2, 3-dihydro-1H-indol-5-yl ] pyrazin-2-yl } -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 5-bromo-2, 3-dihydro-1H-indole (1.00g, 5.07mmol, 1eq) was dissolved in dichloromethane (15 mL), 2-methylpropionaldehyde (402mg, 5.58mmol, 1.1eq) and acetic acid (1 mL) were added to the above mixture, and after stirring at 25 ℃ for 30min, sodium triacetoxyborohydride (2.15g, 10.14mmol, 2eq) was added to the reaction mixture, and stirring was carried out at room temperature for 16 hours. LCMS showed reaction complete, dichloromethane extraction, brineAfter washing, washing with water and drying over anhydrous sodium sulfate, filtration was carried out, the filtrate was concentrated under reduced pressure and purified by flash chromatography on silica gel (PE: EA = 5). MS (ESI) M/z 254.9 (M + H) + .
The second step: compound 122a (450mg, 1.77mmol, 1.5eq), potassium acetate (290mg, 2.95mmol, 2.5eq) and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (173mg, 0.24mmol, 0.2eq) was added to dioxane (4 mL) in sequence, warmed to 100 ℃ under nitrogen and stirred for 3 hours, LCMS showed reaction complete, after the reaction system cooled to room temperature, filtered through celite, the filtrate was concentrated under reduced pressure and separated by flash silica gel chromatography (PE: EA =4: 1) to give compound 122b (243 mg, yield: 68.3%). MS (ESI) M/z 302.0 (M + H) + .
The third step: compound 122b (100mg, 033mmol, 1.0eq), intermediate A (87.53mg, 0.33mmol, 1eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (48.53mg, 0.66mmol, 0.2eq) and anhydrous sodium carbonate (70.37mg, 0.66mmol,2.0 eq) are sequentially added into a mixed solution of dioxane/water (10 mL/1 mL), protected by nitrogen, heated to 100 ℃ and stirred for 16 hours. LCMS showed the reaction was complete, the reaction was concentrated and the residue was purified by reverse phase preparative chromatography Prep-HPLC to give the title compound 122 (16.13 mg, yield: 12.1%). MS (ESI): M/z 403.0 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ9.96(s,1H),9.67(s,1H),8.70(s,1H),8.68(s,1H),8.53(d,J=2.4Hz,1H),7.91(dd,J=8.4,2.8Hz,1H),7.78-7.76(m,2H),7.26(d,J=8.0Hz,1H),6.56(d,J=8.4Hz,1H),3.49(t,J=8.8Hz,2H),3.03(t,J=8.8Hz,2H),2.94(d,J=7.2Hz,2H),2.44(s,3H),1.99-1.94(m,1H),0.94(d,J=6.4Hz,6H).
Example 37
Synthesis of 1- (6- (1- (3-methyloxyethane-3-carbonyl) indol-5-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 3-methyl-3-carboxy-1-oxetane (100mg, 0.86mmol, 1equiv.) was added to N, N-dimethyl formamideTo a solvent of amide (6 mL) was added 5-bromo-2, 3-dihydro-1H-indole (255.85mg, 1.29mmol,1.5 equiv.), N, N-dimethylpyridin-4-amine (126.25mg, 1.03mmol, 1.2eq), and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (294.12mg, 1.89mmol, 2.2eq) and the reaction system was stirred at 25 ℃ for 16 hours after replacing nitrogen. LCMS showed the reaction was complete, and the reaction was filtered and concentrated, and separated by flash silica gel chromatography (PE: EA = 1) to obtain compound 123a (110 mg, yield: 43.2%). MS (ESI): M/z 295.8 (M + H) + .
The second step is that: the compound 123a (110mg, 0.37mmol, 1equiv.) was added to a solvent of 1,4-dioxane (8 mL), followed by addition of pinacol diboron (188.64mg, 0.74mmol, 2.0equiv.), potassium acetate (91mg, 0.93mmol, 2.5eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (27mg, 0.037mmol, 0.1eq) was stirred at 100 ℃ for 3 hours after nitrogen gas was replaced in the reaction system. LCMS showed the reaction was complete, the reaction was filtered and concentrated, and flash chromatography on silica gel (PE: EA = 1) was used to isolate compound 123b (120 mg, yield: 94.5%). MS (ESI) M/z 344.0 (M + H) + .
The third step: compound 123b (120mg, 0.35mmol, 1equiv.) is added to a mixed solvent of 1,4-dioxane (8 mL) and water (0.8 mL), followed by addition of 3- (6-chloropyrazin-2-yl) -1- (6-methylpyridin-3-yl) urea (138mg, 0.52mmol, 1.5eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (26mg, 0.035mmol, 0.1eq), sodium carbonate (74mg, 0.70mmol,2.0 eq), and the reaction system was purged with nitrogen and then stirred at 100 ℃ for 16 hours. LCMS showed the reaction was complete, the reaction was filtered through celite, concentrated and purified by reverse phase preparative chromatography Pre-HPLC to give the title compound 123 (9.11 mg, yield: 6%). MS (ESI): M/z 445.6 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ9.80-9.73(m,2H),8.92(s,1H),8.82(s,1H),8.51(d,J=2.4Hz,1H),8.01(s,1H),7.98-7.94(m,1H),7.91-7.87(m,1H),7.64-7.52(m,1H),7.23(d,J=8.4Hz,1H),4.99(d,J=6.0Hz,1H),4.29(d,J=5.6Hz,1H),3.88(t,J=8.2Hz,1H),3.22(t,J=8.0Hz,1H),2.43(s,3H),1.71(s,3H).
Example 38
Synthesis of 1- {6- [1- (2-hydroxy-2-methylpropyl) -2, 3-dihydro-1H-indol-5-yl ] pyrazin-2-yl } -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: a50 mL single-neck flask was charged with 5-bromoindoline (1g, 5.05mmol, 1equiv.) and THF (20mL, 100%), ice-cooled, sodium hydride (404mg, 10.10mmol, 2equiv.), stirred for 2 minutes, added with methyl propylene oxide (546mg, 7.57mmol, 1.5equiv.), and reacted at room temperature overnight. LCMS showed the reaction was complete, and water (30 mL) was added to quench the reaction, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate and concentrated, filtered, the filtrate was concentrated, and the compound 124a (1109 mg, yield: 90.4%) was isolated and purified by flash silica gel chromatography (PE: EA = 10. MS (ESI) M/z 270.11 (M + H) + ; 1 H NMR(400MHz,CDCl3)δ7.15(s,1H),7.13(dd,J=8.3,2.1Hz,1H),6.40(d,J=8.3Hz,1H),3.52(t,J=8.5Hz,2H),3.06–2.91(m,4H),1.28(s,6H).
The second step is that: compound 124a (500mg, 1.85mmol, 1equiv.), pinacol diboron (563.96mg, 2.22mmol, 1.2equiv.), pd (dppf) Cl was added to a 100mL single-necked flask 2 (271mg, 0.37mmol, 0.2equiv.), potassium acetate (726.51mg, 7.4mmol, 4equiv.) and 1,4-dioxane (40 mL). The reaction system was purged with nitrogen three times and stirred at 90 ℃ for 8 hours. LCMS showed the reaction was complete, the solvent was dried, dissolved with water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and separated by flash chromatography on silica gel (PE: EA =20 1-10) to give compound 124b (152 mg, yield: 26%). MS (ESI) M/z 318.25 (M + H) + ; 1 H NMR(400MHz,CDCl 3 )δ7.56(d,J=7.9Hz,1H),7.53(s,1H),6.53(d,J=7.9Hz,1H),3.56(t,J=8.5Hz,2H),3.05(s,2H),3.01(t,J=8.5Hz,2H),1.32(s,12H),1.29(s,6H).
The third step: compound 124b (123mg, 0.39mmol, 1.0eq), intermediate A (102.24mg, 0.39mmol, 1.0eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (56.74mg, 0.078mmol, 0.2eq) and anhydrous sodium carbonate (82.19mg, 0.78mmol, 2.0eq) were sequentially added to a mixed solution of dioxane/water (10 mL/1 mL), nitrogen gas was substituted for 3 times, and the temperature was raised toStirred at 100 ℃ for 16 hours. LCMS showed the reaction was complete, the reaction was concentrated and the residue was purified by reverse phase preparative chromatography Prep-HPLC to give the title compound 124 (53.7 mg, yield 33.5%). MS (ESI) M/z 419.3 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ10.00(s,1H),9.68(s,1H),8.69(s,1H),8.68(s,1H),8.53(d,J=2.8Hz,1H),7.93-7.90(m,1H),7.77-7.76(m,2H),7.25(d,J=8.4Hz,1H),6.59(d,J=8.8Hz,1H),4.48(s,1H),3.66(t,J=8.8Hz,2H),3.06–3.02(m,3H),2.44(s,3H),1.18(s,6H).
Example 39
Synthesis of 3- (6- {1- [ (3-methyloxoalk-3-yl) methyl ] -2, 3-dioxy-2, 3-dihydro-1H-indol-5-yl ] pyrazin-2-yl) -1- (6-methylpyridin-3-yl) urea:
the first step is as follows: 5-bromo-2, 3-dihydro-1H-indole-2, 3-dione (2.0g, 8.85mmol, 1equiv.), potassium carbonate (1.47g, 10.62mmol, 1.2equiv.), and N, N-dimethylformamide (20 mL) were subjected to nitrogen substitution, followed by stirring at 70 ℃ for 1 hour, followed by addition of potassium iodide (734.42mg, 4.42mmol, 0.5equiv.), and 3-chloromethyl-3-methyloxetane (1.28g, 10.62mmol, 1.2equiv.), 70 ℃ and stirring at 1.5 hours. The reaction solution was cooled to room temperature, then water (20 mL) was added, extraction was performed with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the residue was separated by flash chromatography on silica gel (PE: EA = 3) to obtain compound 125a (1.4 g, yield: 51%). MS (ESI) M/z 312.0 (M + H) + 。
The second step: compound 125a (100mg, 0.32mmol, 1equiv.) is dissolved in 1,4-dioxane (2 mL), pinacol diboron (106.44mg, 0.42mmol, 1.3equiv.), potassium acetate (94mg, 0.96mmol, 3.0equiv.), and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (12mg, 0.02mmol, 0.05equiv.) was purged with nitrogen and then stirred at 100 ℃ for 3 hours. The reaction solution was cooled to room temperature, followed by filtration, and the filtrate was spin-dried to obtain crude compound 125b (110 mg, yield: 94%). MS (ESI): M/z 358.3 (M + H) + . Used in the next step without purification。
The third step: compound 125b (110mg, 0.31mmol, 1equiv.) was dissolved in 1,4-dioxane (1 mL)/water (0.1 mL), intermediate A (73.08mg, 0.28mmol, 0.9equiv.), sodium carbonate (82mg, 0.78mmol, 2.5equiv.), and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (22mg, 0.03mmol, 0.1equiv.) was purged with nitrogen and then stirred at 100 ℃ for 2 hours. LCMS showed the reaction was complete, the reaction liquid was cooled to room temperature, filtered and then isolated and purified by reverse phase preparative chromatography Pre-HPLC to give the title compound 125 (7.79 mg, yield: 5.5%). MS (ESI) M/z 459.1 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ9.76(s,1H),9.57(s,1H),9.00(s,1H),8.92(s,1H),8.53(d,J=2.4Hz,1H),8.42–8.35(m,1H),8.27(d,J=1.6Hz,1H),7.95–7.85(m,1H),7.45(d,J=8.4Hz,1H),7.23(d,J=8.4Hz,1H),4.61(d,J=6.0Hz,2H),4.21(d,J=6.0Hz,2H),3.93(s,2H),2.43(s,3H),1.37(s,3H).
Example 40
Synthesis of 3- (6- {1- [ (3-methyloxetan-3-yl) methyl ] -2-oxo-2, 3-dihydro-1H-indol-5-yl } pyrazin-2-yl) -1- (6-methylpyridin-3-yl) urea:
the first step is as follows: a microwave tube was charged with compound 125a (600mg, 1.93mmol, 1equiv.) and hydrazine hydrate (6.0 mL), followed by nitrogen bubbling and stirring at 120 ℃ for 1 hour. After the reaction solution was cooled to room temperature, water (10 mL) was added to dilute the solution, the solution was extracted with ethyl acetate, and the organic phases were combined, washed with saturated brine (20mL × 3), dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and purified by flash chromatography on silica gel (PE: EA = 1) to obtain compound 126a (180 mg, yield: 31.5%). MS (ESI) M/z 297.8 (M + H) + .
The second step: compound 126a (100mg, 0.34mmol, 1equiv.) is dissolved in 1,4-dioxane (2 mL), and pinacol diboron (111.47mg, 0.44mmol, 1.3equiv.), potassium acetate (100mg, 1.02mmol, 3.0equiv.) and [1,1' -bis (diphenylphosphino) ferrocene are added]Palladium dichloride (12mg, 0.02mmol, 0.05equiv.) was purged with nitrogen and then stirred at 100 ℃ for 3 hours. LC (liquid Crystal)MS showed the reaction was complete, the reaction solution was cooled to room temperature, then filtered, and the filtrate was spin-dried to give crude compound 126b (110 mg, yield: 94.3%). MS (ESI): M/z 344.0 (M + H) + . Was used in the next step without further purification.
The third step: compound 126b (110mg, 0.32mmol, 1equiv.) is dissolved in 1,4-dioxane (1mL, 90.91%)/water (0.1mL, 9.09%), intermediate A (76.05mg, 0.29mmol, 0.9equiv.), sodium carbonate (85mg, 0.8mmol, 2.5equiv.) and [1,1' -bis (diphenylphosphino) ferrocene ] are added]Palladium dichloride (22mg, 0.03mmol, 0.1equiv.) was purged with nitrogen and then stirred at 100 ℃ for 2 hours. LCMS shows the reaction is complete, the reaction is cooled to room temperature, filtered, the filtrate is concentrated and purified by reverse phase preparative chromatography Pre-HPLC to afford the title compound 126 (46.8 mg, yield: 32%). MS (ESI) M/z 445.1 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ9.73(s,1H),9.71(s,1H),8.92(s,1H),8.83(s,1H),8.54(d,J=2.4Hz,1H),8.05–8.00(m,2H),7.95–7.85(m,1H),7.30–7.20(m,2H),4.60(d,J=6.0Hz,2H),4.19(d,J=6.0Hz,2H),3.89(s,2H),3.74(s,2H),2.44(s,3H),1.33(s,3H).
EXAMPLE 41
Synthesis of 1- (6- (1- ((1-methyl-1H-pyrazol-3-yl) methyl) indol-5-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 5-bromo-2, 3-dihydro-1H-indole (500mg, 2.52mmol, 1equiv.), 1-methyl-1H-pyrazole-3-carbaldehyde (416.96mg, 3.79mmol, 1.5equiv.), zinc chloride (34.41mg, 0.25mmol, 0.1equiv.) were added to methanol (10 mL), sodium cyanoborohydride (302.03mg, 5.05mmol, 2equiv.) was added at room temperature, and stirring was continued for 1 hour at room temperature. LCMS showed the reaction was complete and the reaction was quenched by pouring into saturated sodium bicarbonate solution (100 mL), extracted with ethyl acetate, the organic phases combined, dried over anhydrous sodium sulfate, filtered and the filtrate spun dry to give crude product which was chromatographed on flash silica gel (PE/EtOAc = 3/1) to give compound 127a (600 mg, yield: 88.8%). MS (ESI) M/z =2.231 (M + H) + ; 1 H NMR(400MHz,CDCl 3 )δ7.27(d,J=2.2Hz,1H),7.15–7.11(m,2H),6.48–6.43(m,1H),6.12(d,J=2.2Hz,1H),4.23(s,2H),3.87(s,3H),3.37(t,J=8.4Hz,2H),2.92(t,J=8.4Hz,2H).
The second step: the compound 127a (600mg, 2.05mmol, 1equiv.), bisphenonal borate (782.24mg, 3.08mmol, 1.5equiv.), pd (dppf) Cl 2 (150 mg), potassium acetate (604.62mg, 6.16mmol, 3equiv.), dissolved in dioxane (10 mL) and reacted at 90 ℃ for 3 hours under nitrogen. LCMS showed the reaction was complete, the reaction was poured into water (100 mL), extracted with ethyl acetate, the organic phases combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give the crude product, which was purified by flash chromatography on silica gel (PE/EtOAc = 3/1) to give compound 127b (650 mg, yield: 93.5%). MS (ESI): M/z 340.30 (M + H) + ; 1 H NMR(CDCl 3 ,400MHz)δ7.57(d,J=7.9Hz,1H),7.50(s,1H),7.25(d,J=2.1Hz,1H),6.59(d,J=7.9Hz,1H),6.11(d,J=2.2Hz,1H),4.32(s,2H),3.86(s,3H),3.41(t,J=8.4Hz,2H),2.94(t,J=8.4Hz,2H),1.31(s,12H).
The third step: intermediate A (150mg, 0.54mmol, 1equiv.), compound 127b (289.48mg, 0.85mmol, 1.5equiv.), and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (40 mg), sodium carbonate (180.88mg, 1.71mmol,3 equiv.) were dissolved in dioxane (4 mL) and water (2 mL) and stirred at 100 ℃ for 3 hours under nitrogen. LCMS showed reaction complete, pour reaction into water (200 mL), filter with celite, wash celite with ethyl acetate; celite was then soaked with dichloromethane (30 mL) and methanol (8 mL), filtered, the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give the crude product which was isolated and purified by flash chromatography on silica gel (DCM/MeOH = 10/1) to give the title compound 127 (78.41 mg). MS (ESI) M/z 441.36 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ9.95(s,1H),9.67(s,1H),8.71(s,1H),8.68(s,1H),8.51(s,1H),7.89(d,J=6.8Hz,1H),7.83–7.71(m,2H),7.59(s,1H),7.22(d,J=8.3Hz,1H),6.75(d,J=8.2Hz,1H),6.13(s,1H),4.31(s,2H),3.79(s,3H),3.46(t,J=8.3Hz,2H),2.97(t,J=8.0Hz,2H),2.42(s,3H).
Example 42
Synthesis of 1- (6- (1- ((1H-pyrazol-3-yl) methyl) indol-5-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
synthesis of compound 128 the same as in example 127 was used, except that 1H-pyrazole-3-carbaldehyde was used in the first step instead of 1-methyl-1H-pyrazole-3-carbaldehyde. Compound 128: MS (ESI) M/z 427.36 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ12.58(brs,1H),9.93(s,1H),9.67(s,1H),8.72(s,1H),8.69(s,1H),8.52(d,J=2.6Hz,1H),7.89(dd,J=8.4,2.6Hz,1H),7.82–7.75(m,2H),7.59(s,1H),7.23(d,J=8.4Hz,1H),6.77(d,J=8.3Hz,1H),6.17(d,J=2.1Hz,1H),4.38(s,2H),3.46(t,J=8.5Hz,2H),2.98(t,J=8.4Hz,2H),2.43(s,3H).
Example 43
Synthesis of 1- (6- (1- ((1-methyl-1H-pyrazol-5-yl) methyl) indol-5-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
synthesis of compound 129 the same procedure used in example 127 was followed, the first step being the use of 1-methyl-1H-pyrazole-5-carbaldehyde instead of 1-methyl-1H-pyrazole-3-carbaldehyde. Compound 129: MS (ESI) M/z 441.33 (M + H) + ; 1 H NMR(400MHz,MeOD)δ8.58(s,1H),8.56(d,J=2.4Hz,1H),8.46(s,1H),8.03(dd,J=8.5,2.7Hz,1H),7.80(d,J=5.8Hz,2H),7.40(d,J=1.9Hz,1H),7.30(d,J=8.4Hz,1H),6.79(d,J=8.8Hz,1H),6.26(d,J=1.9Hz,1H),4.45(s,2H),3.88(s,3H),3.40(t,J=8.4Hz,2H),3.07(t,J=8.3Hz,2H),2.50(s,3H).
Example 44
Synthesis of 1- (6- (1-isobutyl-1H-indazol-5-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 5-bromo-1H-indazole (200mg, 1.02mmol, 1.0equiv.) and potassium carbonate (211mg, 1.53mmol, 1.5equiv.) were placed in a two-port reaction flask, then 10mL of DMF was added, and finally bromoisobutane (210mg, 1.53mmol, 1.5equiv.) was added dropwise with stirring. The reaction solution was heated to 120 ℃ and stirred for 16 hours. The reaction solution was cooled to room temperature, 10mL of distilled water was added, followed by extraction with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified by flash chromatography on silica gel (PE: EA = 10) to give compound 130a (154 mg, yield: 59.9%). MS (ESI): M/z 252.8 (M + H) + ; 1 H NMR(400MHz,CDCl 3 ):δ7.93(d,J=0.8Hz,1H),7.86(dd,J=2.0,0.4Hz,1H),7.43(dd,J=8.8,2.0Hz,1H),7.28(d,J=8.8Hz,1H),4.15(d,J=7.2Hz,2H),2.38-2.27(m,1H),0.91(d,J=6.8Hz,6H).
The second step is that: compound 130a (130mg, 0.52mmol, 1.0equiv.), pinacol diboron ester (197mg, 0.77mmol, 1.5equiv.), potassium acetate (101mg, 1.03mmol, 2.0equiv.), and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (37mg, 0.05mmol, 0.1equiv.) was added to a dioxane (10 mL) solution and the reaction stirred at 100 ℃ for 5 hours under nitrogen. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was chromatographed on flash silica gel (PE: EA = 10). MS (ESI) M/z301.0 (M + H) + ; 1 H NMR(400MHz,CDCl 3 ):δ8.27(s,1H),8.00(s,1H),7.78(d,J=8.4Hz,1H),7.38(d,J=8.4Hz,1H),4.17(d,J=7.2Hz,2H),2.34-2.29(m,1H),1.37(s,12H),0.91(d,J=6.8Hz,6H).
The third step: to a solution of compound 130b (70mg, 0.24mmol,1.0 equiv.) in 1,4-dioxane (10 mL) under nitrogen, intermediate A (71mg, 0.27mmol,1.1 equiv.) and [1,1' -bis (diphenylphosphino) ferrocene were added]Palladium dichloride (17.1mg, 0.023mmol, 0.1equiv.), and finally an aqueous solution (1 mL) of sodium carbonate (59mg, 0.49mmol,2.0 equiv.) were added. The reaction solution was heated to 100 ℃ and stirred for 16 hours. LCMS shows the reaction is complete, the reaction solution is cooled to room temperature, concentrated, the residue is added with water (20 mL), extracted with ethyl acetate, the organic phases are combined, dried over anhydrous sodium sulfate, filtered, the filtrate is concentrated, and the residue is purified by chromatographySeparation by flash chromatography on silica gel (DCM: meOH = 15) gave the title compound 130 (35.54 mg, yield: 36.8%). MS (ESI) M/z 402.2 (M + H) + ; 1 H NMR(400MHz,CDCl 3 ):δ9.86(s,1H),9.84(s,1H),8.94(s,1H),8.89(s,1H),8.53–8.51(m,2H),8.21(s,1H),8.11(d,J=8.8Hz,1H),7.89(dd,J=8.0,2.4Hz,1H),7.85(d,J=8.8Hz,1H),7.23(d,J=8.4Hz,1H),4.26(d,J=7.2Hz,2H),2.42(s,3H),2.28-2.21(m,1H),0.87(d,J=6.4Hz,6H).
Example 45
Synthesis of 1- {6- [1- (2-cyano-2, 2-dimethylethyl) -2, 3-dihydro-1H-indol-5-yl ] pyrazin-2-yl } -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: reacting 5-bromo-1- [ (3- { [ (tert-butyldiphenylsilyl) oxy)]Methyl } oxoalk-3-yl) methyl]-2, 3-dihydro-1H-indole (180mg, 0.64mmol, 1eq), pinacol diboron (327.45mg, 1.29mmol, 2eq), potassium acetate (158.19mg, 1.61mmol, 2.5eq) and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (93.66mg, 0.128mmol, 0.2eq) was dissolved in 3mL of 1,4-dioxane, and the mixture was stirred at 85 ℃ for 3 hours after replacement of nitrogen. LCMS showed the reaction was complete, filtered over celite, the filtrate was concentrated, and separated by flash silica gel chromatography (PE: EA = 100. MS (ESI): M/z 327.2 (M + H) + 。
The second step is that: compound 131a (50mg, 0.153mmol, 1eq) and intermediate A (80.82mg, 0.307mmol, 2eq), sodium carbonate (32.54mg, 0.307mmol, 2eq) and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (22.46mg, 0.0307mmol, 0.2eq) was added to a mixed solution of dioxane (2 mL) and water (0.2 mL), nitrogen gas was replaced, and the reaction solution was heated to 100 ℃ and stirred for 16 hours. The reaction mixture was cooled to room temperature, filtered, and the filtrate was concentrated by rotary evaporation, dissolved in 3mL of N, N-dimethylformamide, filtered again, and purified by reverse phase preparative chromatography pre-HPLC to give the title compound 131 (37.1 mg, yield: 25.7%). MS (ESI) M/z 428.2 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ9.93(s,1H),9.69(s,1H),8.75(s,1H),8.72(s,1H),8.54(d,J=2.4Hz,1H),7.92(dd,J=8.4,2.4Hz,1H),7.82-7.78(m,2H),7.27(d,J=8.4Hz,1H),6.78(d,J=9.2Hz,1H),3.69(t,J=8.8Hz,2H),3.36(s,2H),3.08(t,J=8.4Hz,2H),2.44(s,3H),1.40(s,6H).
Example 46
Synthesis of 3- (6- { 7-fluoro-1- [ (3-methyloxetan-3-yl) methyl ] -2, 3-dihydro-1H-indol-5-yl } pyrazin-2-yl) -1- (6-methylpyridin-3-yl) urea:
the first step is as follows: 7-fluoro-1H-indole (3g, 22.2mmol, 1equ.) was added to acetic acid (22 mL) and sodium cyanoborohydride (2.79g, 44.4mmol, 2equ.) was added portionwise. The reaction was allowed to proceed overnight at room temperature, LCMS showed completion, the reaction system was poured into NaOH solution (2M, 270ml), extracted with ethyl acetate, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and subjected to flash chromatography on silica gel (PE) to give compound 132a (1914 mg, yield: 62.9%). MS (ESI) M/z 138.07 (M + H) + ; 1 H NMR(400MHz,CDCl3)δ6.90(dd,J=7.3,0.9Hz,1H),6.82–6.77(m,1H),6.63(ddd,J=8.1,7.4,4.7Hz,1H),3.61(t,J=8.4Hz,2H),3.07(t,J=8.4Hz,2H).
The second step is that: compound 132a (1.5 g,10.94mmol, 1equiv.) was added to acetonitrile (80 mL), and a solution of N-bromosuccinimide (1.95g, 10.94mmol, 1equiv.) in acetonitrile (15 mL) was added dropwise under ice-cooling, followed by reaction at room temperature for 2 hours. LCMS showed the reaction was complete, the solvent was dried and flash chromatography on silica gel (PE: EA = 33. MS (ESI) M/z 216.04 (M + H) + ; 1 H NMR(400MHz,CDCl3)δ7.01(dd,J=1.6,0.8Hz,1H),6.99–6.91(m,1H),3.62(t,J=8.5Hz,2H),3.06(t,J=8.5Hz,2H).
The third step: compound 132b (500mg, 2.31mmol, 1equiv.), 3-methyloxetane-3-carbaldehyde (348mg, 3.47mmol, 1equiv.), acetic acid (1 mL) was added to methanol (20 mL), followed by addition of sodium cyanoborohydride (727mg, 11.57mmol, 5equiv.) in portions. The reaction system is stirred at room temperatureAnd (4) at night. LCMS showed the reaction was complete, and water (50 mL) was added to quench the reaction, the organic solvent was dried, then extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and purified by flash chromatography on silica gel to give compound 132c (304 mg, yield: 43.8%). 1 H NMR(400MHz,CDCl3)δ7.03–6.84(m,2H),4.61(d,J=5.8Hz,2H),4.38(d,J=5.8Hz,2H),3.46(s,2H),3.37(t,J=8.7Hz,2H),3.02(t,J=8.6Hz,2H),1.42(s,3H).
The fourth step: compound 132c (304mg, 1.01mmol, 1equiv.), pinacol diboron (309mg, 1.22mmol, 1.2equiv.), pd (dppf) Cl2 (148mg, 0.203mmol, 0.2equiv.), and potassium acetate (398mg, 4.05mmol, 4equiv.) were added to 1,4-dioxane (20 mL). The reaction system was purged with nitrogen three times and stirred at 90 ℃ for 8 hours. LCMS showed the reaction was complete, the solvent was dried, diluted with water, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated by filtration, and separated by flash chromatography on silica gel (PE: EA =33 1-20) to give compound 132d (200 mg, yield: 56.9%). MS (ESI): M/z 348.28 (M + H) + ; 1 H NMR(400MHz,CDCl3)δ7.03(s,1H),6.94(s,1H),4.64(d,J=5.7Hz,2H),4.37(d,J=5.7Hz,2H),3.39(s,2H),3.23(t,J=8.7Hz,2H),2.96(t,J=8.6Hz,2H),2.25(s,3H),1.49(s,3H).
The fifth step: compound 132d (100mg, 0.288mmol, 1equiv.), intermediate A (84mg, 0.32mmol, 1.1equiv.), pd (dppf) Cl2 (21mg, 0.029mmol, 0.1equiv.), and potassium carbonate (80mg, 0.58mmol, 2equiv.) were added to 1,4-dioxane (6 mL) and water (1.5 mL). The reaction system was purged with nitrogen three times and stirred at 90 ℃ for 4 hours. LCMS showed the reaction was complete, the solvent was dried, and flash chromatography on silica gel (DCM: meOH = 15). MS (ESI) M/z 449.32 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ9.74(s,1H),9.66(s,1H),8.80(s,1H),8.73(s,1H),8.51(s,1H),7.89(d,J=8.5Hz,1H),7.64(d,J=13.0Hz,2H),7.23(d,J=8.3Hz,1H),4.52(d,J=5.5Hz,2H),4.27(d,J=5.5Hz,2H),3.54(s,2H),3.47(t,J=8.6Hz,2H),3.09(t,J=8.5Hz,2H),2.43(s,3H),1.36(s,3H).
Example 47
Synthesis of 3- { imidazo [1,2-a ] pyridin-7-yl } -1- (6- {1- [ (3-methyloxyethan-3-yl) methyl ] -2, 3-dihydro-1H-indol-5-yl } pyrazin-2-yl) urea:
under the protection of nitrogen and with stirring, compound 60d (182.77mg, 0.62mmol, 1.0eq.), imidazo [1,2-a ] was added]To a solution of pyridine-7-carboxylic acid (150mg, 0.93mmol, 1.5eq.) and azido diphenyl phosphate (254.57mg, 0.93mmol, 1.5eq.) in toluene (5.0 mL) was added triethylamine (187.21mg, 1.85mmol, 3.0eq.). The reaction was stirred at 110 ℃ for 16 h, LCMS showed complete reaction, solvent was spun dry, and separated by TLC plate (dichloromethane: methanol =8 f = 0.5) to obtain the title compound 133 (8.63 mg, yield: 3.2%). MS (ESI) M/z 456.2 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ10.04(s,1H),9.68(s,1H),8.77(s,1H),8.71(s,1H),8.49(d,J=7.6Hz,1H),7.83-7.80(m,4H),7.46(s,1H),6.93-6.88(m,1H),6.63(d,J=8.8Hz,1H),4.50(d,J=5.6Hz,2H),4.29(d,J=5.6Hz,2H),3.47(t,J=8.8Hz,2H),3.37(s,2H),3.06(t,J=8.4Hz,2H),1.34(s,3H).
Example 48
Synthesis of 1- (6- (1- (2-hydroxypropyl) -1H-indazol-5-yl) pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
compound 134 was synthesized as in example 118, substituting 5-bromo-1H-indazole for 5-bromoindoline in the first step. Compound 134: MS (ESI) M/z 404.2 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ9.76(s,2H),8.94(s,1H),8.91(s,1H),8.52(d,J=2.8Hz,1H),8.51(s,1H),8.20(s,1H),8.11(dd,J=8.8,1.6Hz,1H),7.91(dd,J=8.4,2.6Hz,1H),7.84(d,J=8.8Hz,1H),7.24(d,J=8.4Hz,1H),4.92(d,J=4.8Hz,1H),4.41–4.31(m,2H),4.14-4.08(m,1H),2.43(s,3H),1.10(d,J=6.4Hz,3H).
Example 49
Synthesis of 1- (6- {1- [ (3S, 4S) -4-hydroxy-1-methylpyrrolidin-3-yl ] -2, 3-dihydro-1H-indol-5-yl } pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
compound 50 (30mg, 0.07mmol, 1equiv.), sodium triacetoxyborohydride (42mg, 0.198, 3eq), aqueous formaldehyde (0.3ml, 37wt.% in H 2 O) was added to the methanol solution (3 mL) in turn, under nitrogen, and stirred at 25 ℃ for 1 hour. LCMS indicated complete reaction and flash chromatography on silica gel afforded the title compound 135 (4.91 mg, yield: 15.7%). MS (ESI) M/z 446.3 (M + H) + ; 1 H NMR(400MHz,DMSO-d6):δ9.95(s,1H),9.67(s,1H),8.72(s,1H),8.68(s,1H),8.51(d,J=2.4Hz,1H),7.90-7.88(m,1H),7.78-7.76(m,2H),7.23(d,J=8.4Hz,1H),6.71(d,J=8.4Hz,1H),5.18(s,1H),4.25-4.23(m,1H),3.92-3.88(m,1H),3.57-3.52(m,2H),2.98(t,J=8.4Hz,2H),2.87-2.83(m,1H),2.72-2.62(m,2H),2.43(s,3H),2.28-2.25(m,1H),2.23(s,3H).
Example 50
Synthesis of 3- (6- { 7-methyl-1- [ (3-methyloxetan-3-yl) methyl ] -2, 3-dihydro-1H-indol-5-yl } pyrazin-2-yl) -1- (6-methylpyridin-3-yl) urea:
the first step is as follows: 7-methyl-1H-indole (2g, 15.25mmol, 1equiv.) was added to acetic acid (15 mL) and sodium cyanoborohydride (1.92g, 30.49mmol, 2equiv.) was added in portions. The reaction was allowed to react overnight at room temperature, LCMS showed completion, the reaction was quenched by pouring into aqueous NaOH (190ml, 2m), extracted with ethyl acetate, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and separated by flash chromatography on silica gel (PE: EA =33: 1) to give compound 136a (1678 mg, yield: 91.8%). MS (ESI) M/z 134.12 (M + H) + ; 1 H NMR(400MHz,CDCl3)δ7.01(d,J=7.3Hz,1H),6.88(d,J=7.5Hz,1H),6.68(t,J=7.4Hz,1H),3.58(t,J=8.4Hz,2H),3.07(t,J=8.4Hz,2H),2.16(s,3H).
The second step is that: compound 136a (1.678g, 12.60mmol, 1equiv.) was added to acetonitrile (80 mL), and a solution of N-bromosuccinimide (2.24g, 12.60mmol, 1equiv.) in acetonitrile (30 mL) was added dropwise under ice-cooling, and the mixture was reacted at room temperature for 2 hours. LCMS showed completion of the reaction, solvent was dried by rotation, and flash column chromatography gave compound 136b (1401 mg, yield: 52.4%). MS (ESI) M/z 212.06 (M + H) + ; 1 H NMR(400MHz,CDCl3)δ7.07(s,1H),6.98(s,1H),3.58(m,2H),3.05(m,2H),2.09(s,3H).
The third step: compound 136b (1.2g, 5.66mmol, 1equiv.), 3-methyloxetane-3-carbaldehyde (850mg, 8.49mmol, 1.5equiv.) was added to methanol (50 mL), and sodium cyanoborohydride (711mg, 11.32mmol, 2equiv.) was added in portions and reacted at room temperature for 4 hours. LCMS shows the reaction is complete, water (50 mL) is added to quench the reaction, organic solvent is spun off, extracted with ethyl acetate, the organic phases are combined, dried over anhydrous sodium sulfate, filtered, the filtrate is concentrated, and the residue is chromatographed on flash silica gel to give compound 136c (587 mg, yield: 35%). MS (ESI) M/z 296.11 (M + H) + ; 1 H NMR(400MHz,CDCl3)δ7.03(s,1H),6.94(s,1H),4.64(d,J=5.7Hz,2H),4.37(d,J=5.7Hz,2H),3.39(s,2H),3.23(t,J=8.7Hz,2H),2.96(t,J=8.6Hz,2H),2.25(s,3H),1.49(s,3H).
The fourth step: compound 136c (323mg, 1.09mmol, 1equiv.), pinacolate diboron (332mg, 1.31mmol, 1.2equiv.), pd (dppf) Cl2 (160mg, 0.218mmol, 0.2equiv.), and potassium acetate (428mg, 4.36mmol, 4equiv.) were added to 1,4-dioxane (20 mL). The reaction system was purged with nitrogen three times and stirred at 90 ℃ for 8 hours. LCMS showed the reaction was complete, after solvent was dried, dissolved in water, extracted with ethyl acetate, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and separated by flash chromatography on silica gel (PE: EA =20: 1-15) to give compound 136d (174 mg, yield: 46%). MS (ESI) M/z 344.36 (M + H) + ; 1 H NMR(400MHz,CDCl3)δ7.39(s,1H),7.32(s,1H),4.65(d,J=5.7Hz,2H),4.38(d,J=5.8Hz,2H),3.53(s,2H),3.31–3.19(m,2H),2.97(t,J=8.7Hz,2H),2.30(s,3H),1.48(s,3H),1.32(s,12H).
The fifth step: compound 136d (174mg, 0.51mmol, 1equiv.), intermediate A (147mg, 0.56mmol, 1.1equiv.), pd (dppf) Cl 2 (37mg, 0.05mmol, 0.1equiv.), and potassium carbonate (140mg, 1.01mmol, 2equiv.) were added to 1,4-dioxane (8 mL) and water (2 mL). The reaction system was purged with nitrogen three times and stirred at 90 ℃ for 4 hours. LCMS showed the reaction was complete, the solvent was spun off, and flash chromatography on silica gel (DCM: meOH = 15). MS (ESI): M/z 445.37 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ10.01(s,1H),9.72(s,1H),8.70(s,1H),8.69(s,1H),8.53(d,J=2.5Hz,1H),7.90(dd,J=8.4,2.7Hz,1H),7.64(s,1H),7.58(s,1H),7.24(d,J=8.4Hz,1H),4.56(s,1H),4.54(s,1H),4.28(s,1H),4.26(s,1H),3.55(s,2H),3.30(t,J=8.7Hz,2H),3.00(t,J=8.7Hz,2H),2.43(s,3H),2.34(s,3H),1.41(s,3H).
Example 51
Synthesis of 1- (6-methylpyridin-3-yl) -3- (6- (1- ((3-methyltetrahydrofuran-3-yl) methyl) indol-5-yl) pyrazin-2-yl) urea:
the first step is as follows: a solution of benzyl 3-methyloxazolidine-3-carboxylate (1g, 4.54mmol,1.0 equiv.) in tetrahydrofuran (10 mL) was slowly added dropwise under nitrogen to a solution of lithium aluminum hydride (431mg, 11.4mmol,2.5 equiv.) in tetrahydrofuran (10 mL) at-78 ℃ in a dry ice/acetone bath. The temperature was slowly raised to 25 ℃ and the reaction was stirred for 24 hours. LCMS showed the reaction was complete, water (20 mL) was slowly added dropwise, extracted with ethyl acetate, the organic phase was dried over sodium sulfate, concentrated, and the residue was separated by flash chromatography on silica gel (PE/EA = 1/1) to give compound 137a (700 mg, yield: 74.8%). 1 H NMR(400MHz,CDCl 3 ):δ7.40–7.30(m,5H),4.70(s,2H),3.93–3.84(m,2H),3.73(d,J=8.4Hz,1H),3.49(s,2H),3.39(d,J=8.4Hz,1H),1.90–1.85(m,1H),1.67–1.63(m,1H),1.15(s,3H).
The second step is that: in a solution of compound 137a (1.2g, 5.82mmol,1.0 equiv.) in ethanol (10 mL), N 2 10% Palladium on carbon (200 mg.), H, was added with protection 2 The reaction was stirred at 25 deg.C for 15 hours (15 psi). LCMS shows complete reaction, the reaction solution is filtered, the filtrate is concentrated, and compound 137b is isolated by flash chromatography on silica gel (450 mg, yield: 66.6%). 1 H NMR(400MHz,CDCl 3 ):δ3.93–3.81(m,2H),3.73(d,J=8.8Hz,1H),3.51(s,2H),3.39(d,J=8.8Hz,1H),1.90-1.83(m,1H),1.65–1.62(m,1H),1.13(s,3H).
The third step: to a solution of compound 137b (200mg, 1.72mmol,1.0 equiv.) in dichloromethane (10 mL) was added dess-martin reagent (1.46g, 3.33mmol,2.0 equiv.), and the reaction was stirred at 25 ℃ for 2 hours. LCMS showed reaction completion, the reaction was filtered, the filtrate was concentrated, and the residue was purified by flash silica gel chromatography (PE/EA = 1/1) to obtain compound 137c (30 mg, yield: 15.1%). 1 H NMR(400MHz,CDCl 3 ):δ9.57(s,1H),4.09(d,J=9.2Hz,1H),3.95–3.85(m,2H),3.47(d,J=9.2Hz,1H),2.35–2.28(m,1H),1.75–1.69(m,1H),1.24(s,3H).
The fourth step: to a solution of compound 137c (150mg, 1.31mmol,1.0 equiv.) in dichloromethane (5 mL) were added 5-bromoindole (260mg, 1.31mmol,1.0 equiv.), glacial acetic acid (8mg, 0.13mmol, 0.1equiv.), sodium triacetoxyborohydride (610mg, 2.62mmol,2.0 equiv.), and the reaction was stirred at 25 ℃ for 15 hours. LCMS showed completion of the reaction, the reaction was concentrated, and the residue was separated by flash chromatography on silica gel (PE/EA = 2/1) to obtain compound 137d (35 mg, yield: 9.0%). MS (ESI) M/z 298.0 (M + H) + .
The fifth step: to 1,4-dioxane (10 mL) of compound 137d (50mg, 0.17mmol, 1.0equiv.) was added diboron pinacol ester (64mg, 0.25mmol, 1.5equiv.), potassium acetate (42mg, 0.43mmol, 2.5equiv.), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride dichloromethane complex (14mg, 0.02mmol, 0.1equiv.). Stirring was carried out at 100 ℃ for 3 hours under nitrogen. LCMS showed completion of the reaction, the reaction was filtered, the filtrate was concentrated, and the residue was purified by flash chromatography on silica gel (PE/EA = 3/1) to give compound 137e (40 mg, yield: 69.0%). MS (ESI) M/z 343.4 (M + H) + .
And a sixth step: to compound 137e (40mg, 0.12mmol,1.0 equiv.) in 1,4-dioxane (10 mL) and water (1 mL) was added intermediate A (R)37mg,0.14mmol, 1.2equiv.), sodium carbonate (31mg, 0.29mmol, 2.5equiv.), and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride dichloromethane complex (8mg, 0.01mmol, 0.1equiv.). Stirring was carried out at 100 ℃ for 3 hours under nitrogen. LCMS showed reaction complete, reaction filtered and filtrate concentrated. The residue was purified by preparative reverse phase chromatography pre-HPLC to give the title compound 137 (20 mg, yield: 34.3%). MS (ESI) M/z 444.8 (M + H) + ; 1 H NMR(400MHz,DMSO-d6):δ9.95(s,1H),9.68(s,1H),8.72(s,1H),8.69(s,1H),8.54(d,J=2.4Hz,1H),7.92(dd,J=8.4,2.8Hz,1H),7.79-7.77(m,2H),7.26(d,J=8.4Hz,1H),6.60(d,J=8.8Hz,1H),3.88-3.76(m,2H),3.59-3.52(m,3H),3.39-3.37(m,1H),3.17-3.11(m,2H),3.05(t,J=8.8Hz,2H),2.44(s,3H),1.88-1.78(m,1H),1.74-1.65(m,1H),1.13(s,3H).
Example 52
Synthesis of 1- (6- (hydroxymethyl) pyridin-3-yl) -3- (6- (1- ((3-methyloxan-3-yl) methyl) indol-5-yl) pyrazin-2-yl) urea:
the first step is as follows: to a solution of the compound methyl 6- (hydroxymethyl) nicotinate (500mg, 2.99mmol, 1.0eq.) and Imidazole (Imidazole, 610.91mg,8.97mmol, 3.0eq.) in N, N-dimethylformamide (5.0 mL) was added tert-butyldiphenylchlorosilane (1.23g, 4.49mmol, 1.5eq.). The reaction was stirred at 30 ℃ for 16 hours, LCMS showed completion of the reaction, and the reaction was concentrated and purified by flash chromatography on silica gel (ethyl acetate/petroleum ether = 1/10) to obtain compound 138a (1.0 g, yield: 82%). 1 H NMR(400MHz,CDCl 3 )δ9.07(d,J=1.6Hz,1H),8.35(dd,J=8.4,2.0Hz,1H),7.79(d,J=8.0Hz,1H),7.75–7.60(m,4H),7.46–7.42(m,1H),7.42–7.40(m,1H),7.37–7.30(m,4H),4.92(s,2H),3.95(s,3H),1.14(s,9H).
The second step is that: to a solution of compound 138a (200mg, 0.49mmol,1.0 eq.) in tetrahydrofuran (3.0 mL) and methanol (3.0 mL) was added a solution of lithium hydroxide monohydrate (62.14mg, 1.47mmol,3.0 eq.) in water (3.0 mL). The reaction solution is stirred and reacted for 2 hours at the temperature of 0DEG CThe reaction was run through TLC plate (ethyl acetate/petroleum ether =1/10 f =0.4, disappearance of starting material). After completion of the reaction, the reaction mixture was concentrated to obtain crude compound 138b (300 mg). MS (ESI): M/z 391.8 (M + H) + .
The third step: triethylamine (193.6 mg,1.9mmol, 5.0eq.) was added to a solution of the compound 138b (150mg, 0.38mmol, 1.0eq.) and the compound 60d (105.43mg, 0.38mmol, 1.0eq.) in toluene (5.0 mL) with stirring under nitrogen protection. The reaction was stirred at 110 ℃ for 16 h, LCMS showed completion, and the reaction was cooled to room temperature. The reaction solution was concentrated and purified by flash chromatography on silica gel (ethyl acetate/petroleum ether = 1/1) to obtain compound 138c (35 mg, yield: 13%). MS (ESI): M/z 684.8 (M + H) + ; 1 H NMR(400MHz,CDCl 3 )δ11.93(s,1H),9.48(s,1H),8.56(s,1H),8.49(d,J=2.4Hz,1H),8.41(dd,J=8.4,2.4Hz,1H),8.20(s,1H),7.73–7.66(m,7H),7.43–7.36(m,6H),6.56(d,J=8.4Hz,1H),4.87(s,2H),4.60(d,J=6.0Hz,2H),4.45(d,J=6.0Hz,2H),3.53(t,J=8.6Hz,2H),3.37(s,2H),3.14(t,J=8.6Hz,2H),1.43(s,3H),1.15(s,9H).
The fourth step: to a solution of compound 138c (30mg, 0.04mmol,1.0 eq.) in tetrahydrofuran (1.0 mL) was added tetrabutylammonium fluoride in tetrahydrofuran (0.08mL, 0.08mmol,2.0 eq.) under nitrogen protection. The reaction was stirred at 20 ℃ for 1 hour, LCMS showed completion of the reaction, the reaction was filtered, and the filtrate was concentrated and purified by reverse phase preparative chromatography pre-HPLC to give the title compound 138 (11.46 mg, yield: 64.2%). MS (ESI) M/z 446.8 (M + H) + ; 1 H NMR(400MHz,DMSO-d 6 ):δ10.04(s,1H),9.72(s,1H),8.74(s,1H),8.70(s,1H),8.63(s,1H),8.05(dd,J=8.4,2.0Hz,1H),7.81-7.76(m,2H),7.51(d,J=8.8Hz,1H),6.63(d,J=8.8Hz,1H),4.57(s,2H),4.49(d,J=6.0Hz,2H),4.29(d,J=5.6Hz,2H),3.50-3.36(m,4H),3.04(t,J=8.4Hz,2H),1.34(s,3H).
Example 53
Synthesis of 1- (6- ((methylamino) methyl) pyridin-3-yl) -3- (6- (1- ((3-methyloxetan-3-yl) methyl) indolin-5-yl) pyrazin-2-yl) urea:
the first step is as follows: 6-formylpyridine-3-carboxylic acid methyl ester (500mg, 3.03mmol, 1equiv.) was added to methanol (20 mL), methylamine hydrochloride (224.86mg, 3.33mmol, 1.1equiv.) was added thereto, and after stirring for five minutes, sodium cyanoborohydride (382mg, 6.06mmol, 2equiv.) was added thereto, and after nitrogen substitution, stirring was carried out for ten minutes at 30 ℃. Saturated aqueous ammonium chloride (10 mL) was added, followed by di-tert-butyl dicarbonate (1.98g, 9.08mmol, 3equiv.) and stirring at 30 ℃ for 8 hours. Water (10 mL) and ethyl acetate (30 mL) were added to the reaction solution, and after separation, the organic phase was washed with saturated brine, and after concentration, was separated by flash silica gel chromatography (PE: EA = 5) to obtain compound 139a (320 mg, yield: 37.7%). MS (ESI) M/z 281.0 (M + H) + .
The second step: compound 139a (320mg, 1.14mmol, 1equiv.) was dissolved in methanol (5 mL)/tetrahydrofuran (5 mL), and lithium hydroxide monohydrate (143.5mg, 3.42mmol, 3equiv.) was dissolved in water (2.5 mL), and the mixture was added to the above system, and after nitrogen substitution, stirring was performed at 30 ℃ for 1 hour. The reaction solution was directly spin-dried to obtain crude compound 139b (lithium salt). MS (ESI) M/z 267.0 (M + H) + Used directly in the next step.
The third step: after adding compound 60d (350mg, 1.18mmol, 1equiv.), compound 139b (314.48 mg), and triethylamine (596mg, 5.9mmol, 5equiv.), to toluene (5 mL), diphenyl phosphorazidate (325mg, 1.18mmol, 1equiv.) was added dropwise, and the mixture was stirred at 110 ℃ for 4 hours after replacement with nitrogen gas. The reaction solution was subjected to reverse phase preparative chromatography Pre-HPLC) to separate and purify the reaction solution to obtain compound 139c (70 mg, yield: 10.6%). MS (ESI): M/z 560.8 (M + H) + .
The fourth step: compound 139c (70mg, 0.13mmol, 1equiv.) was dissolved in dichloromethane (3 mL), and trifluoroacetic acid (1 mL) was added dropwise, followed by stirring at room temperature for half an hour at 30 ℃. The reaction solution was filtered, and the filtrate was purified by separation by preparative reverse phase chromatography pre-HPLC to give the title compound 139 (4.54 mg, yield: 7.3%). MS (ESI) M/z 460.2 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ10.02(s,1H),9.75(s,1H),8.93(s,1H),8.79(s,1H),8.77(d,J=2.4Hz,1H),8.72(s,1H),8.10–8.00(m,1H),7.85–7.75(m,2H),7.48(d,J=8.0Hz,1H),6.62(d,J=8.0Hz,1H),4.55–4.45(m,2H),4.32–4.28(m,2H),4.26(s,2H),3.46(t,J=8.0Hz,2H),3.37(s,2H),3.04(t,J=8.0Hz,2H),2.63(s,3H),1.34(s,3H).
Example 54
Synthesis of 1-methyl-3- (6- (1- ((3-methyloxycyclohexan-3-yl) methyl) indol-5-yl) pyrazin-2-yl) -1- (6-methylpyridin-3-yl) urea:
the first step is as follows: 6-methylpyridin-3-amine (1.00g, 9.25mmol, 1equiv.) and formaldehyde (833.09mg, 27.74mmol, 3equiv.) were dissolved in 20mL of methanol under nitrogen, and sodium methoxide (2.49g, 46.24mmol, 5equiv.) was added to the reaction mixture in portions, followed by heating to 50 ℃ and stirring for 16 hours. Then, sodium borohydride (1.05g, 27.74mmol,3 equiv.) was added in portions to the reaction solution under ice bath, and then the reaction was stirred at 30 ℃ for 5 hours. LCMS showed the reaction was complete, quenched with 20mL of water, then extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated and purified by flash chromatography on silica gel (DCM: meOH = 19) to afford compound 140a (450 mg, yield: 39.8%). MS (ESI): M/z 123.2 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ7.80(d,J=2.8Hz,1H),6.94(d,J=8.4Hz,1H),6.79(dd,J=8.4,2.8Hz,1H),5.58(s,1H),2.65(d,J=5.2Hz,3H),2.28(s,3H).
The second step: under nitrogen protection, compound 140a (50.00mg, 0.41mmol, 1equiv.) and 4-nitrophenylcarbonyl chloride (164.98mg, 0.82mmol, 2equiv.) were placed in a 25mL two-necked flask, then 5mL of THF was added, and finally triethylamine (207.07mg, 2.05mmol, 5equiv.) was added dropwise to the reaction mixture, and the reaction was stirred at 30 ℃ for 3 hours. LCMS showed the reaction was complete, the reaction was concentrated and purified by TLC large plate (PE: EA = 1. MS (ESI): M/z 287.8 (M + H) + ; 1 H NMR(400MHz,CDCl 3 )δ8.54-8.52(m,1H),8.24-8.22(m,2H),7.56(s,1H),7.26–7.21(m,3H),3.41(s,3H),2.59(s,3H).
The third step: compound 60d (70.00mg, 0.24mmol, 1equiv.) was dissolved in 2mL of DMF under nitrogen, and sodium hydride (30.00mg, 0.71mmol,3equiv, 60%) was added to the reaction solution, and after stirring for 5 minutes, compound 140b (81.42mg, 0.28mmol, 1.2equiv.) was added to the reaction solution, and the reaction was stirred at 30 ℃ for 5 hours. LCMS showed the reaction was complete, and the reaction was quenched by addition of two drops of water and purified by reverse phase preparative chromatography pre-HPLC to give the title compound 140 (5.38 mg, yield: 5.1%). MS (ESI) M/z 445.2 (M + H) + ; 1 H NMR(400MHz,MeOD)δ8.84(s,1H),8.45(s,1H),8.36(d,J=2.4Hz,1H),7.64(dd,J=8.4,2.4Hz,1H),7.57(d,J=8.8Hz,2H),7.29(d,J=8.3Hz,1H),6.40(d,J=8.0Hz,1H),4.52(d,J=6.0Hz,2H),4.30(d,J=6.0Hz,2H),3.37(t,J=8.4Hz,2H),3.27(s,3H),3.22-3.20(m,2H),2.91(t,J=8.4Hz,2H),2.47(s,3H),1.30(s,3H).
Example 55
Synthesis of 1- (6- {1- [ (3S, 4R) -4-hydroxyoxazolidin-3-yl ] -2, 3-dihydro-1H-indol-5-yl } pyrazin-2-yl) -3- (6-methylpyridin-3-yl) urea:
the first step is as follows: 5-bromo-2, 3-dihydro-1H-indole (2g, 10.1mmol, 1equiv.) was dissolved in tetrahydrofuran (40 mL), sodium hydride (60%, 808mg,20.2mmol, 2.0equiv.) was added under ice-bath, and after stirring for 30 minutes, 3, 6-dioxabicyclo [3.1.0 ] was added]Hexane (1.3g, 15.15mmol, 1.5equiv.) was substituted with nitrogen, and the mixture was heated to 90 ℃ and stirred for 6 hours. LCMS showed the reaction was complete, and water (10 mL) was added to the reaction solution to quench, followed by extraction with ethyl acetate, and the organic phases were combined, backwashed with saturated brine, then dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and separated by flash chromatography on silica gel (PE: EA = 1) to obtain compound 141a (2.4 g, yield: 83.6%). MS (ESI) M/z =286.0 (M + H) + ; 1 H NMR(400MHz,CDCl 3 )δ7.19–7.12(m,2H),6.45–6.39(m,1H),4.50–4.40(m,1H),4.15–4.02(m,2H),4.01–3.95(m,1H),3.94–3.88(m,1H),3.72(dd,J=10.8,3.2Hz,1H),3.52-3.36(m,2H),2.94(t,J=8.4Hz,2H).
The second step is that: compound 141a (1g, 3.52mmol, 1equiv.) is dissolved in 1,4-dioxane (15 mL), and pinacol diboron ester (1.34g, 5.28mmol, 1.5equiv.), potassium acetate (862mg, 8.8mmol, 2.5equiv.) and [1,1' -bis (diphenylphosphino) ferrocene ] are added]Palladium dichloride (256mg, 0.35mmol, 0.1equiv.) was purged with nitrogen and then stirred at 100 ℃ for 3 hours. LCMS showed the reaction was complete, the reaction was filtered, the filtrate was concentrated, and then separated by flash silica gel column chromatography (PE: EA = 10) to give compound 141b (1.3 g, yield: 66.1%). MS (ESI): M/z 332.2 (M + H) + .
The third step: compound 141b (100mg, 0.3mmol, 1equiv.), intermediate a (119.42mg, 0.45mmol, 1.5equiv.), and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (44mg, 0.06mmol, 0.2eq) and anhydrous sodium carbonate (96mg, 0.90mmol, 3.0eq) were sequentially added to a mixed solution of dioxane/water (10 mL/1 mL), and the mixture was heated to 100 ℃ under nitrogen protection and stirred for 16 hours. LCMS showed the reaction was complete, the reaction was concentrated, and the residue was purified by reverse phase preparative chromatography Prep-HPLC to give the title compound 141 (22 mg, yield: 17.0%). MS (ESI) M/z 432.8 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)(EN1078-156-P):δ9.98(s,1H),9.67(s,1H),8.73(s,1H),8.70(s,1H),8.51(d,J=2.8Hz,1H),7.91-7.88(m,1H),7.81–7.78(m,2H),7.24(d,J=8.8Hz,1H),6.71(d,J=8.0Hz,1H),5.39(d,J=4.0Hz,1H),4.26-4.25(m,1H),3.98–3.88(m,4H),3.57–3.44(m,3H),2.98(t,J=8.4Hz,2H),2.42(s,3H).
Example 56
Synthesis of 3- {6- [2- (2-hydroxypropyl) -2H-indazol-5-yl ] pyrazin-2-yl } -1- (6-methylpyridin-3-yl) urea:
the first step is as follows: compound 134a (200mg, 0.787mmol, 1.0equiv.), pinacol ester diborate (299.92mg, 1.181mmol, 1.5equiv.), potassium acetate (231.71mg, 2.361mmol, 3.0equiv.), and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (86.41mg, 0.118mmol, 0.15equiv.) was added to dioxane (10 mL) solutionIn the solution, the reaction was stirred at 100 ℃ for 16 hours under nitrogen protection. LCMS shows reaction complete, filtration and concentration of the filtrate under reduced pressure to give crude compound 142a (400 mg), MS (ESI): M/z 303.0 (M + H) + Used in the next step without further purification.
The second step is that: to a solution of compound 142a (200mg, 0662mmol, 1equiv.) in 1,4-dioxane (10 mL) were added intermediate A (261.78mg, 0.993mmol, 1.5equiv.) and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (96.88mg, 0.066mmol, 0.1equiv) was added, and an aqueous solution (1 mL) of sodium carbonate (140.33mg, 1.324mmol, 2equiv.) was added, and the reaction was stirred at 100 ℃ for 16 hours under nitrogen. LCMS shows the reaction is complete, the reaction is cooled to room temperature, filtered off with suction, concentrated and the residue is purified by preparative HPLC to give the title compound 142 (2.88 mg, yield: 1.5%). MS (ESI) M/z 404.2 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ9.81(s,1H),9.78(s,1H),8.94(s,1H),8.89(s,1H),8.56(d,J=2.8Hz,1H),8.51-8.49(m,2H),7.99-7.90(m,2H),7.76(d,J=9.2Hz,1H),7.28(d,J=8.8Hz,1H),5.05(s,1H),4.46-4.30(m,2H),4.18-4.15(m,1H),2.45(s,3H),1.11(d,J=6.4Hz,3H).
Example 57
Synthesis of 3- {6- [1- (2-hydroxycyclopentyl) -2, 3-dihydro-1H-indol-5-yl ] pyrazin-2-yl } -1- [ (3S) -piperidin-3-yl ] urea:
the first step is as follows: 6-bromopyrazin-2-amine (900mg, 5.17mmol, 1equiv.), (3S) -1- [ (tert-butoxy) carbonyl]Piperidine-3-carboxylic acid (2.37g, 10.34mmol, 2equiv.), diphenylphosphorylazide (2.8g, 10.34mmol, 2equiv.), triethylamine (1.57g, 15.51mmol,3.0 equiv.) were added to toluene (15 mL). After nitrogen substitution, the mixture was stirred at 110 ℃ for 4 hours. LCMS showed reaction completion, the reaction was concentrated, dissolved in dichloromethane (10 mL) and separated by flash silica gel column chromatography (PE: EA = 1) to give (compound 143a (460 mg, yield: 21.4%). MS (ESI): M/z 344.0 (M + H) + .
The second step is that: compound 143a (100mg, 0.25mmol, 1equiv.) was dissolved in 1, 4-bisOxirane (1 mL)/water (0.1 mL), compound 49b (90.48mg, 0.27mmol, 1.1equiv.), sodium carbonate (22mg, 0.425mmol, 1.7equiv.) and [1,1' -bis (diphenylphosphino) ferrocene ] were added]Palladium dichloride (7 mg,0.018mmol, 0.07equiv.) was stirred at 100 ℃ for 3 hours, after nitrogen substitution. LCMS showed reaction completion, the reaction was filtered, the filtrate was concentrated, and was isolated and purified by TLC plate (DCM: meOH = 20. MS (ESI) M/z 523.2 (M + H) + .
The third step: compound 143b (30mg, 0.06mmol, 1equiv.) was dissolved in dichloromethane (2 mL), and trifluoroacetic acid (0.4 mL) was added dropwise slowly, and the mixture was stirred at 25 ℃ for 1 hour after replacement with nitrogen. LCMS showed the reaction was complete and the reaction was concentrated and purified by reverse phase preparative chromatography pre-HPLC to afford the title compound 143 (5.56mg, 0.01mmol, 22.7% yield). MS (ESI) M/z 423.3 (M + H) + ; 1 H NMR(400MHz,CD3OD)δ8.52(s,1H),8.47(s,1H),8.25(s,1H),7.66(d,J=8.4Hz,1H),7.62(s,1H),6.62(d,J=8.0Hz,1H),4.30–4.20(m,1H),4.10–3.95(m,1H),3.90–3.75(m,1H),3.65–3.45(m,3H),3.10–2.95(m,4H),2.30–2.12(m,1H),2.09–1.91(m,3H),1.90–1.59(m,6H).
Example 58
Synthesis of 3- (6- {1- [ (4R) -4-hydroxyoxazol-3-yl ] -2, 3-dihydro-1H-indol-5-yl } pyrazin-2-yl) -1- [ (3S) -piperidin-3-yl ] urea:
the first step is as follows: dissolving compound 143a (100mg, 0.25mmol, 1equiv.) in 1,4-dioxane (1 mL)/water (0.1 mL), adding compound 141b (91.02mg, 0.27mmol, 1.1equiv.), sodium carbonate (66mg, 0.63mmol, 2.5equiv.), and [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (22mg, 0.03mmol, 0.1equiv.) was purged with nitrogen and then stirred at 100 ℃ for 3 hours. LCMS showed the reaction was complete, and after the reaction was filtered, the filtrate was concentrated and isolated and purified by TLC plate (DCM: meOH = 20). MS (ESI): M/z 525.2 (M + H) + .
The second step is that: compound 144a (30mg, 0.06mmol, 1equiv.) is dissolved inDichloromethane (2 mL) was added dropwise to trifluoroacetic acid (0.4 mL) slowly, and the mixture was stirred at 25 ℃ for 1.5 hours, with replacement by nitrogen. LCMS indicated complete reaction, the reaction was filtered and purified by reverse phase preparative chromatography pre-HPLC to give the title compound 144 (7.9 mg, yield: 30.5%). MS (ESI) M/z 425.3 (M + H) + ; 1 H NMR(400MHz,CD 3 OD)δ8.52(s,1H),8.51(s,1H),8.31(s,1H),7.71(d,J=8.4Hz,1H),7.68(s,1H),6.69(d,J=8.4Hz,1H),4.38(s,1H),4.12–4.05(m,2H),4.04–3.95(m,3H),3.71–3.67(m,1H),3.66–3.57(m,1H),3.55–3.47(m,2H),3.06–2.94(m,4H),2.25–2.15(m,1H),2.10–2.00(m,1H),1.94–1.69(m,2H).
Example 59
Synthesis of (3- (6- {1- [ (3-methyloxoalk-3-yl) methyl ] -2-oxo-2, 3-dihydro-1H-indol-5-yl ] pyrazin-2-yl) -1- [ (3S) -piperidin-3-yl ] urea:
the first step is as follows: compound 143a (210mg, 0.52mmol, 1equiv.) was dissolved in methylene chloride (2 mL), and trifluoroacetic acid (0.4 mL) was added dropwise thereto slowly, and the mixture was stirred at 20 ℃ for 1 hour after nitrogen substitution. LCMS showed the reaction was complete and the reaction was spin dried to give crude compound 145a (120 mg, yield: 66.3%) which was used in the next step without further purification. MS (ESI) M/z 302.1 (M + H) + .
The second step: compound 126b (100mg, 0.29mmol, 1equiv.) is dissolved in 1,4-dioxane (2 mL)/water (0.2 mL), compound 145a (104.94mg, 0.35mmol, 1.2equiv.) is added]]Sodium carbonate (77mg, 0.73mmol,2.5equiv. And [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (22mg, 0.03mmol, 0.1equiv.) was purged with nitrogen and then stirred at 100 ℃ for 3 hours. LCMS showed the reaction was complete, and the reaction was filtered and subjected to preparative reverse phase chromatography pre-HPLC to isolate and purify to obtain the title compound 145 (10.99 mg, yield: 8.6%). MS (ESI) M/z 437.3 (M + H) + ; 1 H NMR(400MHz,DMSO-d6)δ9.63(s,1H),8.72(s,1H),8.63(s,1H),8.29(s,1H),8.20(s,1H),8.09–8.03(m,2H),7.24(d,J=8.0Hz,1H),4.59(d,J=6.0Hz,2H),4.18(d,J=5.6Hz,2H),3.88(s,2H),3.83–3.78(m,1H),3.73(s,2H),3.07–2.96(m,1H),2.85–2.72(m,2H),2.70–2.60(m,1H),1.85–1.62(m,2H),1.60–1.40(m,2H),1.32(s,3H).
Biological test evaluation
The present invention is further described and explained below in conjunction with test examples, which are not intended to limit the scope of the present invention.
Test example 1
1. Purpose of the experiment:
the purpose of this experiment was to examine the ability of the inventive compounds to inhibit the activity of PolQ polymerase. Mixing the template and the primer according to the proportion of 1:1.1, carrying out heat treatment in a reaction buffer solution at 95 ℃ for 5 minutes, slowly cooling, treating the PolQ protein by using compounds with different concentrations, incubating at room temperature, measuring fluorescence in a 525/598nm module on an Envision instrument, and reading data. Four parameters were fitted to the processed data to obtain IC50 values, and thus the biological activity of the compound was calculated.
2. Experimental materials and equipment:
1) Material
Primer [ P ] 5 'GACGGGAAGG-3' (Shanghai Biotech)
5-TAMRA-CCTTCCTCTCCCTGTGTTGTACTGTACCTTCCGTCAGGAGGAAGG-BHQ-3' (Shanghai worker)
DNA-polymerase: POL theta (Shanghai Ruizi chemical)
2) Reagents & manufacturer:
·dNTP(10mM),
·MgCl 2 ,Thermo Fisher#R0971;
·NaCl,Sigma#10708976001
·BSA,Sigma#10%
·DTT,Sigma#10197777001;
3) Consumable material:
·Compound plate:96-well plate-V bottom(Haimen Qunchao,Cat#FPT019),store at RT
·Compound plate:384-LDV plate(LABCYTE,Cat#LP-0200),store at RT
4) Equipment:
·Liquid handler:Echo(LABCYTE Echo550)
·Plate reader:Envision multiple plate reader(Perkin Elmer)
cell Counter (Counter star-IC-1000)
·CO 2 Incubator MCO-15AC (Thermo Fisher)
Pipette tip 0.2-10. Mu.L, 5-50. Mu.L, 20-300. Mu.L
Centrifuge Thermo Centrifuge ST 40R
Millipore Milli-Q Reference system
A refrigerator: haier-20degree freezer
3. Experimental procedure
The polymerase active fragment of PolQ (amino acids 1-987) was expressed and purified in SF9 insect cell line, dispensed and stored in a-80 ℃ refrigerator. The reaction was carried out in a1 Xbuffer system (20mM Tris pH7.8, 10mM MgCl2, 50mM KCl,1mM DTT,0.01% Tween-20 and 0.01% BSA).
The compound powder was dissolved in DMSO to a concentration of 10mM. Compounds were diluted in 3-fold gradients at 11 concentrations tested, and transferred to 384-well reaction plates (Corning 4514) at 150nL using ECHO, with a maximum final concentration of 10 μ M, and 150nL of DMSO was added to each of the positive and negative controls. The content of DMSO in the final reaction system is 1%.
Form board
5-TAMRA-CCTTCCTCTCCTCCTGTGTTACCTCCGTCAGGAGGAAGG-BHQ-3 ' (SEQ IDNO 3) and primer 5' GACGGGAAGG-3' (SEQ IDNO 3) were mixed at a ratio of 1.1, heat-treated at 95 ℃ for 5 minutes in a heat-treatment reaction buffer (10 mM Tris (pH 8.0), 100mM NaCl and H2O), and slowly cooled. mu.L of a mixture of PolQ protein and dNTP was added to the reaction plate (final concentration of PolQ protein 2.5nM, final concentration of dNTP 48. Mu.M) and incubated for 15 min at room temperature. A DNA mixture (96 nM for the final reaction) was prepared, 5. Mu.L was transferred to the reaction plate and incubated for 60 min at room temperature. After the incubation, the fluorescence intensity was measured at 525/598nm on Envision and the data were recorded. IC50 values for compounds were determined by a four parameter dose response equation.
4. The experimental results are as follows:
remarking: a represents IC50<100n Μ.
The above data show that: the compound has strong inhibition effect on the POLQ enzyme.
Test example 2hERG assay
1. Experimental methods
1.1 storage of Compounds
After receiving the compound, the compound administrator dissolved the powder in 100% dmso to prepare a 20mM stock solution.
1.2 cell culture and treatment
CHO cells stably expressing hERG were cultured in 35mm diameter cell culture dishes at 37 ℃ in a 5% CO2 incubator. On the day of the experiment, the cell culture fluid was aspirated, washed once with the extracellular fluid, and then added with 0.25% of the total
Trypsin-EDTA solution, digested at room temperature for 3-5 minutes. The digestion solution was aspirated, resuspended in extracellular fluid and the cells transferred to a petri dish for electrophysiological recording.
1.3 preparation of Compounds
The compound stock solution was diluted with 100% DMSO, i.e., 10 μ L of the compound stock solution was added to 20 μ L DMSO and serially diluted 3-fold to an intermediate concentration.
Then, 10. Mu.L of the intermediate compound concentration was added to 4990. Mu.L of the extracellular fluid and diluted 500-fold to give the final concentration to be tested.
Positive control compound Cisapride preparation: mu.L of stock cisaprideDMSO at 150. Mu.M was added to 4990. Mu.L of extracellular fluid and diluted 500-fold to give the final concentration to be tested, 300nM. The final concentration of DMSO in the test concentration did not exceed 0.2%, and the concentration of DMSO had no effect on the hERG potassium channel.
1.4 electrophysiological recording procedure
CHO cells stably expressing the hERG potassium channel were subjected to whole-cell patch clamp technique at room temperature to record the hERG potassium channel current. The glass microelectrode is formed by drawing a glass electrode blank (BF 150-86-10, sutter) by a drawing instrument, the tip resistance after filling the liquid in the electrode is about 2-5M omega, and the glass microelectrode can be connected to a patch clamp amplifier after being inserted into an amplifier probe. The clamped voltage and data recording is controlled and recorded by a pClamp 10 software through a computer, the sampling frequency is 10kHz, and the filtering frequency is 2kHz. After a whole cell record was obtained, the cells were clamped at-80 mV and the voltage at the step inducing the hERG potassium current (IhERG) was given a depolarization voltage of 2s from-80 mV to +20mV, repolarized to-50 mV, and returned to-80 mV after 1 s. This voltage stimulus was given every 10s and the dosing process was started after (1 min) the hERG potassium current was determined to be stable. The compounds were administered for at least 1 minute per concentration tested, with at least 2 cells tested per concentration (n.gtoreq.2).
1.5 data processing
The data analysis was performed using pClamp 10, graphPad Prism 5 and Excel software. The degree of inhibition of hERG potassium current (-50 mV induced hERG tail current peak) by different compound concentrations was calculated using the following equation: inhibition% = [1- (I/Io) ] x 100%
Where Inhibition% represents the percentage of Inhibition of the compound on the hERG potassium current, I and Io represent the magnitude of the hERG potassium current after and before dosing, respectively.
Compound IC50 was calculated using GraphPad Prism 5 software by equation fitting: y = Bottom + (Top-Bottom)/(1 +10^ ((LogicC 50-X) > HillSlope))
Wherein X is the Log value of the detected concentration of the test sample, Y is the inhibition percentage under the corresponding concentration, and Bottom and Top are respectively the minimum and maximum inhibition percentages.
2. The experimental results are as follows:
the test results show that the compounds of the present application have an I of more than 30. Mu.MC 50 The value has no obvious inhibition effect on the hERG channel in the detection concentration range of the test, can reflect that the compound has lower cardiotoxicity to a certain extent, and has positive significance on drug safety evaluation.
Claims (13)
1. A compound of formula (I) or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof, having the structure:
wherein X is selected from O and S;
w and V are independently selected from N or C (R) w );R w Represents hydrogen, halogen or C 1-6 An alkyl group;
a is selected from hydrogen, halogen, amino, cyano, hydroxy, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-6 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Hydroxyalkyl, halo C 1-6 Alkyl radical, C 1-6 Alkylamino, -CO-C 1-6 Alkyl, -CO-C 1-6 Haloalkyl, -NHCO-C 1-6 Alkyl, -CH 2 CONR a1 R a2 ;R a1 And R a2 Independently selected from H and C 1-6 Alkyl radical, C 1-6 Alkoxy radical, C 1-6 Hydroxyalkyl, halo C 1-6 An alkyl group;
ring B is selected from C 6-14 Aryl, 5-16 membered heteroaryl and 5-16 membered heterocyclyl, said C 6-14 Aryl, 5-16 membered heteroaryl and 5-16 membered heterocyclyl are optionally substituted with n R b Substituted when more than one R b When occurring simultaneously, each R b May be the same or different; wherein n is selected from 0, 1,2,3,4 and 5;
R b selected from halogen, cyano, hydroxy, nitro, amino, oxo, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy radicalBase, C 1-6 Alkylthio radical, C 1-6 Hydroxyalkyl, 4-to 10-membered heterocyclic group, C 6-12 Aryl, 5-10 membered heteroaryl, -C 1-6 alkyl-C 3-8 Cycloalkyl, -C 1-6 Alkyl-4-10 membered heterocyclyl, -C 1-6 alkyl-C 6-12 Aryl radical, -C 1-6 Alkyl-5-10 membered heteroaryl, -NH-C 3-8 Cycloalkyl, -NH-4-10 membered heterocyclyl, -NH-C 6-12 Aryl, -NH-5-10 membered heteroaryl, -NH-C 1-6 alkyl-C 3-8 Cycloalkyl, -NH-C 1-6 Alkyl-4-10 membered heterocyclyl, -NH-C 1-6 alkyl-C 6-12 Aryl, -NH-C 1-6 Alkyl-5-10 membered heteroaryl, -O-C 1-6 alkyl-C 3-8 Cycloalkyl, -O-C 1-6 Alkyl-4-10 membered heterocyclyl, -O-C 1-6 alkyl-C 6-12 Aryl and-O-C 1-6 Alkyl-5-10 membered heteroaryl; said C is 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Alkylthio radical, C 1-6 Hydroxyalkyl, 4-to 10-membered heterocyclyl, C 6-12 Aryl, 5-10 membered heteroaryl, -C 1-6 alkyl-C 3-8 Cycloalkyl, -C 1-6 Alkyl-4-10 membered heterocyclyl, -C 1-6 alkyl-C 6-12 Aryl, -C 1-6 Alkyl-5-10 membered heteroaryl, -NH-C 3-8 Cycloalkyl, -NH-4-10 membered heterocyclyl, -NH-C 6-12 Aryl, -NH-5-10 membered heteroaryl, -NH-C 1-6 alkyl-C 3-8 Cycloalkyl, -NH-C 1-6 Alkyl-4-10 membered heterocyclyl, -NH-C 1-6 alkyl-C 6-12 Aryl, -NH-C 1-6 Alkyl-5-10 membered heteroaryl, -O-C 1-6 alkyl-C 3-8 Cycloalkyl, -O-C 1-6 Alkyl-4-10 membered heterocyclyl, -O-C 1-6 alkyl-C 6-12 Aryl and-O-C 1-6 Alkyl-5-10 membered heteroaryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, nitro, oxo, -NH (C) 1-3 Alkyl), -N (C) 1-3 Alkyl) (C 1-3 Alkyl), -C 1-3 alkyl-NH 2 、-NH-C(O)C 1-3 Alkyl, -C (O) C 1-3 Alkyl, halo C 1-6 Alkyl radical, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy radical, C 1-6 Alkylthio radical, C 1-6 Hydroxyalkyl, 4-to 10-membered heterocyclic group, C 6-12 Aryl, 5-10 membered heteroaryl;
R 1 is selected from C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Hydroxyalkyl, halogeno C 1-6 Alkyl radical, C 1-6 Alkylamino, -CO-C 1-6 Alkyl, -CO-C 1-6 Haloalkyl, -NHCO-C 1-6 Alkyl, 4-12 membered heterocyclyl, 5-12 membered heteroaryl, C 6-12 An aryl group; said C is 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Hydroxyalkyl, halo C 1-6 Alkyl radical, C 1-6 Alkylamino radical, -CO-C 1-6 Alkyl, -CO-C 1-6 Haloalkyl, -NHCO-C 1-6 Alkyl, 4-12 membered heterocyclyl, 5-12 membered heteroaryl, C 6-12 Aryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, nitro, oxo, -NH (C) 1-3 Alkyl), -N (C) 1-3 Alkyl) (C 1-3 Alkyl), -C 1-3 alkyl-NH 2 、-NH-C(O)C 1-3 Alkyl, -C (O) C 1-3 Alkyl, halo C 1-6 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl, -C 1-3 alkyl-N (C) 1-3 Alkyl) C 1-3 Alkyl radical, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Alkylthio radical, C 1-6 Hydroxyalkyl, 4-to 10-membered heterocyclyl, C 6-12 Aryl, 5-10 membered heteroaryl;
R 2 and R 3 Independently selected from H, C 1-4 Alkyl radical, C 1-4 Haloalkyl, C 1-4 Alkoxy radical, C 1-4 Halogenoalkoxy, C 3-8 A cycloalkyl group; or R 2 And R 3 Together with the atoms to which they are attached form a 5-or 6-membered heterocyclic ring;
unless otherwise specified, the heteroatoms in the above heterocyclic groups, heteroaryl groups are independently selected from O, N or S, and the number of heteroatoms is 1,2,3 or 4.
2. The compound of claim 1, or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof, wherein W and V are both selected from N.
3. The compound of claim 1 or 2, or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof, wherein a is selected from the group consisting of hydrogen, halogen, amino, cyano, hydroxy, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-6 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Hydroxyalkyl, halo C 1-6 An alkyl group; more preferably, a is selected from hydrogen, halogen, amino, cyano, hydroxy, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, cyclopropyl, methoxy; most preferably, a is selected from hydrogen.
4. The compound of any one of claims 1 to 3, or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof, wherein ring B is selected from the group consisting of phenyl, 5-7 membered monocyclic heteroaryl, 5-7 membered monocyclic heterocyclyl, naphthyl, phenanthryl, anthracenyl, 8-14 membered bicyclic heteroaryl, 8-14 membered bicyclic heterocyclyl, 9-14 membered tricyclic heteroaryl, 9-14 membered tricyclic heterocyclyl;
preferably, ring B is selected from 8-14 membered bicyclic fused ring heteroaryl, 8-14 membered bicyclic fused ring heterocyclyl, 9-14 membered fused ring tricyclic heteroaryl, 9-14 membered fused ring tricyclic heterocyclyl;
preferably, ring B is selected from C 6-12 Aryl, 5-14 membered heteroaryl and 5-14 membered heterocyclyl, said C 6-12 Aryl, 5-14 membered heteroaryl and 5-14 membered heterocyclyl are optionally substituted with n R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or differentThe same is carried out; wherein n is selected from 0, 1,2,3 and 4; more preferably, ring B is selected from C 6 Aryl, 6-14 membered heteroaryl and 6-14 membered heterocyclyl, said C 6 Aryl, 6-14 membered heteroaryl and 6-14 membered heterocyclyl is optionally substituted with n R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different; wherein n is selected from 0, 1,2 and 3;
further preferably, ring B is selected from C 6 <xnotran> ,5 ,6 ,7 ,5 ,6 ,7 ,6 /6 ,4 /4 ,4 /5 ,5 /4 ,5 /5 ,5 /6 ,6 /5 ,4 /6 ,6 /4 ,6 /6 ,4 /4 ,4 /5 ,5 /4 ,5 /5 ,5 /6 ,6 /5 ,4 /6 ,6 /4 ,6 /6 ,5 /6 /6 ,6 /5 /6 ,6 /6 /5 ,5 /5 /6 ,5 /6 /5 ,6 /5 /5 ,6 /6 /6 ,5 /6 /6 ,6 /5 /6 ,6 /6 /5 , </xnotran> 5-membered/6-membered tricyclic fused heterocyclic group, 5-membered/6-membered/5-membered tricyclic fused heterocyclic group, 6-membered/5-membered tricyclic fused heterocyclic group, 6-membered/6-membered tricyclic fused aryl group, wherein hetero atoms in the heterocyclic group and the heteroaryl group are independently selected from O, N or S, and the number of hetero atoms is 1,2 or 3; the above groups are optionally substituted by n R b Substituted when more than one R b When occurring simultaneously, each R b May be the same or different; wherein n is selected from 0, 1,2 and 3;
preferably, ring B is selected from the group consisting of 6-12 membered bicyclic heteroaryl, 6-14 membered bicyclic heterocyclyl and 12-14 membered bicyclic heteroarylA tricyclic heterocyclyl, said 6-12 membered bicyclic heteroaryl, 6-14 membered bicyclic heterocyclyl and 12-14 membered tricyclic heterocyclyl optionally substituted with n R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different, wherein n is selected from 0, 1,2,3 and 4; more preferably, ring B is selected from the group consisting of 8-10 membered bicyclic heteroaryl, 8-10 membered bicyclic heterocyclyl and 14 membered tricyclic heterocyclyl, wherein the heteroatoms in the heteroaryl, heterocyclyl are independently selected from O or N, the number of heteroatoms is 1,2 or 3, and wherein the 8-10 membered bicyclic heteroaryl, 8-10 membered bicyclic heterocyclyl and 14 membered tricyclic heterocyclyl are optionally substituted with N R b Substituted when multiple R b At the same time, each R b May be the same or different, wherein n is selected from 0, 1,2 and 3; more preferably, ring B is selected from 9-10 membered bicyclic heteroaryl and 9-10 membered bicyclic heterocyclyl, wherein the heteroatom in the heteroaryl or heterocyclyl is O or N and the number of heteroatoms is 1,2 or 3, wherein the 9-10 membered bicyclic heteroaryl and 9-10 membered bicyclic heterocyclyl are optionally substituted with N R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different, wherein n is selected from 0, 1,2 and 3; more preferably, ring B is selected from 9-10 membered bicyclic heterocyclic group, wherein the heteroatom in said heterocyclic group is N and the number of heteroatoms is 1, said 9-10 membered bicyclic heterocyclic group being optionally substituted by N R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different, wherein n is selected from 0, 1 and 2; preferably, ring B is selected from 9-10 membered bicyclic heteroaryl, wherein the heteroatoms in the heteroaryl are independently selected from O or N, the number of heteroatoms is 1,2 or 3, and the 9-10 membered bicyclic heteroaryl is optionally substituted with N R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different, wherein n is selected from 0, 1,2 and 3; preferably, ring B is selected from C 6-10 Aryl radical, said C 6-10 Aryl is optionally substituted by n R b Substituted when multiple R b At the same time, each R b May be the same or different; wherein n is selected from 0, 1,2,3 and 4; more preferably, ring B is selected from phenyl optionally substituted by n R b Substituted when more than one R b When occurring simultaneously, each R b Which may be the same or different from each other,wherein n is selected from 0, 1,2 and 3; more preferably, ring B is selected from phenyl optionally substituted by n R b Substituted when multiple R b At the same time, each R b May be the same or different, wherein n is selected from 0, 1 and 2;
even more preferably, ring B is selected from the following structures, optionally substituted by n R b Substituted when more than one R b When occurring simultaneously, each R b May be the same or different; wherein n is selected from 0, 1,2 and 3:
even more preferably, R b -ring B is selected from the following structures:
5. the compound of any one of claims 1-4, or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R b Selected from halogen, cyano, hydroxy, nitro, amino, oxo, C 1-4 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-6 Cycloalkyl radical, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-to 10-membered heterocyclic group, C 6-12 Aryl, 5-10 membered heteroaryl, -C 1-4 alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-4-10 membered heterocyclyl, -C 1-4 alkyl-C 6-12 Aryl, -C 1-4 Alkyl-5-10 membered heteroaryl, -NH-C 3-8 Cycloalkyl, -NH-4-10 membered heterocyclyl, -NH-C 6-12 Aryl, -NH-5-10 membered heteroaryl, -NH-C 1-4 alkyl-C 3-8 Cycloalkyl, -NH-C 1-4 Alkyl-4-10 membered heterocyclyl, -NH-C 1-4 alkyl-C 6-12 Aryl, -NH-C 1-4 Alkyl-5-10 membered heteroaryl, -O-C 1-4 alkyl-C 3-8 Cycloalkyl, -O-C 1-4 Alkyl-4-10 membered heterocyclyl, -O-C 1-4 alkyl-C 6-12 Aryl and-O-C 1-4 Alkyl-5-10 membered heteroaryl; said C is 1-4 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-6 Cycloalkyl radical, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-to 10-membered heterocyclic group, C 6-12 Aryl, 5-10 membered heteroaryl, -C 1-4 alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-4-10 membered heterocyclyl, -C 1-4 alkyl-C 6-12 Aryl radical, -C 1-4 Alkyl-5-10 membered heteroaryl, -NH-C 3-8 Cycloalkyl, -NH-4-10 membered heterocyclyl, -NH-C 6-12 Aryl, -NH-5-10 membered heteroaryl, -NH-C 1-4 alkyl-C 3-8 Cycloalkyl, -NH-C 1-4 Alkyl-4-10 membered heterocyclyl, -NH-C 1-4 alkyl-C 6-12 Aryl, -NH-C 1-4 Alkyl-5-10 membered heteroaryl, -O-C 1-4 alkyl-C 3-8 Cycloalkyl, -O-C 1-4 Alkyl-4-10 membered heterocyclyl, -O-C 1-4 alkyl-C 6-12 Aryl and-O-C 1-4 Alkyl-5-10 membered heteroaryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, nitro, oxo, -NH (C) 1-3 Alkyl), -N (C) 1-3 Alkyl) (C) 1-3 Alkyl), -C (O) C 1-3 Alkyl, halo C 1-6 Alkyl radical, C 1-6 Alkyl radical, C 2-6 Alkenyl radical, C 2-6 Alkynyl, C 3-8 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 Alkylthio radical, C 1-6 A hydroxyalkyl group;
further preferably, R b Selected from halogen, cyano, hydroxy, nitro, amino, oxo, C 1-4 Alkyl radical, C 3-6 Cycloalkyl, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-10 membered heterocyclyl, -C 1-4 alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-4-10 membered heterocyclyl, -C 1-4 Alkyl-5-10 membered heteroaryl, -NH-C 3-8 Cycloalkyl, -NH-4-10 membered heterocyclyl, -NH-5-10 membered heteroaryl, -NH-C 1-4 alkyl-C 3-8 Cycloalkyl, -NH-C 1-4 Alkyl-4-10 membered heterocyclyl, -NH-C 1-4 Alkyl-5-10 membered heteroaryl, -O-C 1-4 alkyl-C 3-8 Cycloalkyl, -O-C 1-4 Alkyl-4-10 membered heterocyclyl and-O-C 1-4 Alkyl-5-10 membered heteroaryl; said C is 1-4 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-10 membered heterocyclyl, -C 1-4 alkyl-C 3-8 Cycloalkyl, -C 1-4 Alkyl-4-10 membered heterocyclyl, -C 1-4 Alkyl-5-10 membered heteroaryl, -NH-C 3-8 Cycloalkyl, -NH-4-10 membered heterocyclyl, -NH-5-10 membered heteroaryl, -NH-C 1-4 alkyl-C 3-8 Cycloalkyl, -NH-C 1-4 Alkyl-4-10 membered heterocyclyl, -NH-C 1-4 Alkyl-5-10 membered heteroaryl, -O-C 1-4 alkyl-C 3-8 Cycloalkyl, -O-C 1-4 Alkyl-4-10 membered heterocyclyl and-O-C 1-4 Alkyl-5-10 membered heteroaryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, nitro, oxo, -NH (C) 1-3 Alkyl), -N (C) 1-3 Alkyl) (C 1-3 Alkyl), -C (O) C 1-3 Alkyl radical, C 1-6 Alkyl radical, C 1-6 A hydroxyalkyl group;
further preferably, R b Selected from halogen, cyano, hydroxy, nitro, amino, oxo, C 1-4 Alkyl radical, C 5-6 Cycloalkyl radical, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-6 membered heterocycloalkyl, 4-6 membered heterocycloalkenyl, 7-8 membered bicyclic heterocyclyl, -C 1-4 alkyl-C 3-6 Cycloalkyl, -C 1-4 Alkyl-4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkenyl, -NH-C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl; the heteroatom in the heterocycloalkyl, heterocycloalkenyl, heterocyclyl or heteroaryl is O or N, and the number of heteroatoms is 1,2 or 3; said C is 1-4 Alkyl radical, C 5-6 Cycloalkyl radical, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-6 membered heterocycloalkyl, 4-6 membered heterocycloalkenyl, 7-8 membered bicyclic heterocyclyl, -C 1-4 alkyl-C 3-6 Cycloalkyl, -C 1-4 Alkyl-4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkenyl, -NH-C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, nitro, oxo, -NH (C) 1-3 Alkyl), -N (C) 1-3 Alkyl) (C 1-3 Alkyl), -C (O) C 1-3 Alkyl radical, C 1-4 Alkyl radical, C 1-3 A hydroxyalkyl group;
further preferably, R b Selected from halogen, cyano, hydroxy, nitro, amino, oxo, C 1-4 Alkyl radical, C 5-6 Cycloalkyl radical, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-6 membered heterocycloalkyl, 4-6 membered heterocycloalkenyl, 7-8 membered bicyclic heterocyclyl, -C 1-4 alkyl-C 3-6 Cycloalkyl, -C 1-4 Alkyl-4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkenyl, -NH-C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl; the heteroatom in the heterocycloalkyl, the heterocycloalkenyl, the heterocyclyl and the heteroaryl is O or N, and the number of the heteroatoms is 1 or 2; said C is 1-4 Alkyl radical, C 5-6 Cycloalkyl, C 1-4 Alkoxy radical, C 1-4 Alkylthio radical, C 1-4 Hydroxyalkyl, 4-6 membered heterocycloalkyl, 4-6 membered heterocycloalkenyl, 7-8 membered bicyclic heterocyclyl, -C 1-4 alkyl-C 3-6 Cycloalkyl, -C 1-4 Alkyl-4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -NH-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkyl, -NH-C 1-4 Alkyl-4-6 membered heterocycloalkenyl, -NH-C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, nitro, oxo, -NHCH 3 、-N(CH 3 )(CH 3 )、-C(O)CH 3 Methyl, ethyl, hydroxymethyl;
even more preferably, R b Selected from the group consisting of halogen, cyano, hydroxy, nitro, amino, oxo, methyl, ethyl, n-propyl, isopropyl, methoxy, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-10 membered heterocyclyl, -CH 2 -cyclopropyl, -CH 2 -cyclobutyl, -CH 2 -cyclopentyl, -CH 2 -4-6 membered heterocyclyl, -CH 2 -5-6 membered heteroaryl, -NHCH 2 -cyclopropyl, -NHCH 2 -cyclobutyl, -NHCH 2 -cyclopentyl, -NHCH 2 -4-6 membered heterocyclyl, -NHCH 2 -5-6 membered heteroaryl, -NH-cyclopropyl, -NH-cyclobutyl, -NH-cyclopentyl, -NH-4-6 membered heterocyclyl, -NH-5-6 membered heteroaryl, -OCH 2 -cyclopropyl, -OCH 2 -cyclobutyl, -OCH 2 -cyclopentyl, -OCH 2 -4-6 membered heterocyclyl and-OCH 2 -5-6 membered heteroaryl, said methyl, ethyl, n-propyl, isopropyl, methoxy, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-10 membered heterocyclyl, -CH 2 -cyclopropyl, -CH 2 -cyclobutyl, -CH 2 -cyclopentyl, -CH 2 -4-6 membered heterocyclyl, -CH 2 -5-6 membered heteroaryl, -NHCH 2 -cyclopropyl, -NHCH 2 -cyclobutyl, -NHCH 2 -cyclopentyl, -NHCH 2 -4-6 membered heterocyclyl, -NHCH 2 -5-6 membered heteroaryl, -NH-cyclopropyl, -NH-cyclobutyl, -NH-cyclopentyl, -NH-4-6 membered heterocyclyl, -NH-5-6 membered heteroaryl, -OCH 2 -cyclopropyl, -OCH 2 -cyclobutyl, -OCH 2 -cyclopentyl, -OCH 2 -4-6 membered heterocyclyl and-OCH 2 -5-6 membered heteroaryl is unsubstituted or substituted by one or more of the following substituents, respectively: halogen, cyano, hydroxy, nitro, oxo, -NH CH 3 、-N(CH 3 )(CH 3 )、-C(O)CH 3 Methyl, ethyl, hydroxymethyl;
most preferably, R b Selected from the group consisting of halogen, cyano, hydroxy, nitro, amino, oxo, methyl ethyl, n-propyl, isopropyl, methoxy, methylthio, methyl,
6. The compound of any one of claims 1-5, or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof, wherein ring B is selected from the group consisting of a 9-10 membered bicyclic heteroaryl and a 9-10 membered bicyclic heterocyclyl, said 9-10 membered bicyclic heteroaryl and 9-10 membered bicyclic heterocyclyl being optionally substituted with n R b Substituted when multiple R b At the same time, each R b May be the same or different, wherein n is selected from 1 or 2; r is b Selected from halogen, oxo, C 1-6 Alkyl, -C 1-4 Alkyl-4-6 membered heterocycloalkyl, C 5-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl, said C 1-6 Alkyl, -C 1-4 Alkyl-4-6 membered heterocycloalkyl, C 5-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, C 1-4 An alkyl group; the heteroatom in the heterocycloalkyl or heteroaryl is O or N, and the number of the heteroatoms is 1 or 2;
preferably, ring B is selected from 9-10 membered bicyclic heteroaryl and 9-10 membered bicyclic heterocyclyl, said 9-10 membered bicyclic heteroaryl and 9-10 membered bicyclic heterocyclyl being optionally substituted by n R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different, wherein n is selected from 1 or 2; r b Selected from halogen, oxo, C 1-4 Alkyl and substituted benzeneC 1-4 Alkyl-4-6 membered heterocycloalkyl, C 5-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl, said C 1-6 Alkyl, -C 1-4 Alkyl-4-6 membered heterocycloalkyl, C 5-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -C 1-4 Alkyl-5-6 membered heteroaryl, -O-C 1-4 Alkyl-4-6 membered heterocycloalkyl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, methyl; the heteroatom in the heterocycloalkyl and heteroaryl is O or N, and the number of the heteroatoms is 1 or 2.
7. The compound of any one of claims 1-6, or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R 1 Selected from phenyl, 5-7 membered monocyclic heteroaryl, 5-7 membered monocyclic heterocyclyl, naphthyl, 8-14 membered bicyclic heteroaryl, 8-14 membered bicyclic heterocyclyl;
preferably, R 1 Selected from phenyl, 5-7 membered monocyclic heteroaryl, 5-7 membered monocyclic heterocyclyl, naphthyl, 8-14 membered bicyclic fused ring heteroaryl, 8-14 membered bicyclic fused ring heterocyclyl;
preferably, R 1 Selected from the group consisting of 4-12 membered heterocyclyl, 5-12 membered heteroaryl and C 6-12 An aryl group; the 4-12 membered heterocyclic group, 5-12 membered heteroaryl group and C 6-12 Aryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, amino, hydroxy, nitro, oxo, -NH (C) 1-3 Alkyl), -N (C) 1-3 Alkyl) (C) 1-3 Alkyl), -C 1-3 alkyl-NH 2 、-NH-C(O)C 1-3 Alkyl, -C (O) C 1-3 Alkyl, halo C 1-3 Alkyl radical, C 1-3 Alkyl radical, C 3-8 Cycloalkyl radical, C 1-3 Alkoxy radical, C 1-3 Alkylthio radical, C 1-3 A hydroxyalkyl group;
preferably, R 1 Selected from 5-10 membered heterocyclyl, 6-10 membered heteroaryl; the 5-10 membered heterocyclyl, 6-10 membered heteroaryl are unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyanoHydroxy, amino, -NH-C (O) C 1-3 Alkyl, halo C 1-6 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl, -C 1-3 alkyl-N (C) 1-3 Alkyl) C 1-3 Alkyl radical, C 1-3 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-3 Alkoxy radical, C 1-3 A hydroxyalkyl group;
preferably, R 1 Selected from the group consisting of 5-6 membered heterocycloalkyl, 8-10 membered bicyclic heterocyclyl, 6 membered monocyclic heteroaryl, 8-10 membered bicyclic heteroaryl; the heteroatom in the heterocycloalkyl, the heterocyclic group and the heteroaryl is O or N, and the number of the heteroatoms is 1,2 or 3; the 5-6 membered heterocycloalkyl, 8-10 membered bicyclic heterocyclyl, 6 membered monocyclic heteroaryl, 8-10 membered bicyclic heteroaryl are unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, -NH-C (O) C 1-3 Alkyl, halo C 1-3 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl, -C 1-3 alkyl-N (C) 1-3 Alkyl) C 1-3 Alkyl radical, C 1-3 Alkyl radical, C 3-6 Cycloalkyl, C 1-3 Alkoxy radical, C 1-3 A hydroxyalkyl group;
preferably, R 1 Selected from the group consisting of 5-6 membered heterocycloalkyl, 5-membered/6-membered bicyclic fused heterocyclic group, 6-membered/5-membered bicyclic fused heterocyclic group, 6-membered/6-membered bicyclic fused heterocyclic group, 6-membered monocyclic heteroaryl group, 5-membered/6-membered bicyclic fused heteroaryl group, 6-membered/5-membered bicyclic fused heteroaryl group, 6-membered/6-membered bicyclic fused heteroaryl group; the heteroatom in the heterocycloalkyl, heterocyclic group and heteroaryl is O or N, and the number of the heteroatoms is 1,2 or 3; the 5-6 membered heterocycloalkyl, 5-membered/6-membered bicyclic fused heterocyclic group, 6-membered/5-membered bicyclic fused heterocyclic group, 6-membered/6-membered bicyclic fused heterocyclic group, 6-membered monocyclic heteroaryl, 5-membered/6-membered bicyclic fused heteroaryl, 6-membered/5-membered bicyclic fused heteroaryl, 6-membered/6-membered bicyclic fused heteroaryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methoxy, -NH-C (O) CH 3 、-CH 2 NHCH 3 Trifluoromethyl, difluoromethyl, monofluoromethyl, hydroxymethyl;
more preferably, R 1 Selected from 5-10 membered heterocyclic groups6-10 membered heteroaryl and C 6-10 An aryl group; the 5-to 10-membered heterocyclic group, 6-to 10-membered heteroaryl group and C 6-10 Aryl is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, nitro, oxo, -NHCH 3 、-N(CH 3 )(CH 3 )、-NH-C(O)CH 3 、-C(O)CH 3 Methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methoxy, methylthio, trifluoromethyl, difluoromethyl, monofluoromethyl;
further preferably, R 1 Is selected from C 6 Aryl, 5-membered monocyclic heteroaryl, 6-membered monocyclic heteroaryl, 7-membered monocyclic heteroaryl, 5-membered monocyclic heterocyclyl, 6-membered monocyclic heterocyclyl, 7-membered monocyclic heterocyclyl, 6/6-membered bicyclic fused aryl, 4-membered/4-membered bicyclic fused heteroaryl, 4-membered/5-membered bicyclic fused heteroaryl, 5-membered/4-membered bicyclic fused heteroaryl, 5-membered/5-membered bicyclic fused heteroaryl, 5-membered/6-membered bicyclic fused heteroaryl, 6-membered/5-membered bicyclic fused heteroaryl, 4-membered/6-membered bicyclic fused heteroaryl, 6-membered/4-membered bicyclic fused heteroaryl, 6-membered/6-membered bicyclic fused heteroaryl, 4-membered/4-membered bicyclic fused heterocyclyl, 4-membered/5-membered bicyclic fused heterocyclyl, 5-membered/4-membered bicyclic fused heterocyclyl, 5-membered/6-membered bicyclic fused heterocyclyl, 6-membered/5-membered bicyclic fused heterocyclyl, 4-membered/6-membered bicyclic fused heterocyclyl, 6-membered/6-membered bicyclic fused heterocyclyl, the heteroatoms in the heterocyclic group and the heteroaryl group are independently selected from O, N or S, and the number of the heteroatoms is 1,2 or 3; r is as defined above 1 The group is unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, nitro, oxo, -NHCH 3 、-N(CH 3 )(CH 3 )、-NH-C(O)CH 3 、-C(O)CH 3 Methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methoxy, methylthio, trifluoromethyl, difluoromethyl, monofluoromethyl;
preferably, R 1 Selected from 6-membered monocyclic heteroaryl, 9-membered bicyclic heteroaryl; the heteroatom in the heteroaryl is N, and the number of the heteroatoms is 1 or 2; the 6-membered monocyclic heteroaryl and the 9-membered bicyclic heteroaryl are unsubstituted or substituted with one or more of the following substituents, respectively: which is unsubstituted or substitutedSubstituted with one or more of the following substituents: halogen, hydroxy, halogeno C 1-3 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl radical, C 1-3 Alkyl radical, C 1-3 A hydroxyalkyl group;
further preferably, R 1 Selected from 6-membered monocyclic heteroaryl, 5-membered/6-membered bicyclic fused heteroaryl, 6-membered/5-membered bicyclic fused heteroaryl, 6-membered/6-membered bicyclic fused heteroaryl; the heteroatom in the heteroaryl is N, and the number of the heteroatoms is 1 or 2; the 5-membered/6-membered bicyclic fused heteroaryl, 6-membered/5-membered bicyclic fused heteroaryl, 6-membered/6-membered bicyclic fused heteroaryl is unsubstituted or substituted with one or more of the following substituents, respectively: which is unsubstituted or substituted, respectively, by one or more of the following substituents: halogen, -C 1-3 alkyl-NH-C 1-3 Alkyl radical, C 1-3 Alkyl radical, C 1-3 A hydroxyalkyl group;
even more preferably, R 1 Selected from the following structures, which are unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, nitro, oxo, -NHCH 3 、-N(CH 3 )(CH 3 )、-NH-C(O)CH 3 、-C(O)CH 3 Methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methoxy, methylthio, trifluoromethyl, difluoromethyl, monofluoromethyl,
most preferably, R 1 Selected from the following structures:
8. a compound according to any one of claims 1 to 7, or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof, whichIn (c), ring B is selected from phenyl optionally substituted by n R b Substituted when multiple R b When occurring simultaneously, each R b May be the same or different, wherein n is selected from 0, 1,2 and 3; r 1 Selected from 5-10 membered bicyclic heterocyclyl, 6-10 membered bicyclic heteroaryl; the 5-10 membered bicyclic heterocyclyl, 6-10 membered bicyclic heteroaryl are unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, -NH-C (O) C 1-3 Alkyl, halo C 1-6 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl, -C 1-3 alkyl-N (C) 1-3 Alkyl) C 1-3 Alkyl radical, C 1-6 Alkyl radical, C 3-8 Cycloalkyl radical, C 1-6 Alkoxy radical, C 1-6 A hydroxyalkyl group;
preferably, ring B is selected from phenyl optionally substituted by n R b Substituted when more than one R b When occurring simultaneously, each R b May be the same or different, wherein n is selected from 0, 1,2 and 3; r is 1 Selected from 8-10 membered bicyclic heterocyclic group, 8-10 membered bicyclic heteroaryl; the 8-10 membered bicyclic heterocyclyl, 8-10 membered bicyclic heteroaryl are unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, -NH-C (O) C 1-3 Alkyl, halo C 1-6 Alkyl, -C 1-3 alkyl-NH-C 1-3 Alkyl, -C 1-3 alkyl-N (C) 1-3 Alkyl) C 1-3 Alkyl radical, C 1-3 Alkyl radical, C 3-6 Cycloalkyl radical, C 1-3 Alkoxy radical, C 1-3 A hydroxyalkyl group;
further preferably, ring B is selected from phenyl optionally substituted with n R b Substituted when multiple R b At the same time, each R b May be the same or different, wherein n is selected from 1,2 and 3; r is 1 Selected from the group consisting of 5-membered/6-membered bicyclic fused heterocyclic group, 6-membered/5-membered bicyclic fused heterocyclic group, 6-membered/6-membered bicyclic fused heterocyclic group, 5-membered/6-membered bicyclic fused heteroaryl group, 6-membered/5-membered bicyclic fused heteroaryl group, 6-membered/6-membered bicyclic fused heteroaryl group; the heteroatom in the heterocyclic group and the heteroaryl group is O or N, and the number of the heteroatoms is 1,2 or 3; the 5-membered/6-membered bicyclic fused heterocyclic group, 6-membered/5-membered bicyclic fused heterocyclic group, 6-membered/6-membered bicyclic fused heterocyclic groupCyclyl, 5-membered/6-membered bicyclic fused heteroaryl, 6-membered/5-membered bicyclic fused heteroaryl, 6-membered/6-membered bicyclic fused heteroaryl are unsubstituted or substituted with one or more of the following substituents, respectively: halogen, cyano, hydroxy, amino, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methoxy, -NH-C (O) CH 3 、-CH 2 NHCH 3 Trifluoromethyl, difluoromethyl, monofluoromethyl, hydroxymethyl;
preferably, ring B is selected from phenyl optionally substituted with 2R b Substituted when more than one R b When occurring simultaneously, each R b May be the same or different; r is b Selected from methyl,R 1 Is selected from C 1-3 Pyridyl optionally substituted with one or more of alkyl;
preferably, R b -ring B is selected from the following structures:
9. The compound of any one of claims 1-8, or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof, wherein R 2 And R 3 Independently selected from hydrogen, methyl; or R 2 And R 3 Together with the atoms to which they are attached form a 5-or 6-membered heterocyclic ring; preferably, R 2 And R 3 Independently selected from hydrogen, methyl; or R 2 And R 3 Together with the atoms to which they are attached form a 5-membered heterocycloalkyl or 6-membered heterocycloalkyl group, in which the heteroatoms are N, the number of heteroatoms being 2.
11. a pharmaceutical composition comprising a compound of any one of claims 1 to 10, or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative thereof, or a pharmaceutically acceptable salt thereof.
12. Use of a compound according to any one of claims 1 to 10, or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 11, for the manufacture of a medicament for the treatment of a disease mediated by POLQ; preferably, the disease mediated by POLQ is cancer or a tumor-related disease; preferably, the cancer or tumor comprises a solid tumor and a hematological tumor; preferably, the solid tumor comprises breast cancer, colorectal cancer, cervical cancer, ovarian cancer, prostate cancer, gastric cancer (including gastrointestinal junction cancer), esophageal cancer, head and neck cancer, lung cancer; preferably, the hematological neoplasm comprises lymphoma and leukemia.
13. A compound according to any one of claims 1 to 10, or a prodrug, tautomer, stereoisomer, solvate, isotopic derivative or pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 11, for use in combination with one, two or more additional anti-cancer agents or immune checkpoint modulators or therapeutic means (e.g. radiotherapy) for the treatment of cancer or tumors; preferably, the additional anti-cancer agent or immune checkpoint modulator for the treatment of cancer or tumor comprises a PARP inhibitor, an ATR inhibitor, an ATM inhibitor, a WEE1 inhibitor, a topoisomerase inhibitor and a DNA damaging chemotherapeutic; preferably, the DNA damaging chemotherapeutic comprises cisplatin, bleomycin, gemcitabine, docetaxel; the topoisomerase inhibitor comprises etoposide and irinotecan.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021108764437 | 2021-07-30 | ||
CN202110876443 | 2021-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115353512A true CN115353512A (en) | 2022-11-18 |
Family
ID=84032566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210897430.2A Pending CN115353512A (en) | 2021-07-30 | 2022-07-28 | Heterocyclic urea compound and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115353512A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117865993A (en) * | 2023-01-10 | 2024-04-12 | 杭州师范大学 | AAK1 inhibitor and preparation and application thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020173507A1 (en) * | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
CN1507436A (en) * | 2001-03-02 | 2004-06-23 | Aryl and heteroaryl urea CHK1 inhibitors for use as radiosensitizers and chamosensitizers | |
CN101754759A (en) * | 2007-05-18 | 2010-06-23 | 史密丝克莱恩比彻姆公司 | Quinoline derivatives as PI3 kinase inhibitors |
WO2013134562A1 (en) * | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
CN105037355A (en) * | 2009-08-10 | 2015-11-11 | 萨穆梅德有限公司 | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
CN106535890A (en) * | 2014-03-20 | 2017-03-22 | 萨穆梅德有限公司 | 5-substituted indazole-3-carboxamides and preparation and use thereof |
WO2018075858A1 (en) * | 2016-10-21 | 2018-04-26 | Samumed, Llc | Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
WO2020006115A1 (en) * | 2018-06-26 | 2020-01-02 | Betty Tam | Methods of treating cancer using a clk inhibitor |
CN111093659A (en) * | 2017-04-30 | 2020-05-01 | 财团法人生物技术开发中心 | Medicine for resisting cancer dryness |
WO2020264176A1 (en) * | 2019-06-28 | 2020-12-30 | Rti International | Urea derivatives as cb1 allosteric modulators |
-
2022
- 2022-07-28 CN CN202210897430.2A patent/CN115353512A/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020173507A1 (en) * | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
CN1507436A (en) * | 2001-03-02 | 2004-06-23 | Aryl and heteroaryl urea CHK1 inhibitors for use as radiosensitizers and chamosensitizers | |
CN101754759A (en) * | 2007-05-18 | 2010-06-23 | 史密丝克莱恩比彻姆公司 | Quinoline derivatives as PI3 kinase inhibitors |
CN105037355A (en) * | 2009-08-10 | 2015-11-11 | 萨穆梅德有限公司 | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
WO2013134562A1 (en) * | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
CN106535890A (en) * | 2014-03-20 | 2017-03-22 | 萨穆梅德有限公司 | 5-substituted indazole-3-carboxamides and preparation and use thereof |
WO2018075858A1 (en) * | 2016-10-21 | 2018-04-26 | Samumed, Llc | Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
CN111093659A (en) * | 2017-04-30 | 2020-05-01 | 财团法人生物技术开发中心 | Medicine for resisting cancer dryness |
WO2020006115A1 (en) * | 2018-06-26 | 2020-01-02 | Betty Tam | Methods of treating cancer using a clk inhibitor |
WO2020264176A1 (en) * | 2019-06-28 | 2020-12-30 | Rti International | Urea derivatives as cb1 allosteric modulators |
Non-Patent Citations (1)
Title |
---|
JANE F. DJUNG,等: "The synthesis and evaluation of indolylureas as PKCa inhibitors", 《BIOORGANIC & MEDICINAL CHEMISTRY》, vol. 19, 26 February 2011 (2011-02-26), pages 2742 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117865993A (en) * | 2023-01-10 | 2024-04-12 | 杭州师范大学 | AAK1 inhibitor and preparation and application thereof |
CN117865993B (en) * | 2023-01-10 | 2024-09-27 | 杭州师范大学 | AAK1 inhibitor and preparation and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109311864B (en) | Heteroaryl substituted pyridines and methods of use | |
CN110088099B (en) | Amine-substituted heterocyclic compounds as EHMT2 inhibitors and methods of use thereof | |
TW202043212A (en) | Shp2 inhibitor and application thereof | |
TW201825472A (en) | Novel compounds | |
EP2943485B1 (en) | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors | |
EP3333157B1 (en) | Vinyl compounds as fgfr and vegfr inhibitors | |
BR112014010179B1 (en) | compound, pharmaceutical composition, and, use of a compound | |
BR112014010177B1 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND | |
WO2021115457A9 (en) | Pyrazolo[1,5-a]pyridine compound, preparation method therefor and use thereof | |
BR112018014675B1 (en) | SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING THEM | |
EP3741752A1 (en) | Tam family kinase /and csf1r kinase inhibitor and use thereof | |
WO2021197452A1 (en) | Crystal form of free alkali of nitrogen-containing aromatic derivatives | |
WO2023280237A1 (en) | Synthesis and application of phosphatase degrader | |
EP3694330A1 (en) | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
WO2019076336A1 (en) | Pyrazolyl-containing tricyclic derivative, preparation method therefor and use thereof | |
KR20220140710A (en) | Triazolopyridazine derivatives, methods for their preparation, drug compositions and uses | |
WO2021197467A1 (en) | Multi-target anti-tumor compound, preparation method therefor and use thereof | |
WO2019062657A1 (en) | Nitrogen heterocyclic derivative, preparation method therefor, and pharmaceutical use thereof | |
WO2020098723A1 (en) | Six-membered and six-membered heterocyclic compound and uses thereof serving as protein receptor kinase inhibitor | |
CN115353512A (en) | Heterocyclic urea compound and preparation method and application thereof | |
JP2021504334A (en) | Pyrazolopyridinone compound | |
WO2023142641A1 (en) | Pyridine derivative, preparation method therefor and use thereof | |
WO2024041606A1 (en) | Compound with anti-kras mutant tumor activity | |
CN104936944A (en) | Indole full ketone derivative used as tyrosine-kinase inhibitor | |
CA3234693A1 (en) | Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |